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General introduction including scope of this thesis
Background 
Myelodysplastic syndromes (MDS) are a heterogeneous group of acquired 
clonal stem cell malignancies characterized by disturbed maturation of the 
hematopoietic cell lines, erythropoiesis, myelopoiesis or megakaryopoiesis, 
and an inherent risk of progression to acute myeloid leukemia. Establishing 
the diagnosis of MDS requires exclusion of alternative causes for cytopenias 
coupled with cytomorphologic, histopathologic assessment, cytogenetic, 
and molecular data.1, 2 For more than two decades, MDS has been categorized 
according to the 1982 French-American-British (FAB) classifi cation that was 
based on morphologic criteria.3 However, signifi cant heterogeneity has been 
noted within FAB subgroups.4 Therefore, from 2001, the WHO classifi cation of 
MDS was established, with an updated classifi cation in 2008, and more recently 
the WHO 2016 classifi cation (tables 1-3).5-9
Flow cytometry and molecular analysis provide additional valuable information 
alongside the morphology to refi ne the diagnosis of MDS, but the clinical and 
therapeutic impact of these methods are under investigation.10, 11
Prognostic scoring systems have been developed for risk assessment in the 
individual patient, the most widely used being the International Prognostic 
Scoring System (IPSS; table 4), which categorizes patients based on percentage 
of bone marrow blasts, karyotype and number of cytopenias in peripheral blood. 
More recently, the Revised International Prognostic Scoring System (IPSS-R; 
table 5), which categorizes patients according to percentage bone marrow 
blasts and karyotype in a more refi ned way, as well as scoring the hemoglobin 
level, platelet level and absolute neutrophil count (ANC) separately.4, 12, 13  
Anemia is the fi rst clinical presentation in about 80% of the patients with MDS, 
of which 40% will be treated with supportive care consisting of erythropoiesis 
stimulating agents (ESA) and other grow factors like granulocyte colony 
stimulating factors (G-CSF), either combined with red blood cell transfusions.4, 14-16
The majority of lower-risk MDS (LR-MDS) patients, defi ned as patients with low or 
intermediate-1 MDS according to the International Prognostic Risk Score (IPSS), 
become transfusion dependent, usually early after diagnosis in order to improve 
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quality of life and to prevent ischemic organ damage. Every unit of red blood 
cells contains ~200mg of iron, 100 times the required daily dose.15, 17, 18 With an 
expected median survival of 2.4 to 11.8 years and no physiologic mechanisms to 
decrease the excessive iron load, these patients are prone to tissue accumulation 
of iron due to red blood cell (RBC) transfusions.12, 19-22 Iron overload predominantly 
in parenchymal cells may also occur in LR-MDS patients with ringed sideroblasts 
(RS) who do not receive RBC transfusions, due to the stimulation of intestinal iron 
absorption and iron release from the reticulo-endothelial cells, mediated through 
suppression of hepcidin production in patients with ineffective erythropoiesis.23
Iron toxicity
Iron is essential for all living cells, its biggest consumers are the bone marrow for 
the production of erythrocytes with 2-2.5 g of iron circulating in hemoglobin, 
and the skeletal and cardiac muscles for the production of myoglobin (~300 
mg), accounting for around 70% of the total body iron.24, 25 
The human body is able to passively eliminate 1-2 mg of iron per day via faeces 
or skin by sweating, but no mechanisms are available to actively excrete excess 
iron. Iron is physiologically stored in ferritin, in epithelial and parenchymal cells 
and macrophages, but to a limited extent. 
Hepcidin is the most important regulator of the human systemic iron 
homeostasis, a 25-aminoacid hormone produced by the hepatocytes.26 
Hepcidin triggers internalization and lysosomal degradation of ferroportin, 
a membrane bound cellular iron exporter present on macrophages and the 
basolateral site of enterocytes that releases iron into the circulation.26, 27. In 
case of iron deficiency anemia the hepcidin synthesis is decreased, leading to 
increased dietary iron absorption.28 A part of the offered iron will immediately 
be stored in the available ferritin in the enterocytes and the rest will be released 
by ferroportin into the circulation and bound to transferrin and transported to 
the tissues. Decreased hepcidin levels will also increase iron release from the 
macrophages of the reticuloendothelial system (RES), ~20mg daily.14  In case 
of infection or inflammation hepcidin levels increase, iron is entrapped in the 
RES and transferrin saturation (TSAT) decreases, leading to less available iron 
for extracellular micro-organisms that need iron for their proliferation.20, 27, 29 
GDF15 is a protein produced by erythroid precursors and has been reported to 
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be involved in the communication between bone marrow and liver in case of an 
increased erythroid demand, functioning as a suppressor of hepcidin synthesis, 
as shown for  β-thalassemia.20, 23, 30 However, its role in MDS is still debated 
because of confl icting results.20, 30-34 Twisted gastrulation factor 1 (TWSG1) and 
Erythroferrone (ERFE) are also erythroid factors reported to suppress hepatic 
hepcidin production, recently a human assay for ERFE has been validated.23, 26, 35
Of additional interest in iron homeostasis is soluble transferrin receptor (sTfR); 
the serum concentration of sTfR is proportional to the quantity of the Transferrin 
Receptors 1 (TfR1) on cellular membranes, especially on erythroid precursors, 
and TfR1 is a valuable parameter of erythroid proliferation rate and iron 
supplies.36, 37 Among others, sTfR levels are elevated in case of high erythroid 
proliferation rates especially in combination with adequate iron supply,37 as 
in diseases characterized by ineff ective erythropoiesis such as thalassemia 
syndromes, and suppressed in case of decreased erythropoietic activity as in 
anemia of chronic disease, and diseases with erythroid hypoplasia.27, 34, 38  Earlier 
studies showed that sTfR levels are increased in MDS-RS20, including SF3B1-
positive MDS, patients.33
When the binding capacity of TSAT is exceeded non-transferrin-bound iron 
species (NTBI; circulating iron not bound to transferrin, ferritin or heme appear in 
the plasma.39-42 Plasma NTBI has been described to comprise several subspecies, 
which may be classifi ed by their chemical composition, chemical reactivity 
or susceptibility to chelation. Among these subspecies are, Fe(III) bound to 
albumin and citrate and potentially to acetate, malate and phosphate.43-51 The 
fraction of plasma NTBI that is redox active and can be chelated is defi ned as 
labile plasma iron (LPI).49-52
NTBI and LPI complexes are taken up by susceptible cell types like hepatocytes, 
cardiomyocytes and pancreatic islet cells, and consequently initiate oxidative 
stress by generating reactive oxygen species (ROS) via the Fenton reaction 
(Iron(II) oxidized by hydrogen peroxide to iron(III), forming a hydroxyl radical
and a hydroxide ion) which may lead to damaging mitochondria, proteins, 
lipids and DNA.53-55 Oxidative stress and ROS-induced damage is a potential 
trigger for increased apoptosis of the erythroid precursors in MDS via up 
regulation of the Fas receptor and its ligand FasL.56 
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Clinical consequences of iron overload
In low and intermediate-1 risk MDS patients according to IPSS median survival 
is 5.7 and 3.5 years, respectively. The survival is significantly reduced in patients 
with a median survival of 1.2 years in intermediate-2 risk MDS, and 0.4 year in 
high risk MDS.4 A long lasting dilemma in MDS remains whether the impact 
of transfusions on survival is mainly caused by progression of bone marrow 
failure leading to increased demand for transfusions or caused by toxicity of 
the transfusions itself (short term and/or long term). 
The only curative option in patients who progress to high-risk MDS or acute 
myeloid leukaemia (AML) is allogeneic stem cell transplantation. Retrospective 
studies showed that patients with high ferritin levels before transplantation 
had a higher transplantation-related risk of death compared to patients with 
a low-normal ferritin level.57, 58 Another retrospective analysis showed that the 
cumulative numbers of transfusions was an independent prognostic factor for 
survival in patients with alloSCT.59
The toxic effects of iron overload in other iron loading diseases, such as 
hereditary hemochromatosis33 and the thalassemia syndromes60, are well 
known. In long-term transfusion dependent thalassemia patients the organs 
prone to iron overload are the heart, liver and pancreatic islets. In patients with 
MDS the consequences of tissue iron overload remain to be elucidated. This 
is mainly due to the heterogeneous nature of the disease, but could also be 
attributed to shorter expected survival, considering an average age of 74 years 
and an increased incidence of co-morbidities17. Patients’ exposure may not be 
long enough to develop classical tissue damage due to iron overload, but they 
may suffer from oxidative stress caused by toxic iron species, including NTBI, 
LPI and oxidative stress, in combination with subsequent decrease in cellular 
antioxidants, may lead to oxidation of lipids, proteins and DNA causing cell 
and tissue damage.61, 62 Indeed, biomarkers of oxidative stress have been found 
to be increased in patients with MDS and iron overload.63-67 In iron loading 
anemias, such as thalassemia syndromes, NTBI and LPI have been suggested 
to serve as early indicators of iron toxicity.22, 49, 68   Moreover, iron toxicity might 
be restricted to specific subgroups of MDS patients: patients receiving red 
blood cell transfusions and a subgroup of patients with distinctive ineffective 
erythropoiesis like MDS-RS, but firm proof is lacking.17, 20, 21, 23 
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Determination of iron status
The general advice, according to expert opinion-based guidelines, is 
to determine patients’ iron status after 20-25 units of red blood cell 
transfusions.69-76 The current gold standard is to determine iron status by the 
measurement of serum ferritin, but this -as a marker of iron overload related 
toxicity- may be compromised by the stage of MDS, and its properties as an 
acute phase protein. Moreover, the level of ferritin does not indicate whether 
iron is stored in parenchymal cells or in the reticulo-endothelial system (RES), 
of which the former is considered to be a more toxic form of iron overload.77-79
However, TSAT, hepcidin, LPI and NTBI have not been systematically evaluated 
and are therefore not yet recommended in the current consensus guidelines 
on determining iron status.80
The gold standard to determine iron overload of the liver is a liver biopsy. 
However, this is an invasive procedure with serious bleeding risks, and very 
often not feasible due to thrombocytopenia or thrombocytopathy in MDS 
patients. Liver iron content measured in biopsy samples is directly related to 
liver iron content measured using MRI T2* which has been demonstrated to be 
a reliable method to determine iron overload in liver in a non-invasive way.81, 82
MRI T2* is the current gold standard and only non-invasive method to determine 
iron overload in the heart (CMR).83-89  Cardiac iron overload as measured by CMR 
is defi ned as a myocardial T2* echo time < 20ms in the interventricular septum 
of the heart. CMR T2* <10ms indicates a high risk of toxic heart failure that 
can rapidly spiral into death and is superior to liver iron and serum ferritin in 
assessing prognosis.85, 90 There is no signifi cant relationship between the serum 
ferritin level and the degree of iron overload in the heart.86, 91, 92
Treatment with iron chelation therapy
The Dutch expert opinion guidelines for therapy in MDS advise to start with 
iron chelation therapy in patients receiving regular transfusions and a serum 
ferritin level >2,000 mg/L, but only if the patients’ life expectancy based on 
IPSS-R is above 3 years.68, 80
In case of elevated serum ferritin but no regular transfusions the advice is 
to evaluate a patients’ ferritin status every 3-4 months. Adequate studies to 
support this advice are lacking. 
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In the Netherlands deferoxamine is the current preference for iron chelation 
therapy in patients with thalassemia, because of the extended experience.80 
The major disadvantage of deferoxamine is its parenteral administration. 
Deferasirox, an oral iron chelator with longer half-life compared to deferiprone 
and deferoxamine, has been on the market for around a decade. The efficacy of 
deferoxamine and deferasirox in patients with MDS has not been compared in 
prospective clinical trials.  
A large prospective multicentre, open-label phase 3 study in 341 patients with 
MDS shows that iron chelation therapy does not only decrease serum ferritin 
levels and NTBI, but may also improve haemoglobin levels, platelet counts and 
number of neutrophils.93 Patients received treatment with deferasirox over a 
year and stratified in a group with either responders or non-responders based 
on their ferritin levels. The group with responders showed an erythroid response 
in ~20% of the patients after ~100 days (11.3% a decrease in transfusion 
frequency and 8.8% a rise in haemoglobin level), a response of platelet counts 
in 13% after ~170 days (average response rate 168 days), and a response of 
neutrophil counts in 22% after ~230 days of treatment (average response rate 
154 days). Other prospective studies confirmed these results.68, 93-96 In LR-MDS 
patient studies on iron chelation therapy suggest to have a beneficial influence 
on overall survival, but available data from randomised controlled trials to 
confirm these findings are lacking.97, 98 
Dosage and side-effects of iron chelators according to The Dutch expert opinion 
guidelines 
The most relevant side-effects concerning treatment with deferoxamine 
and deferasirox are cytopenias, especially neutropenia, and impaired kidney 
function. Both complications can be a serious impediment to start iron 
chelation therapy in patients with MDS. Other frequent side-effects are nausea 
and diarrhoea, arthropathy, temporarily impaired liver function and zinc 
deficiency.96, 99, 100 
The initial daily dose of both deferoxamine and deferasirox is 20 mg/kg body 
weight, but it is recommended to start with a lower dosage of 10 mg/kg because 
of the described side-effects above. During the following months, the daily 
dose of deferoxamine can be augmented up to 20 to 30 mg/kg with a maximum 
of 50 mg/kg and for deferasirox to 30-40 mg/kg. Therapeutic effect (decrease 
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of serum ferritin) can be expected after 3-6 months.68 It is recommended to 
determine serum ferritin, kidney and liver function every month in the initial 
phase of treatment with iron chelation therapy. Once serum ferritin levels are 
responding, 3-monthly follow-up is advised. There is no available data about 
the need of ophthalmologic or audiologic checks.
The general advice is to adjust iron chelation therapy to the individual patient, 
especially to the frequency of receiving red blood cell transfusions and 
variability in co-morbidities.69-76
Outline and aims of the thesis 
In this thesis, we have studied patients with LR-MDS, with the aim to provide 
a better understanding of the pathophysiology and prognostic value of iron 
overload and iron mediated oxidative stress and to identify relevant markers in 
iron homeostasis over time. 
We anticipated that improved insights in levels and roles of key players of iron 
metabolism during treatment with transfusions in the various MDS subtypes 
may provide leads for novel diagnostic and iron reducing treatment strategies.
The majority of this work has been executed within the framework of the 
European LeukemiaNet MDS (EUMDS) registry.  The EUMDS registry was 
initiated in order to obtain a detailed and accurate prospective data set on LR- 
MDS patient diagnosis and disease-management in newly diagnosed patients 
in secondary and tertiary care centres across diff erent countries.
The primary objective of the EUMDS registry is to collect and describe 
demographics, clinical and lab manifestations, epidemiological data, genetic 
characteristics, quality of life by EQ-5D, disease-management (including 
transfusions), and treatment outcomes of MDS patients. Therefore, we 
describe in Chapter 2 the baseline characteristics (demographic, clinical 
and laboratory parameters) of the fi rst 1000 patients included in the EUMDS 
registry, the disease management of these patients, and we validated the 
prognostic discrimination of the International Prognostic Scoring System (IPSS) 
and recently Revised International Prognostic Scoring System (IPSS-R) in this 
prospective, observational registry.
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Chapter 3 comprises a cytomorphology review of 100 newly diagnosed LR-
MDS patients in the European LeukemiaNet MDS (EUMDS) Registry. This 
study was primarily aimed at validation and reproducibility of the WHO 2001 
criteria for MDS by an international panel, and at the validation of original 
cytomorphologic accuracy and correct diagnostic inclusion into the registry. 
The aims of the study were i) quality assessment of cytomorphologic diagnoses 
in the EUMDS registry and ii) assessment of inter-observer variability in the 
review panel regarding diagnosis and degree of dysplasia.
In Chapter 4 we investigated the prognostic impact of examining a suboptimal 
number of metaphases in 1,999 patients recruited to the EUMDS Registry with 
low and intermediate-1 risk according to IPSS.
The primary aim of the present study was to assess whether the number of MP 
examined in patients with normal karyotype provide any additional prognostic 
information about overall survival (OS) and progression-free survival (PFS) in 
patients with LR-MDS participating in the EUMDS registry. The secondary aim 
was to assess the impact of the number of analyzed metaphases on outcome 
in patients with an abnormal karyotype. To the best of our knowledge, this is 
the first prospective study in this field. We hypothesized that a higher number 
of analyzed nMP does have a positive impact on survival in patients with lower-
risk MDS.
Chapter 5 describes the second international round robin for the quantification 
of serum NTBI and LPI in patients with iron overload disorders. 
The possibility of using NTBI and LPI measures as clinical indicators of overt 
iron overload and/or of treatment efficacy would largely depend on the 
rigorous validation and standardization of available assays. We compared ten 
worldwide leading assays (6 for NTBI and 4 for LPI) as part of an international 
interlaboratory study. The aims of our study were to define the clinical utility 
of the various NTBI and LPI levels measured by assays in four different groups 
of iron overloaded patients (those with HFE-hereditary hemochromatosis, 
ß-thalassemia, MDS, and sickle cell disease) undergoing various treatments 
(phlebotomy, iron chelation, red blood cell transfusion). More specifically, in 
these populations of patients, we aimed to: (i) establish correlations between 
assays (ii) establish levels of reproducibility of each of the assays (iii) assess 
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levels of the NTBI fraction consisting of iron citrate, and (iv) correlate assays with 
other established parameters of iron overload (e.g. TSAT and serum ferritin).
In Chapter 6 we analyzed serum samples from 100 lower-risk patients with MDS 
included in the EUMDS registry at six-month intervals for TSAT, hepcidin-25, 
GDF15, sTfR, NTBI and LPI in order to evaluate temporal changes in iron 
metabolism and presence of potentially toxic iron species and their impact on 
survival. Serum samples were collected prospectively, at registration and at 
6-month intervals, from 109 patients from six countries who participated in this 
study from April 2008 to December 2010. The total number of analyzed serum 
samples was 454. We hypothesized that patients develop oxidant mediated 
tissue injury through the formation of toxic iron species, caused either by red 
blood cell transfusions or by ineff ective erythropoiesis. 
Chapter 7 focusses on the impact of red blood cell transfusion intensity 
on progression-free survival in >2000 LR-MDS patients included from 
16 European countries and Israel newly diagnosed since December 2007 in the 
EUMDS registry. MDS patients are generally older than patients with other iron 
loading disorders. Therefore, their exposure to RBCT may not be long enough 
to develop classical tissue damage due to iron overload, but they may suff er 
from oxidative stress. The aim of this analysis is to assess the eff ect of RBCT rate 
on progression-free survival (PFS) of patients with LR-MDS. The hypothesis is 
that transfusional iron is toxic and associated with oxidative stress which may 
lead to BM failure, genetic imbalance and increased risk for progression. Two 
countervailing forces play a role in this analysis: fi rstly, patients are receiving 
transfusions because they are becoming anemic. Secondly, patients that are 
more ill are more likely to receive RBCT and the more likely they are to receive 
more frequently transfusions. In addition, deterioration of the disease itself 
may lead to a higher RBCT need and to a higher risk of progression.
Finally, Chapter 8 provides a summary, general discussion and future 
perspectives for research in this fascinating patient population.
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Table 1 FAB classification Myelodysplastic syndromes
Category Dysplasia % BM blasts % PB blasts
Refractory anemia (RA) Erythroid <5 <1
Refractory anemia with ring sideroblasts (RARS) Erythroid <5 <1
Refractory anemia with excess blasts (RAEB) 2 or more lineages 5–20 0–4
Refractory anemia with excess blasts in 
transformation (RAEB-T)
Usually 2 or more 
lineages
21–30 ≥5
Chronic myelomonocytic leukemia (CMML) Variable ≥1 × 109/L 
monocytes
<20
Table 2 WHO 2001/2008 classification
Disease entity Blood findings Bone marrow findings
Refractory cytopenias with 
unilineage dysplasia (RCUD): 
refractory anemia (RA), refractory 
neutropenia (RN), refractory 
thrombocytopenia (RT)
Unicytopenia or 
bicytopeniaa 
No or rare blasts 
(<1%)b
Unilineage dysplasia: ≥10% of the cells in 
one myeloid lineage 
<5% blasts 
15% of erythroid precursors are ring 
sideroblasts
Refractory anemia with ring 
sideroblasts (RARS)
Anemia 
No blasts
≥15% of the erythroid precursors are ring 
sideroblasts 
Dyserythropoiesis only 
<5% blasts
Refractory anemia with 
multilineage dysplasia (RCMD)
Cytopenia(s), no or 
rare blastsb 
No Auer rods 
<1 × 109/L 
monocytes
Dysplasia in >10% of cells in 2 or more 
lineages 
<5% blasts in marrow 
No Auer rods 
<1 × 109/L monocytes
Refractory anemia with excess 
blasts-1 (RAEB-1)
Cytopenia(s) 
<5% blasts 
No Auer rods 
<1 × 109/L 
monocytes
Unilineage or multilineage dysplasia 
5–9% blasts 
No Auer rods
Refractory anemia with excess 
blasts-2 (RAEB-2)
Cytopenia(s) 
5–19% blasts 
Auer rods ±c 
<1 × 109/L 
monocytes
Unilineage or multilineage dysplasia 
0–19% blasts 
Auer rods ±c
MDS, unclassifiable (MDS-U) Cytopenias 
<1% blastsb
Unequivocal dysplasia in less than 10% 
of cells in one or more myeloid lines 
when accompanied by a cytogenetic 
abnormality considered as presumptive 
evidence for a diagnosis of MDS 
<5% blasts
MDS associated with isolated 
del(5q)
Anemia 
Usually normal to 
elevated platelets 
No or rare blasts
Normal to increased megakaryocytes 
with hypolobated nuclei 
<5% blasts del(5q) is the sole cytogenetic 
abnormality 
No Auer rods
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Table 3 WHO 2016 classifi cation Myelodysplastic syndromes revision
Lower Risk: <5% Blasts Higher Risk: 5%-19% Blasts
Myelodysplastic syndrome (MDS) with single-
lineage dysplasia
MDS-Excess Blasts (EB) 1: 5%-9% blasts and/or 
2%-4% in peripheral blood smear
MDS with single-lineage dysplasia and ring 
sideroblasts (RSs)
MDS-EB2: 10%-19% blasts; auer rods or 5%-19% 
in peripheral blood smear
MDS with multilineage dysplasia
 Without RS
 With RS
MDS with isolated del(5q) Now includes most cases previously classifi ed as 
acute erythroid leukemia
MDS unclassifi able (MDS-U)
Table 4 IPSS for MDS
Prognostic Variable Score Value
0 0.5 1.0 1.5 2.0
BM blasts (%) <5 5-10 — 11-20 21-30
Karyotype* Good Intermediate Poor
Cytopenias 0/1 2/3
Scores for risk groups are as follows: Low, 0; INT-1, 0.5-1.0; INT-2, 1.5-2.0; and High, ≥2.5.
* Good, normal, −Y, del(5q), del(20q); Poor, complex (≥3 abnormalities) or chromosome 7 anomalies; 
Intermediate, other abnormalities.
Table 5 IPSS-R prognostic score values
Prognostic variable 0 0.5 1 1.5 2 3 4
Cytogenetics Very good — Good — Intermediate Poor Very poor
BM blast, % ≤ 2 — > 2%- < 5% — 5%-10% > 10% —
Hemoglobin ≥ 10 — 8- < 10 < 8 — — —
Platelets ≥ 100 50-< 100 < 50 — — — —
ANC ≥ 0.8 < 0.8 — — — — —
— indicates not applicable.
IPSS-R prognostic risk categories/scores
Risk category Risk score
Very low ≤ 1.5
Low > 1.5-3
Intermediate > 3-4.5
High > 4.5-6
Very high > 6
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Summary 
Baseline characteristics, disease-management and outcome of 1000 lower-risk 
MDS patients within the European LeukemiaNet MDS (EUMDS) Registry are 
described in conjunction with the validation of the IPSS-R. The EUMDS registry 
confi rmed established prognostic factors like age, gender, and WHO 2001 
classifi cation. Low quality of life (EQ-5D VAS score) was signifi cantly associated 
with reduced survival. A high co-morbidity index predicted poor outcome in 
univariate analyses. The IPSS-R identifi ed a large group of 247 patients with Low 
(43%) and Very Low (23%) risk score within the IPSS intermediate-1 patients. 
The IPSS-R also identifi ed 32 High or Very High risk patients within the IPSS 
intermediate-1 patients. IPSS-R was superior to the IPSS for predicting both 
disease progression and survival. Seventy percent of patients received MDS-
specifi c treatment or supportive care, including red blood cell transfusions 
(51%), haematopoietic growth factors (58%) and iron chelation therapy (8%), 
within 2 years of diagnosis; while 30% of the patients only required active 
monitoring. The IPSS-R proved its utility as a more refi ned risk stratifi cation tool 
for the identifi cation of patients with a very good prognosis and patients with 
poor prognosis in this lower-risk MDS population.
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Introduction
Myelodysplastic syndromes (MDS) are a heterogeneous group of clonal 
haematopoietic stem cell malignancies characterized by a defect in 
haematopoietic cell maturation and/or differentiation, with an inherent 
potential for acute leukemic transformation. Establishing the diagnosis of 
MDS requires exclusion of alternative causes for cytopenias coupled with 
characteristic bone marrow morphological abnormalities and cytogenetic 
data. Recently, the most widely used prognostic scoring system (IPSS) has been 
revised (IPSS-R) by the International Working Group for the Prognosis of MDS.
(Greenberg et al., 1997),(Greenberg et al., 2012; Schanz et al., 2012) Emerging 
data from immunophenotyping and molecular diagnostics in MDS will have 
an impact on the classification and prognostication in the near future. (van de 
Loosdrecht et al., 2013) (Bejar et al., 2011)
MDS registries have been established to provide better insight into the clinical 
outcome and to be able to study new treatment strategies. Since many registries 
have been initiated by tertiary referral centres they often reflect a selected 
study population of relatively young patients with more advanced MDS who 
are candidates for participation in clinical trials or stem cell transplantation. 
This is in contrast to the majority of MDS patients who have either IPSS low 
or intermediate-1 risk (71%)(Greenberg et al., 1997). These patients are 
generally managed in community hospitals with treatment mainly consisting 
of supportive care, including red blood cell transfusions and hematopoietic 
growth factors. Therefore, the European LeukemiaNet MDS (EUMDS) registry 
was initiated in order to obtain a detailed and accurate prospective dataset 
on lower-risk MDS patient diagnosis and disease-management in newly 
diagnosed patients across different countries from both secondary and tertiary 
care centres. Importantly, the data collected includes patient-specific (medical 
history, concomitant medications, performance status, quality of life) and 
disease-specific (WHO 2001 classification, IPSS and IPSS-R) data, the former 
having a potentially greater influence on outcome in an elderly lower-risk MDS 
population than in high-risk MDS.(Kuendgen et al., 2006; Nosslinger et al., 2010) 
The aims of the current analysis were 1) to describe the baseline characteristics 
(demographic, clinical and laboratory parameters) of the first 1000 patients, 2) 
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to describe the disease management of these patients and 3) to validate the 
prognostic discrimination of the IPSS and IPSS-R in a prospective, observational 
registry.   
Design and Methods
Patients were eligible to be included if they were newly diagnosed with MDS 
according to the WHO 2001 classifi cation(Bennett, 2000) and had a low or 
intermediate-1 risk score according to the IPSS.(Greenberg et al., 1997)  To ensure 
that patients were newly diagnosed they had to be enrolled within 100 days 
from the date of the diagnostic bone marrow aspirate. Patients were required 
to provide written informed consent. Patients with IPSS intermediate-2, high-
risk MDS, or with secondary or therapy-related MDS were excluded from this 
registry. The ethics committees of all participating countries and centres have 
approved the EUMDS registry (trial number NCT00600860).
The fi rst 1000 patients in the registry were diagnosed with MDS between 
December 2007 and December 2010. The median follow-up was 2.4 years 
(range: 0-4.9 years) for the surviving patients. Baseline data were entered via 
a bespoke web-based interface linked to a centralized database. Information 
was collected on: demographics, anthropometric measures, concurrent 
and antecedent co-morbidities, performance status, quality of life (EQ-5D) 
(Herdman et al., 2011), concomitant medication, laboratory parameters, 
diagnostics including information on bone marrow morphology, histology and 
cytogenetics. Given that cytogenetic analysis was not always locally available 
or successful, patients were nevertheless considered eligible for the registry 
providing that the morphological criteria for MDS in the bone marrow were 
present, the percentage of blasts in the bone marrow was <5% and having 
none or a single cytopenia according to the IPSS. The IPSS cytogenetic score 
and the IPSS-R cytogenetic score were both determined (where possible) from 
the diagnostic cytogenetic reports. The local investigator assigned the IPSS 
cytogenetic scores. The IPSS-R cytogenetic scores were retrospectively assigned 
by one of the investigators of the EUMDS registry and verifi ed by an independent 
expert of the international IPSS working group of the MDS Foundation (D. 
Haase). Overall IPSS and IPSS-R scores were automatically calculated. Patient-
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specific, intervention and outcome data were collected at baseline and at each 
6-monthly follow-up visit when patients visit the outpatient clinic for routine 
clinical care of their MDS. Red blood cell transfusion episodes and total number 
of transfused units were collected for each follow-up interval. All subjects were 
prospectively followed until death, progression to high risk MDS or leukaemia, 
loss to follow-up or withdrawal of informed consent.
Statistical analysis
Standard descriptive techniques were used to assess the distribution of 
baseline patient characteristics including chi-squared test and Wilcoxon rank 
sum test. Overall survival (OS) was defined as the time from date of diagnosis 
to death, or for subjects still alive to the date of the last follow-up visit. Time 
to disease progression (DP) was measured from date of diagnosis to date of 
disease-progression to either high risk MDS or acute leukaemia. Patients 
without disease-progression were censored at date of death or date of last 
follow-up visit. Standard methods were used to assess time to event, namely 
Cox proportional hazards regression models and Kaplan-Meier survival curves. 
Hazard ratios (HR) and 95% confidence intervals (95% CI) are reported for 
univariate analyses, unadjusted and adjusted for sex and age at diagnosis. The 
discriminatory ability of IPSS and IPSS-R in predicting OS and DP was assessed 
using the Akaike information criterion (AIC) (Akaike, 1974) - with the lowest 
AIC value indicating a more explanatory and informative model -   and Harrell’s 
concordance index, ranging from 0.5 (no discrimination for predicting OS/DP) 
to 1.0 (perfect discrimination). (Harrell et al., 1996) All analyses were undertaken 
in Stata 12 (StataCorp, College Station, TX).
Results
Patient characteristics at registration
The first 1000 patients in the EUMDS registry were included from 14 countries 
and 118 participating centres, including general hospitals and referral centres. 
Today, 131 centres in 17 countries are participating in the Registry. The average 
time from date of diagnosis to inclusion was 43 days (s.d. 28 days). Overall, 
a male predominance of 60% was observed across all diagnostic categories 
with the exception of 5q-Syndrome where 80% of the patients were female. 
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The majority of the patients (93%) were of European descent. Median age at 
diagnosis was 75 years (range: 19-95). Refractory cytopenia with multilineage 
dysplasia (RCMD) was the most common diagnosis (35%) and refractory 
anaemia with excess blast (RAEB-2) the least common (0.4%). The four patients 
diagnosed with RAEB-2 had exactly 10% blasts in their bone marrow and 
were thus eligible for inclusion (IPSS intermediate-1) (table 1). Table 1 and 
supplementary table 1 also describe the impact of the general patient features 
on overall survival (until maximum potential follow-up).
At time of diagnosis the most common comorbidity was hypertension 
(45%), followed by diabetes mellitus (18%), arrhythmia (16%) and thyroid 
disease (11%). In concordance, the most frequently prescribed concomitant 
medications were anti-hypertensives (44%), proton pump inhibitors (21%), 
cholesterol lowering drugs (20%) and anti-diabetic drugs (17%). Other relevant 
concomitant medication is presented in supplementary table 2. 
The MDS-specifi c comorbidity index (MDS-CI) was calculated (Della Porta et al., 
2011) (n=1000): 64% of patients were assigned to the low risk category and 
diff erences were seen by country (p = 0.005) with Portugal, Germany and Czech 
Republic having the highest proportion of low MDS-CI risk patients. Eighty-six 
percent of patients completed an EQ-5D questionnaire at time of registration 
and no diff erences by completion rate were observed by age or sex. The median 
patient-reported quality of life at registration, measured by the visual analogue 
scale (EQ-5D VAS), was 70 (range 4-100). Variation occurred by country ranging 
from a mean of 51 in Poland to 78 in Romania. For every point decrease in EQ-
5D VAS score, there was a 1% reduction in survival (HR 0.99, 95%CI: 0.99-1.00). 
The performance status as reported by health care professionals was recorded 
by the Karnofsky score (n=889). 
The median baseline blood count values and additional laboratory results are 
presented in supplementary table 3. 
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Table 1 Baseline Patient Characteristics and Overall Survival 
Total
N (%)
Status N (%) HR (95%CI) 1 Adjusted HR 
(95%CI)1Alive Dead
Total 1000 (100) 694 306
Sex:
Males 602 (60.2) 402 (57.8) 200 (65.4) 1 1
Females 398 (39.8) 292 (42.1) 106 (34.6) 0.76 (0.60-0.97) 0.77 (0.61-0.97)
Age at Diagnosis (Years):
Median (range) 74.6 (18.7-95.3) 73.9 (18.7-94.7) 76.1 (46.8-95.3) 1.04 (1.03-1.05) 1.03 (1.02-1.05)
<60 111 (11.1) 91 (13.1) 20 (6.5) 1 1
60-74 407 (40.7) 288 (41.5) 119 (38.9) 1.77 (1.10-2.84) 1.74 (1.08-2.79)
75+ 482 (48.2) 315 (45.4) 167 (54.6) 2.58 (1.62-4.11) 2.56 (1.60-4.07)
Diagnosis (WHO 2001)2:
RA 179 (17.9) 134 (19.3) 45 (14.7) 1 1
RARS 183 (18.3) 134 (19.3) 49 (16.0) 0.94 (0.63-1.41) 0.90 (0.60-1.35)
RCMD 354 (35.4) 237 (34.1) 117 (38.2) 1.39 (0.98-1.95) 1.47 (1.04-2.07)
RCMD-RS 73 (7.3) 55 (7.9) 18 (6.0) 0.87 (0.50-1.50) 0.85 (0.49-1.47)
RAEB-I 115 (11.5) 66 (9.5) 49 (16.0) 2.24 (1.49-3.36) 2.38 (1.59-3.58)
RAEB-II 4 (0.4) 0 (0.0) 4 (1.3) 10.08 (3.59-28.26) 12.15 (4.32-34.12)
MDS-U 30 (3.0) 21 (3.0) 9 (2.9) 1.38 (0.68-2.83) 1.55 (0.76-3.18)
5q-Syndrome 62 (6.2) 47 (6.8) 15 (4.9) 0.76 (0.43-1.37) 0.84 (0.46-1.52)
MDS-CI Risk3:
Low 642 (64.2) 459 (66.7) 183 (59.8) 1 1
Intermediate 303 (30.3) 205 (29.5) 98 (32.0) 1.12 (0.88-1.44) 0.94 (0.73-1.21)
High 55 (5.5) 30 (4.3) 25 (8.2) 1.68 (1.10-2.55) 1.24 (0.81-1.90)
EQ-5D VAS4: 843 (84.3)
Median (range) 70 (4-100) 75 (4-100) 70 (14-100) 0.99 (0.98-99) 0.99 (0.99-1.00)
Karnofsky Status:
80-100 699 (69.9) 506 (72.9) 193 (63.1) 1 1
50-70 176 (17.6) 97 (14.0) 79 (25.8) 2.25 (0.93-5.49) 2.20 (0.90-5.40)
≤40 14 (1.4) 9 (1.3) 5 (1.6) 2.01 (1.55-2.61) 1.78 (1.36-2.33)
Unknown 111 (11.1) 82 (11.8) 29 (9.5) 1.29 (0.87-1.90) 1.15 (0.77-1.71)
Serum Ferritin (µg/l)5:
≤300 360 (36.0) 270 (38.9) 90 (29.4) 1 1
300-1000 306 (30.6) 206 (29.7) 100 (32.7) 1.31 (0.98-1.74) 1.29 (0.97-1.72)
≥1000 71 (7.1) 29 (4.2) 42 (13.7) 3.13 (2.17-4.52) 3.17 (2.18-4.60)
Unknown 263 (26.3) 189 (27.2) 74 (24.2) 1.30 (0.96-1.77) 1.21 (0.89-1.65)
Erythropoietin (I/U)6:
<100 368 (36.8) 264 (38.0) 104 (34.0) 1 1
100-500 134 (13.4) 78 (11.2) 56 (18.3) 1.61 (1.16-2.22) 1.49 (1.07-2.08)
>500 45 (4.5) 25 (3.6) 20 (6.5) 2.15 (1.33-3.48) 1.35 (0.80-2.25)
Unknown 453 (45.3) 327 (47.1) 126 (41.2) 1.09 (0.84-1.41) 1.09 (0.84-1.42)
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1 Hazard Ratios (HR) & 95% Confi dence Intervals (CI) adjusted for age at diagnosis and sex, indicating 
survival until maximum potential follow-up (2.4-5.4 years) 2Refractory anaemia (RA), Refractory 
anaemia with ringed sideroblasts (RARS), Refractory cytopenia with multilineage dysplasia (RCMD), 
Refractory cytopenia with multilineage dysplasia & ringed sideroblasts (RARS), Refractory anaemia with 
excess blasts-1 (RAEB-I), Refractory anaemia with excess blasts-2 (RAEB-II), Myelodysplastic syndrome, 
unclassifi able  (MDS-U), 5q-Syndrome 3Myelodysplastic syndrome-specifi c comorbidity index (MDS-CI), 
4Visual analogue scale (VAS), 5Hazard Ratios (HR) & 95% Confi dence Intervals (CI) adjusted for age at 
diagnosis, sex and WHO 2001 diagnosis, 6Hazard Ratios (HR) & 95% Confi dence Intervals (CI) adjusted 
for age at diagnosis, sex and haemoglobin at diagnosis
Prognostic Scoring Systems: baseline characteristics
The IPSS risk score was low (0 points) in 49% and intermediate-1 in 45% (0.5 
points: 32%, 1.0 point: 13%) of the patients. IPSS score could not be calculated 
in 6% of patients where cytogenetic testing was not available or failed. IPSS 
karyotypes were classifi ed as good in 77%, intermediate in 15% and poor in 1%. 
Since the recently published revised IPSS (IPSS-R) became available at the time of 
this analysis, we also analysed the impact of the IPSS-R on prognosis compared 
to the original IPSS. The IPSS-R risk score in 903 patients with all data available 
was very low in 29%, low in 50%, intermediate in 17%, high/very high in 4% of 
the patients (table 2). IPSS-R was unavailable in 10% of the patients because 
of incomplete data; cytogenetics (8%), platelets (0.5%) or absolute neutrophil 
count (1.2%). All four patients with RAEB-2 had either a high or very high risk 
score. The number of patients with an intermediate risk score was highest in 
RAEB-1 (38%) and RCMD (36%). Most patients with a low risk score had either 
RCMD (36%) or RA (21%). IPSS-R score was very low in 37% of the patients with 
RCMD, 25% with RARS and 21% with RA (supplementary fi gure 1). 
In terms of IPSS-R cytogenetic groups, age was associated with the cytogenetic 
risk groups, with a higher proportion of patients over the age of 75 being 
classifi ed to a very good risk group and fewer to an intermediate group (P = 
0.034; supplementary table 4). The IPSS-R identifi ed a group of patients with an 
IPSS-R good or very good karyotype within the IPSS Intermediate cytogenetic 
group (31%; supplementary table 5) caused by the incorporation of the –Y and 
del(11q) in the IPSS-R very good cytogenetic group and the del(12p) and two 
cytogenetic abnormalities including del(5q) in the IPSS-R good cytogenetic 
category.
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Figure 1 Reclassification of two IPSS subgroups: low risk and intermediate-1 risk into five IPSS-R 
subgroups
In red the IPSS-R subgroups originating of IPSS low score, in blue the IPSS-R subgroups originating of 
IPSS intermediate-1 score. This analysis is restricted to 887 patients with full data available to subdivide 
the patients according to both IPSS and IPSS-R.
Importantly, the IPSS-R identified a large group of 247 patients with low (42%) 
and very low (23%) risk score within the IPSS intermediate-1 patients (figure 
1). The IPSS-R also identified a total of 32 high- or very high-risk patients (5%), 
within the IPSS low and intermediate-1 risk scores (figure 1). When the IPSS 
intermediate-1 risk score was divided into a 0.5 and 1.0 risk score most patients 
with a 0.5 score (52%) had an IPSS-R low risk and most patients with a 1.0 score 
(48%) had an IPSS-R intermediate score (supplementary table 6).  
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Disease-management
The majority of patients had received MDS-specifi c treatment or supportive 
care (70%), but 30% of the patients did not require any disease specifi c 
therapeutic interventions. Fifty one percent of patients (n=508) had received 
red blood cell transfusions including 197 patients who received transfusions 
prior to the diagnosis of MDS (table 3). For those patients who were 
transfusion independent at diagnosis, the mean interval between diagnosis 
and the fi rst transfusion was 249 days. The percentage of transfused patients 
remained constant at each 6-monthly follow-up point after diagnosis at 
around 30%, presumably infl uenced by response to MDS-specifi c treatments 
like erythropoiesis-stimulating agents (ESAs) or lenalidomide, and by early 
mortality in the transfused patients, as 54% of the patients with transfusions at 
registration had died at two years follow-up.
ESAs were the most common MDS-specifi c treatment modality, increasing 
from 16% of patients at diagnosis to 32% at two years of follow-up. Serum 
erythropoietin (EPO) was <100 U/l in 67% (n=368) of the patients at diagnosis, 
100-500 U/l in 25% (n=134; HR 1.43, 95%CI 1.02-2.02) and >500 U/l in 8% (n=45; 
HR 1.13, 95%CI: 0.65-1.99), respectively. Hazard ratios for serum EPO levels were 
adjusted for age, sex and additionally haemoglobin levels at diagnosis in view 
of the signifi cant association between haemoglobin levels and serum EPO 
levels (rs= -0.444, p=<0.000, n=547). Within the fi rst two years of follow-up 8% 
of patients had received iron chelation therapy. As expected this proportion 
increased with longer duration of follow-up. Other MDS-specifi c treatment 
modalities are presented in table 3. The proportion of patients transfused 
varied across countries with Greece and France having the lowest rate, and the 
highest proportion observed in Denmark. The pre-transfusion Hb level was the 
highest in patients from Denmark and Sweden (mean 9 g/dl) and the lowest 
in patients from Romania (7.4), Greece (7.8) and France (7.8). Major diff erences 
were observed by country in the proportion of patients treated with ESA, with 
around 60% of patients in Portugal, Greece and Denmark being treated with 
ESA within 2-years from diagnosis. In contrast, only 30% of UK patients had 
received ESA (supplementary table 7). 
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Outcome
Overall survival (OS) was 69% with a follow-up ranging from 0 to 4.9 years. 
Thirteen per cent of the patients had progressed to higher-risk MDS or Acute 
Myeloid Leukaemia (AML). OS at 2 years was 81% and for 10% of the patients their 
disease had progressed. Median time from date of inclusion until progression 
to higher-risk MDS or AML was 370 days (range 34-1675). Forty-three percent 
(n=131) of the 306 recorded deaths were reported by the investigator to be 
related to the patient’s MDS, with the main known causes of death being 
attributed to infections (20%), AML (17%), and cardiovascular events (10%). 
Overall survival in patients classifi ed as IPSS low and intermediate-1 was 77%, 
and 62% respectively. The separate components of the IPSS score (percentage 
of blasts, karyotype and number of cytopenias) all showed good prognostic 
discrimination in the study population (fi gure 2A, 3AB). 
Overall survival in patients according to the IPSS-R was 80% in the very low 
risk group, 74% in the low risk group, 46% in the intermediate risk group and 
37% in the high/very high risk group (Fig 2B). When adjusting the IPSS-R for age 
(Greenberg et al., 2012) the percentage of patients with an intermediate (25%) 
and high/very high (7%) risk score increased and the percentage of patients 
with a very low (23%) or low (45%) risk score decreased compared to the 
unadjusted IPSS-R groups. Three of the individual components of the IPSS-R 
(Hb level, absolute neutrophil count, platelet level) showed signifi cant 
prognostic discrimination in our study population across all categories in both 
unadjusted and adjusted proportional hazard analysis for age and sex. 
Percentage of bone marrow blasts did not show prognostic discrimination 
<2% compared to >2-<5%. No diff erences in OS were apparent between the 
IPSS-R good cytogenetic and IPSS-R very good cytogenetic group in either 
analysis (fi gure 2B, 3CD). 
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Figure 2A,B Forest plots for overall survival. 2A Hazard ratios (95% CI) for IPSS Score and Components, 
2B Hazard Ratios (95% CI) for IPSS-R Score and Components
To test the prognostic discrimination of the IPSS and IPSS-R in predicting 
clinical outcome the Akaike information criteria (AIC) and Harrell’s c-index 
were estimated for overall survival (OS) and disease progression (DP). Both 
IPSS (AIC 3211.14, c-index 0.5825) and IPSS-R (AIC 3164.45, c-index 0.6323) 
were predictive of overall survival with IPPS-R having more explanatory power 
(table 2). The IPSS scores (0, 0.5 and 1.0) improved the fi t of the IPSS model 
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(AIC OS 3202.95, c-index 0.5953) compared to the two IPSS risk groups, The AIC 
indicated that the age adjusted IPSS-R (AIC OS 3161.17, c-index 0.6545) provided 
the best fit to the survival data and the IPSS-R to the disease progression data 
(AIC 1279.74, c-index 0.7235). The predictive ability of both the IPSS and IPSS-R 
indices was marginally greater when considering disease progression as the 
outcome (table 2). 
Figure 3 Kaplan-Meier curves for overall survival of patients in the EUMDS registry subdivided according 
to A: IPSS Low/Intermediate-1 risk, B: IPSS 0, 0.5,1 points, C: IPSS-R risk groups, and D: IPSS-R risk groups 
adjusted for age
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Discussion
The EUMDS registry is to the best of our knowledge the first international 
prospective, observational registry for newly diagnosed IPSS low- and 
intermediate-1 risk MDS patients. Validation of the IPSS-R proved its utility as a 
more refined risk stratification tool by identifying a group of patients with a high/
very high IPSS-R risk score (5%) within the IPSS low and intermediate-1 groups 
and a large group of low or very low risk patients in the IPSS intermediate-1 group.
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Several European countries have well-established national MDS registries 
(Aul et al., 1998; Phekoo et al., 2006; Germing et al., 2008; Rollison et al., 
2008; Goldberg et al., 2010; Kelaidi et al., 2010; Sekeres, 2010; Smith et al., 
2010; Sekeres, 2011; Ma, 2012; Visser et al., 2012) and these existing national 
infrastructures have been advantageous in establishing the EUMDS registry. 
Published data on demographics and disease-management of MDS are in 
general based on retrospective analyses and often focused on new treatment 
strategies. (Aul et al., 1992; Park et al., 2008; Rollison et al., 2008) Diagnosis of 
MDS in an early stage continues to be a challenge, since many patients are 
not entered into the existing registries until they are referred to a tertiary care 
centre after they have developed need for supportive care or MDS specifi c 
treatment. MDS is predominantly a disease of elderly patients who are usually 
not very keen on participating in clinical studies due to impaired mobility 
or to other co-morbidities. (Stauder, 2012) Therefore, the EUMDS registry 
has been restricted to lower risk MDS patients from both general hospitals 
and referral centres, diagnosed after a confi rmed diagnostic bone marrow 
aspirate or biopsy. Population-based datasets usually experience diffi  culties in 
acquiring a complete dataset, including the diagnostic confi rmation of MDS 
in bone marrow. (Goldberg et al., 2010; Herdman et al., 2011) The currently 
recommended classifi cation system for MDS diagnosis is the WHO 2008 
classifi cation (Vardiman et al., 2009).
Both female gender and young age of the patients in the EU-MDS Registry 
were associated with better survival, as expected. Since the EUMDS Registry 
was established in 2006 when the IPSS was the standard prognostic system, 
inclusion criteria will continue to be based on the IPSS. The WHO 2001 
classifi cation showed clear risk stratifi cation in the EUMDS registry ranging 
from good prognosis in patients with RA and poor prognosis in subtype RAEB-
1. To confi rm the accuracy of MDS classifi cation in the various subtypes a 
cytomorphology review of 100 randomly chosen patients has been performed. 
The outcome of that review will be described in a separate report. 
In order to avert worsening of anaemia and improve quality of life, the majority 
of patients started to receive supportive care with red blood cell transfusions 
within the fi rst 2 years after diagnosis. ESA’s were fi rst choice of MDS specifi c 
treatment in all countries, but the percentage of patients treated with ESA 
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varied considerably between various countries mainly due to different national 
and institutional reimbursement policies. (Stauder, 2012; Fenaux et al., 2013; 
Malcovati et al., 2013) The ESA treatment response score (Hellstrom-Lindberg 
et al., 2003) has previously demonstrated that patients with higher serum EPO 
levels had a lower response to ESA treatment. High EPO levels did not influence 
outcome independently due to the high correlation with low haemoglobin 
levels. More information on outcome after MDS specific interventions will be 
provided in ongoing elaborated analyses addressing time dependent variables.
Quality of life (QoL) as measured by the EQ-5D VAS score was significantly 
associated with reduced survival. Several factors may play a role, including 
age, co-morbidity index and level of anaemia, but QoL remained a negative 
prognostic factor after adjustment for age and gender. A high co-morbidity 
index predicted poor outcome in univariate analysis, but the impact was not 
significant after adjustment for age and gender.
Accurate risk stratification using reliable prognostic scoring systems is important 
to predict patient outcome and is a valuable tool for clinical decision-making. 
The IPSS has been revised (IPSS-R) using data from 7,012 MDS patients from 
the IWG-PM database with a median age of 71 and classified by the French-
American-British (FAB) classification of MDS. (Bennett et al., 1982; Greenberg 
et al., 2012) One of the aims of our study was to determine the significance of 
the IPSS-R prospectively in a generally older (median age 75) lower risk MDS 
population. Using IPSS-R we were able to distinguish four different prognostic 
risk groups, including a combined group of high and very high risk patients, 
compared to two risk groups in the IPSS. The IPSS-R identified a large group 
of patients with Low (43%) and Very Low (14%) risk score within the IPSS 
intermediate-1 patients. The IPSS-R also revealed the poor prognosis in a total 
of 35 High or Very High risk patients within the IPSS Low and Intermediate-1 
risk scores. Specific early intervention with hypomethylating agents, intensive 
chemotherapy or allogeneic stem cell transplantation might be considered 
in these patients. Three of the components of the IPSS-R (Hb level, absolute 
neutrophil count, platelet level) showed significant prognostic discrimination 
in our study population. However, the IPSS-R also showed some limitations 
as there appeared to be little discrimination in terms of OS between the very 
good and good cytogenetic groups and between patients with <2% or 2-<5% 
bone marrow blasts. Further refinement of the IPSS-R might be achieved by 
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introducing transfusion-dependency, transfusion load/transfusion intensity and/or 
serum ferritin levels. At diagnosis 14% (n=74) of the patients with Hb ≥10 g/dL already 
received red blood cell transfusions, 42% (n=150) of the patients with Hb between 
8-<10 g/dL and 55% (n=63) of the patients with Hb <8 g/dL. The percentage of patients 
receiving red blood cell transfusions did not change markedly with time, possibly 
explained by premature death of patients receiving transfusions. (Cazzola et al., 2005) 
Patients with serum ferritin levels >1000 µg/l at diagnosis had a three times poorer 
survival after adjusting for age, sex and WHO 2001 diagnosis. Ferritin levels appeared 
only prognostic in transfusion-dependent patients (data not shown).
The patterns of the HR estimates associated with the IPSS and IPSS-R categories were 
as might be expected, but these estimates have just been adjusted for age and sex of 
the patient and may be confounded by other factors such as MDS treatments received 
by the patients. The assessment of these interventions will be the subject of future 
reports.
The IPSS and IPSS-R were both good prognostic tools for predicting survival outcome 
with a slightly higher impact of the IPSS-R. Both scoring systems appear to be more 
capable of predicting the risk of disease progression than of overall survival, within 
the limitations of a relatively short follow-up. Voso et al. validated the IPSS-R in a 
retrospective analysis including 380 MDS patients from the Italian GROM registry 
classifi ed with FAB (up to 20% blasts), WHO 2001/2008 and a median age of 71 years. 
They assessed the prognostic value of the IPSS, WPSS and IPSS-R using the likelihood 
ratio test and confi rmed that all scoring systems were more strongly associated with 
leukaemia free survival compared to overall survival. (Voso et al., 2013) These fi ndings 
were also confi rmed in a study by Neukirchen et al. (Neukirchen et al., 2014) who 
validated the IPSS-R in 1314 patients from the Düsseldorf MDS Registry and in a study 
by van Spronsen et al.(van Spronsen et al., 2014) who demonstrated the prognostic 
value of the IPSS-R for OS in 222 MDS patients from their tertiary referral center. This 
may refl ect the eff ect of competing causes of death as a consequence of the high 
average age at diagnosis of MDS. Thus, OS and DP might not be the most appropriate 
end-points in this elderly population. (Wildiers et al., 2013; Hamaker et al., 2014) Several 
other groups have evaluated the prognostic impact of IPSS-R, but this was usually 
restricted to patients who have received various treatment modalities including 
azacitidin. (Zeidan et al., 2014; Zipperer et al., 2014)
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In conclusion, the IPSS-R has proven its value as a more refined risk stratification 
tool by identifying a group of patients with a high/very high IPSS-R risk score 
(5%) within the IPSS low and intermediate-1 groups. In contrast, the majority 
(247) of the 419 IPSS intermediate-1 patients could be reclassified as low and 
very low risk using IPSS-R. 
In our view, systematic prospective international registries like the EUMDS 
Registry will be helpful tools to obtain detailed and accurate diagnostic, 
therapeutic and prognostic information and to develop next generation 
international evidence-based treatment guidelines for a heterogeneous 
disease of the elderly like myelodysplastic syndromes. 
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ONLINE ONLY 
Validation of the Revised IPSS in patients with Lower-risk 
Myelodysplastic Syndromes: a Report from the Prospective European 
LeukemiaNet MDS (EUMDS) Registry
Table 1 Baseline Patient Characteristics and Overall Survival 
Total
N (%)
Status N (%) HR (95%CI) 1 Adjusted HR (95%CI)1
Alive Dead
Total 1000 (100) 694 306
Blasts (%):
<5 875 (87.5) 624 (89.9) 251 (82.0) 1 1
5to10 125 (12.5) 70 (10.1) 55 (18.0) 2.08 (1.55-2.79) 2.12 (1.58-2.85)
Cytogenetics (IPSS) 2:
Good 774 (77.4) 553 (79.7) 221 (72.2) 1 1
Intermediate 150 (15.0) 93 (15.4) 57 (18.6) 1.40 (1.05-1.87) 1.43 (1.07-1.91)
Poor 13 (1.3) 7 (1.0) (2.0) 1.83 (0.81-4.11) 1.46 (0.65-3.29)
Unknown 63 (6.3) 41 (5.9) 22 (7.2) 1.19 (0.76-1.84) 1.15 (0.74-1.78)
Cytopenias:
0 204 (22.1) 167 (24.1) 37 (12.1) 1 1
1 514 (55.7) 362 (52.2) 152 (50.8) 1.77 (1.24-2.54) 1.66 (1.16-2.38)
2 205 (22.2) 126 (18.2) 79 (25.8) 2.58 (1.74-3.81) 2.69 (1.82-3.98)
3 77 (8.3) 39 (5.6) 38 (12.4) 4.26 (2.70-6.70) 4.41 (2.80-6.94)
Blasts (%):
<2 568 (56.8) 417 (60.1) 151 (49.3) 1 1
>2 - <5 307 (30.7) 207 (29.8) 100 (32.7) 1.23 (0.95-1.58) 1.21 (0.94-1.56)
≥5 -<10 125 (12.5) 70 (10.1) 55 (18.0) 2.25 (1.65-3.06) 2.28 (1.67-3.11)
Haemoglobin (g/dl):
≥10 546 (54.6) 418 (60.2) 128 (41.8) 1 1
8 - <10 357 (35.7) 228 (32.9) 129 (42.2) 1.71 (1.34-2.19) 1.64 (1.28-2.10)
<8 97 (9.7) 48 (6.9) 49 (16.0) 2.95 (2.12-4.10) 3.39 (2.43-4.72)
ANC (109/L)3:
>0.8 887 (88.7) 626 (90.2) 261 (85.3) 1 1
<0.8 101 (10.1) 59 (8.5) 42 (13.7) 1.47 (1.06-2.04) 1.41 (1.01-1.95)
Unknown 12 (1.2) 9 (1.3) 3 (1.0) 1.01 (0.32-3.15) 1.16 (0.37-3.63)
Platelets (109/L):
>100 753 (75.3) 548 (79.0) 205 (67.0) 1 1
50-<100 161 (16.1) 96 (13.8) 65 (21.2) 1.95 (1.47-2.58) 2.06 (1.55-2.74)
<50 81 (8.1) 47 (6.8) 34 (11.1) 2.45 (1.70-3.53) 2.64 (1.83-3.81)
Unknown 5 (0.5) 3 (0.4) 2 (0.7) 1.36 (0.34-5.47) 1.45 (0.36-5.83)
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Total
N (%)
Status N (%) HR (95%CI) 1 Adjusted HR (95%CI)1
Alive Dead
Cytogenetics (IPSS-R)4:
Very Good 67 (6.7) 46 (6.7) 21 (6.9) 1 1
Good 722 (72.2) 526 (75.8) 196 (64.1) 0.87 (0.55-1.36) 1.20 (0.75-1.91)
Intermediate 106 (10.6) 56 (8.1) 50 (16.3) 1.68 (1.01-2.79) 2.46 (1.45-4.16)
Poor 11 (1.1) 6 (0.9) 5 (1.6) 2.71 (1.02-7.21) 4.65 (1.73-12.53)
Very Poor 11 (1.1) 5 (0.7) 6 (2.0) 2.08 (0.84-5.16) 2.07 (0.83-5.17)
Unknown 83 (8.3) 55 (7.9) 28 (9.2) 1.26 (0.71-2.21) 1.58 (0.90-2.81)
1 Hazard Ratios (HR) & 95% Confi dence Intervals (CI) adjusted for age at diagnosis and sex, indicating 
survival until maximum potential follow-up (2.4-5.4 years), 2International Prognostic Scoring System 
(IPPS), 3Absolute Neutrophil Count (ANC), 4Revised International Prognostic Scoring System (IPPS-R)
Table 2 Concomitant medication in the population
Medication N     (%)
Anti Hypertensives 443 (44.3)
Proton Pump Inhibitors 212 (21.2)
Cholesterol Lowering drugs 201 (20.1)
Anti Diabetic drugs 166 (16.6)
Diuretics 160 (16.0)
Antiplatelet drugs 153 (15.3)
Anti Coagulants 138 (13.8)
Anti Arrhythmic drugs 108 (10.8)
Folic Acid 95   (9.5)
Anti Depressants 95   (9.5)
Thyroid Drugs 90   (9.0)
Vitamin B12 67   (6.7)
Corticosteroids 64   (6.4)
Iron Replacement 57   (5.7)
Anti Infl ammatory drugs 51   (5.1)
Bisphosphate/Calcium Supplements 38   (3.8)
Infection specifi c drugs 37   (3.7)
Eye Drops 35   (3.5)
Opiates/Analgesic drugs 28   (2.8)
Anti Epileptic drugs 17   (1.7)
Immunosuppressives 11   (1.1)
Chemotherapy 6     (0.6)
Home Oxygen 2     (0.2)
Table 1 continued
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Table 3 Baseline laboratory values
Value Recorded Median (IQR)
N %
Haemoglobin (g/dL) 1000 100 10.2 (9-11.3)
WBC (109/L) 996 99.6 4.5 (3.1-6.2)
Platelets (109/L) 990 99 184 (101-283)
RBC (1012/L) 970 97.0 3.1 (2.7-3.6)
MCV (fl) 984 98.4 98.3 (91-104)
Neutrophils (%) 991 99.1 56 (43.1-65)
Lymphocytes (%) 985 98.5 30.0 (22-40.8)
Basophils (%) 971 97.1 0.2 (0-1)
Eosinophils (%) 975 97.5 1.8 (0.5-3)
Monocytes (%) 979 97.9 7.5 (5-11)
Serum Ferritin (µg/L) 741 74.1 311 (131-570)
Iron Binding Capacity (µmol/L) 337 33.7 48.6 (39.8-56.5)
Serum Iron (µmol/L) 656 65.6 19 (13.1-26.4)
Transferrin Saturation (%) 335 33.5 38.3 (26.4-61.3)
Erythropoietin (IU/L) 547 54.7 51.3 (24-141.9)
Glucose (mg/dL) 705 70.5 5.6 (5.1-6.8)
Serum Creatinine (µmol/L) 865 86.5 85 (70.8-102.7)
Creatinine Clearance 766 76.6 67 (49.7-86.7)
Abbreviations: IQR, inter quartile range.
Table 4 Revised International Prognostic Scoring System (IPSS-R): cytogenetic classification stratified by age
Age at Diagnosis (years) N (%)
Total<60 60-74 75+
Cytogenetics:
Very Good 1 (1.5) 26 (38.8) 40 (59.7) 67 (100)
Good 87 (12.0) 286 (39.6) 350 (48.4) 723 (100)
Intermediate 15 (14.2) 52 (49.1) 39 (36.8) 106 (100)
Poor/Very Poor 3 (13.6) 8 (36.4) 11 (50.0) 22 (100)
Total 106 (11.6) 372 (40.5) 440 (47.9) 918 (100)
Table 5 Comparison of International Prognostic Scoring System (IPPS) and Revised International 
Prognostic Scoring System (IPSS-R) cytogenetic categories
International Prognostic Scoring System (IPSS)
TotalCytogenetics Good Intermediate-1 Poor Not Done
IPSS-R:
Very Good 62 3 0 2 67
Good 663 45 1 13 722
Intermediate 16 86 2 2 106
Poor 1 6 2 2 11
Very Poor 0 0 8 3 11
Not Done 32 10 0 41 83
Total 774 150 13 63 1,000
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Table 6 International Prognostic Scoring System (IPPS), subdivided in three groups (0, 0.5 and 1 point) 
and Revised International Prognostic Scoring System (IPSS-R)
International Prognostic Scoring System (IPSS)
Total0 0.5 1
IPSS-R:
Very Low 197 51 7 255
Low 256 161 28 445
Intermediate 8 84 58 150
High/Very high 0 2 30 32
Total 461 298 123 882
Table 7 Proportion of Subjects Transfused (at least 1 RBC units) and Treated Subjects by Country
Transfused 
N (%)
Pre-Transfusion
Haemoglobin level (g/dl)
Mean (sd)
MDS Treatment
N (%)
ESA’s
N (%)
Total 508 (50.8) 8.2 (1.2) 571 (57.1) 475 (47.5)
Country
Austria 21 (55.3) 8.0 (1.1) 20 (52.6) 16 (42.1)
Czech Republic 44 (64.7) 7.9 (1.0) 37 (54.4) 26 (38.2)
Denmark 11 (68.8) 9.0 (0.8) 11 (68.8) 10 (62.5)
France 118 (41.0) 7.8 (1.4) 163 (56.6) 143 (49.7)
Germany 19 (46.3) 8.1 (1.1) 24 (58.5) 13 (31.7)
Greece 41 (36.6) 7.8 (1.0) 77 (68.8) 68 (60.7)
Italy 9 (45.0) 8.0 (0.6) 10 (50.0) 8 (40.0)
Netherlands 16 (57.1) 8.2 (1.3) 16 (57.1) 8 (28.6)
Poland 4 (66.7) 7.9 (0.6) 1 (16.7) 1 (16.7)
Portugal 6 (60.0) 8.3 (0.6) 7 (70.0) 6 (60.0)
Romania 19 (63.3) 7.4 (1.6) 19 (63.3) 16 (53.3)
Spain 57 (53.8) 8.3 (1.3) 69 (65.1) 61 (57.5)
Sweden 61 (64.9) 9.0 (0.9) 60 (63.8) 53 (56.4)
United Kingdom 82 (57.3) 8.4 (1.3) 57 (39.9) 46 (32.2)
Abbreviations: RBC, Red Blood Cell; ESA’s, Erythropoiesis-Stimulating Agents. The proportion of patients 
transfused varied across countries with Greece and France having the lowest rate and the highest 
proportion observed in Denmark. The pre-transfusion hemoglobin level was the highest in patients 
from Denmark and Sweden (mean 9 g/dl) and the lowest in patients from Romania (7.4), Greece (7.8) 
and France (7.8). Major diff erences were observed by country in the proportion of patients on ESA, with 
around 60% of patients in Portugal, Greece and Denmark being treated with ESA within 2-years from 
diagnosis. In contrast, only 30% of UK patients had received ESA.
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Table 8 List of participating centers
Country Description (City, department (when available),Name organisation, [local 
investigator(s)])
N
Austria Innsbruck, Medical University of Innsbruck  [R. Strauder] 14
Lienz, Bezirkskrankenhaus [A. Walder] 7
Vienna, Hanusch Krankenhaus [M. Pfeilstöcker / A. Schoenmetzler-Makrai] 7
Wels, Klinikum Kreuzschwestern [S. Burgstaller / J. Thaler] 10
Czech Republic Brno, The University Hospital Brno, Internal Clinic of Hemato – Oncology 
[M. Krejci]
15
Hradec Kralove, Charles University Faculty of Medicine, Department of 
Clinical Hematology, 2nd Clinic of Internal Medicine  [J. Voglova]
7
Olomouc, University Hospital, Clinic of Hemato – Oncology  [P. Rohon] 7
Prague, General University Hospital, Institute of Hematology and Blood 
Transfusion, U nemocnice 1  [D. Mikulenková]
19
Prague, General University Hospital, 1st Clinic of Internal Medicine: U 
nemocnice 2  [A. Jonasova]
15
Prague, University Hospital Motol  [I. Hochova] 5
Denmark Aalborg, University Hospital, Department of Haematology  [L. Lundby] 1
Aarhus, University Hospital, Department of Haematology  [M.S. Holm] 5
Copenhagen, University Hospital: Rigshospitalet, Department of 
Haematology  [J. Kock]
2
Herlev Ringvej, Herlev Hospital, Department of Haematology  [J. Kock] 3
Odense, Odense University Hospital, Department of Haematology  [C.K. 
Larsen / C. Marcher]
5
France Antibes, Centre Hospital Antibes Juan-les-Pins  [D. Re] 4
Avignon, Centre Hospital  [B. Slama] 33
Bobigny, Hospital Avicenne  [P. Fenaux] 57
Boulogne sur Mer, Centre Hospital  [B. Choufi] 3
Caen, Centre Hospital Universitaire Clemenceau  [S. Cheze] 9
Chalon sur Saone, Centre Hospital William Morey  [D. Klepping / B. Salles] 6
Clermont-ferrand, Centre Hospital Universitaire  [B. Renzis] 2
Cochin, Hospital Hôtel Dieu  [F. Dreyfus] 15
Colombes, CHU Louis Mourier  [D. de Prost] 2
Frejus - St Raphael, Centre Hospital Intercommunal  [J. Gutnecht]  2
Grenoble, CHU Albert Michallon  [S. Courby] 3
Ivry sur Seine, Hospital Charles-Foix  [V. Siguret] 2
Limoges, CHU Limoges Hospital Dupuytren  [M. Chaury] 7
Lille - St Vincent, Hospital St Vincent de Paul  [C. Rose] 3
Le Kremlin Bicêtre, Hospital Bicêtre  [G. Tertian] 7
Lyon, Hospital Edouard Herriot  [E. Wattel] 14
Nancy, CHU Nancy: Hospital Brabois (Van Doeuvre Les Nancy)  [A. Guerci] 34
Nice, CHU de Nice: Hospital l’Archet  [L. Legros] 6
Perpignan, Centre Hospital Maréchal Joffre  [L. Sanhes] 32
Pontoise, Centre Hospital René-Dubos  [R. Benramdane] 1
Rouen, CHU Centre Henri Becquerel de Rouen [A. Stamatoullas] 2
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Table 8 continued
Country Description (City, department (when available),Name organisation, [local 
investigator(s)])
N
Paris , Hospital Saint-Antoine  [I. Françoise] 1
Strasbourg, CHU Hospital Hautepierre de Strasbourg [S. Amé] 7
Toulouse, CHU Toulouse: Hospital Purpan, Toulouse [O. Beyne-Rauzy] 28
Tours, CHRU de Tours  [E. Gyan] 8
Germany Dresden, University Hospital Carl Gustav Carus  [U. Platzbecker] 16
Duisburg, HELIOS: St. Johannes Hospital in Hamborn  [Badrakan] 7
Düsseldorf, Heinrich-Heine Universiti Hospital [U. Germing ] 6
Freiburg - University Hospital Freiburg [M.Lübbert ] 3
Ulm - University Hospital Ulm  [R. Schlenk ] 9
Greece Alexandroupolis, University Hospital of Alexandroupolis, Dept of 
Hematology, Democritus University of Thrace  [Y. Kotsianidis / C. Tsatalas]
9
Athens, Hellenic 251 Air Force General Hospital, Dept of Hematology [E. 
Terpos]
3
Athens, General Hospital Attikon’, Dept of Hematology, University of Athens 
Medical School [V. Pappa] 
3
Athens, General Hospital G.Gennimatas, Dept of Hematology  [A. 
Galanopoulos / E. Michali]
2
Athens, General Hospital Laikon, 1st Dept of Propaedeutic Medicine, 
University of Athens Medical School  [P. Panagiotidis]
21
Athens, General Hospital Sotiria, 3rd Dept of Int. Medicine, University of 
Athens Medical School  [A. Katsigiannis / P. Roussou]
2
Athens, Patission Prefectural General Hospital: Halkida, Dept of 
Haematology  [Z. Kartasis]
14
Ioannina, University Hospital of Ioannina, Dept of Haematology  [V. 
Briasoulis / E. Hatzimichael]
4
Patras, St. Andrew’s General Hospital, Dept of Hematology  [P. Zikos] 6
Patras, General University Hospital of Patras, Hematology Division, Dept of 
Internal Medicine  [A. Symeonidis]
32
Piraeus, Metaxa Hospital, Dept of Hematology  [M. Kotsopoulou / K. 
Megalakaki]
8
Serres, General Hospital of Serres, Dept of Hematology  [M. Protopapa] 5
Thessaloniki, Theagenio Hospital, Dept of Hematology [P. Konstantidinou] 1
Thessaloniki, Hippokration General Hospital, 1st Dept of Internal Medicine, 
University of Thessaloniki  [Y. Klonizakis / E. Vlachaki]
2
Italy Pavia, IRCCS San Matteo Hospital Foundation, Department of Hematology 
[L. Malcovati]
13
Rome, University Cattolica del Sacro Cuore, Policlinico Gemelli, Department 
of Hematology [L. Fianchi]
7
The Netherlands Amsterdam, VU University Medical Center [A. vd Loosdrecht] 2
Arnhem, Rijnstate Hospital  [V. Matthijssen] 5
Doetinchem, Slingeland Hospital  [F. de Vries / N. Aboosy] 2
Ede, Gelderse Vallei Hospital [G. Velders] 1
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Table 8 continued
Country Description (City, department (when available),Name organisation, [local 
investigator(s)])
N
‘s-Hertogenbosch, Jeroen Bosch Hospital  [A. Herbers] 1
Nijmegen, Radboudumc [G. Huls / M. MacKenzie] 16
Veldhoven, Maxima Medical Center [M. Nijziel] 1
Poland Warsaw, Klinika Hematologii, Onkologii i Chorób Wewnetrznych Warszawski 
Uniwersytet Medyczny [K. Madry]
6
Portugal Lisbon, Centro Hospitalar de Lisboa   [M. Câmara/ A. Almeida] 10
Romania Brasov, Districtual Hospital  [G. Vulkan] 6
Bucharest, Fundeni Clinical Institute  [A. Tatic] 14
Bucharest, Coltea Clinical Hospital  [O. Stanca Ciocan] 10
Spain Badalona, Hospital Universitario Germans I Puyol [B. Xicoy] 5
Barcelona, Hospital del Mar [C. Pedro] 12
Cádiz, Hospital Universitario Puerta del Mar  [J. Munoz] 1
Oviedo, Hospital Universitario Central de Asturias [E.L. Fernández] 26
Hospital Del Sas, Jerez De La Frontera [P. Leiva] 3
Lleida, Instituto de Investigación Biomédica [V. Betés] 13
Madrid, Hospital Clínico San Carlos [Ana M. Villegas] 1
Murcia, Hospital Universitario Meseguer[M Lozano/ M. Matinez] 4
Murcia, Hospital Universitario Virgen de la Arrixaca, [P. Iniesta] 1
Salamaca, Hospital Universitario de Salamanca [Cañizo Fernández-Roldán] 6
Valencia, Hospital Dr. Peset [R. Andreu Lapiedra] 8
Valencia, Hospital Clinico Universitario de Valencia [d. Tormo] 13
Valencia, Hospital Universitario La Fe [G. Sanz] 13
Sweden Eskilstuna, Mälarsjukhuset [E. Hesse Sundin] 1
Göteborg, Sahlgrenska University Hospital [H. Garelius] 20
Halmstad, Teaching Hospital of Halmstad [C. Karlsson] 2
Linköping, Linköping University hospital [P.Antunovic] 3
Luleå, Sunderby Hospital [L. Brandefors] 4
Lund, Lund University Hospital [L.Nilsson] 1
Örebro, Örebro University Hospital [P.Kozlowski] 2
Stockholm , Karolinska University hospital [E.Hellström-Lindberg] 44
Stockholm Södersjukhuset, [M. Grövdal] 12
Sundsvall, Sundsvall Hospital [J. Wallvik] 1
Umeå, Umeå regional hospital [F. Lorenz] 3
Uppsala, Uppsala University hospital [E. Ejerblad] 1
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Table 8 continued
Country Description (City, department (when available),Name organisation, [local 
investigator(s)])
N
UK Aberdeen, Aberdeen Royal Infi rmary  [ D. Culligan] 17
Steeton, Airedale NHS Trust  [A. Cuthbert ] 5
Birmingham, Queen Elizabeth Hospital  [C. Craddock ] 1
Blackpool, Blackpool Victoria Hospital  [M. Macheta ] 11
Bournemouth, Royal Bournemouth Hospital  [ S. Killick] 9
Bradford, Bradford Royal Infi rmary  [L. Newton] 3
Cambridge, Addenbrookes Hospital  [A. Warren] 1
Glasgow, Western Infi rmary [M. Drummond] 5
Harrogate, Harrogate District Hospital  [N. Thomas ] 6
Hull, Hull and East Yorkshire Hospitals NHS Trust  [C. Hall ] 8
Leeds, Leeds Teaching Hospitals [D. Bowen; Dr. Marina Karakantza] 32
Manchester, Christie Hospital  [M. Dennis ] 1
Wakefi eld, Mid Yorkshire Hospitals   [J. Ashcroft ] 6
Newcastle upon Tyne, Royal Victoria Infi rmary  [ G. Jones] 3
Northampton, Northampton General Hospital  [J. Parker/A. Bowen ] 4
Nottingham, Nottingham City Hospital  [E. Das-Gupta] 5
Oxford, John Radcliff e Hospitals NHS Trust  [P. Vyas] 3
Truro, Royal Cornwall Hospital  9
Worcester, Worcestershire Acute Hospitals NHS Trust  [J. Mills ] 8
York, York Hospital  [L. Bond ] 6
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Figure 1 IPSS-R score by WHO 2001 classification
All patients with RAEB-2 had either a high or very high risk score. The number of patients with an 
intermediate risk score was highest in RAEB-1 (38%) and RCMD (36%). Most patients with a low risk 
score had either RCMD (36%) or RA (21%). IPSS-R score was very low in 37% of the patients with RCMD, 
25% with RARS and 21% with RA.
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Abstract
The European LeukemiaNet MDS (EUMDS) registry is collecting data of 
myelodysplastic syndromes (MDS) patients belonging to the IPSS low or 
intermediate-1 category, newly diagnosed by local cytologists. The diagnosis 
of MDS can be challenging and some data report inter-observer variability with 
regard to the assessment of the MDS subtype. In order to ensure that correct 
diagnoses were made by the participating centres, blood and bone marrow 
slides of 10% of the fi rst 1000 patients were reviewed by an 11-person panel of 
cytomorphologists. All slides were rated by at least 3 panel members (median 
8 panel members; range 3-9). Marrow slides from 98 out of 105 patients 
were of good quality and therefore could be rated properly according to the 
WHO 2001 classifi cation, including assessment of dysplastic lineages. The 
agreement between the reviewers whether the diagnosis was MDS or non-
MDS was strong with an intra-class correlation coeffi  cient (ICC) of 0.85. 6 cases 
were detected not to fi t the entry criteria of the registry, because they were 
diagnosed uniformly as CMML or AML by the panel members. The agreement 
by WHO 2001 classifi cation was strong as well (ICC=0.83). The concordance of 
the assessment of dysplastic lineages was substantial for megakaryopoiesis 
and myelopoiesis and moderate for erythropoiesis. Our data show that in 
general the inter-observer agreement was high and a very low percentage of 
misdiagnosed cases had been entered into the EUMDS registry. Further studies 
including histomorphology are warranted.
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Introduction
Myelodysplastic syndromes (MDS) are a heterogeneous group of clonal diseases, 
characterized by cytopenias and dysplastic features in blood and bone marrow. 
Due to the heterogeneity of clinical presentation, degree of dysplastic features, 
and a considerable list of differential diagnosis, the diagnosis of MDS is often 
a challenge, particularly in lower-risk MDS. The diagnosis of MDS is primarily 
based on cytomorphologic and histopathologic assessment of dysplasia, but 
cytogenetic evaluation is crucial for the classification and to determine the 
risk assessment using the revised International Prognostic Scoring System 
(IPSS-R) score [1]. Flow cytometry and molecular analysis provide additional 
valuable information to refine the diagnosis and prognosis of MDS, but the 
clinical and therapeutic impact of these methods is under investigation [2, 3]. 
To make a correct diagnosis of MDS, good cytomorphologic experience and 
adequate clinical information is required, including concomitant medication, 
concurrent infections and comorbidity, and other possible causes of cytopenia 
or dysplastic features. Therefore, a multidisciplinary approach is often required 
to make the definite diagnosis of MDS and to exclude the possibility of other 
disorders mimicking MDS [4, 5].
In the prospective European LeukemiaNet MDS (EUMDS) registry, patients 
with a newly diagnosed MDS belonging to the low or intermediate-1 IPSS 
risk group are included, within 100 days of making the definite diagnosis of 
MDS [6]. Patients with higher-risk MDS or therapy-related MDS are excluded. 
National and local ethics committees have approved the study, and all patients 
provided written informed consent for inclusion in the registry. The first 1000 
patients were diagnosed with MDS between December 2007 and December 
2010, and therefore the diagnosis was based on the World Health Organization 
(WHO) 2001 classification, without central revision of diagnosis. Since a correct 
MDS diagnosis and classification are crucial in the EUMDS registry and may 
be difficult in the lower-risk group of MDS, a morphology sub-study was 
performed by reviewing 100 randomly selected cases by a panel group of 11 
MDS cytomorphologists from 9 different countries. The cytomorphology sub-
study was primarily aimed at a validation and reproducibility of the WHO 2001 
criteria for MDS by an international panel, and at the validation of original 
cytomorphologic accuracy and correct diagnostic inclusion into the registry. 
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The aims of the study were i) quality assessment of cytomorphologic diagnoses 
in the EUMDS registry and ii) assessment of inter-observer variability in the 
review panel regarding diagnosis and degree of dysplasia.
Design and Methods
The cytomorphology review was performed by a panel comprising 11 
morphologists during a 3 day meeting at the Heinrich Heine University medical 
Centre in Düsseldorf, Germany. The aim was to review the original diagnosis 
at time of inclusion in 10% of the patients in the EUMDS registry, with fi ve 
additional cases to replace inadequate material (only bone marrow trephine 
biopsy or slides with poor quality unable to examine). 
Selection of cases
A total of 105 cases, representing all participating countries, were randomly 
selected by the Epidemiology and Cancer Statistics Group (ECSG) of the University 
of York who manages the web-based EUMDS database. The distribution of the 
selected samples was dependent on the number of included patients in each 
country. The anonymization of the slides was done in Nijmegen at the Trial 
Offi  ce Hematology (TOH) of the Department of Hematology of the Radboud 
university medical centre (Radboudumc) before transporting the slides to 
Düsseldorf. The demographic, hematologic, and prognostic characteristics of 
the subjects included in the morphology study were generally representative 
of the subjects included in the registry at the time of sampling [6]. 
Clinical and haematologic characteristics
The review panel was provided with the following clinical and haematological 
characteristics of the patients under review: ID number (anonymous), date 
of diagnosis, haemoglobin (Hb), white blood cells (WBC), platelets, absolute 
neutrophil count (ANC), monocytes and IPSS cytogenetics category (good or 
intermediate-1 risk, but not information on del(5q)) at diagnosis. No original 
morphology report or previous diagnosis was provided to any of the panel 
members.
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Handling of slides
A minimum of 1 stained or unstained bone marrow slide, in most cases 1 bone 
marrow iron staining and 1 blood film had been sent to the TOH in Nijmegen. 
All slides had to be from the date of diagnosis, preferably the identical slides on 
which the original diagnosis was made. Twenty unstained slides were stained 
at the Radboudumc using the May-Grünwald-Giemsa stain. The number of 
available iron stained slides was restricted to 45 patients, and in 11 patients 
the percentage of ring sideroblasts were reported to be >14 by the centres. For 
these 11 patients the original iron staining was accepted by the expert panel.
Morphology review session 
The 11 panel members reviewed the slides independently from each other 
during three consecutive days at the University of Düsseldorf. Each panel 
member used a separate Zeiss Axiostar Plus Transmitted-Light Microscope, 
provided by Zeiss, Germany. The percentage of blasts in blood and marrow 
were counted on the basis of 300 nucleated cells precisely by at least 3 
experts during the review procedure; the other panel members estimated 
the blast count divided in categories (< 5%, 5-9% or ≥ 10% blasts). The degree 
of dysplasia in all cell lines was scored semi-quantitatively by each reviewer, 
divided into three categories (absent: <10% dysplastic cells, mild, or obvious 
dysplasia). All slides were reviewed by at least 3 individual panel members. 
Following individual slide review, the full panel met to consider characteristics 
and diagnostic problems of specific cases. Diagnoses were made according to 
the WHO classifications of 2001 [7, 8].
Definition of the review diagnosis:
1.  WHO 2001 Definite diagnosis: MDS diagnosis of each panel 
member based on consensus blast count done by the whole group 
of that specific case and scored dysplasia in the erythropoiesis, 
myelopoiesis, and megakaryopoiesis.
2.  WHO 2001 Expert diagnosis: MDS diagnosis of each panel member 
based on individual blast count (counted or estimated) and MDS 
diagnosis in conclusion.
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Statistical analysis
WHO 2001 diagnoses recorded by the panel members were categorized into 
the following groups: 
1. Refractory anaemia (RA) and Refractory anaemia with ringed 
sideroblasts (RARS),
2. Refractory cytopenia with multilineage dysplasia (RCMD) and 
Refractory cytopenia with multilineage dysplasia & ringed 
sideroblasts (RCMD-RS), 
3. Refractory anaemia with excess blasts-1 (RAEB-1), 
4. Refractory anaemia with excess blasts-2/Acute myeloid leukaemia 
(RAEB-2/AML)
5. 5q-syndrome
6. Chronic myelomonocytic leukaemia (CMML)
7. Possible MDS (not defi nite MDS diagnosis)
All analyses were undertaken in Stata version 14, agreement between the 11 
raters was measured using the intra-class correlation coeffi  cient (ICC) calculated 
using the icc23 command [9]. The average ICC for the reliability of diff erent 
reviewers was reported; ICC can range from 0 to 1, where 1 represents perfect 
agreement; agreement can be interpreted using the following categories 
proposed by Landis and Koch: <0 poor, 0.01-0.20 slight, 0.21-0.40 fair, 0.41-0.60 
moderate, 0.61-0.80 substantial and 0.81-1.00 as almost perfect agreement [10].
Results 
Median age of the randomly selected patients at diagnosis was 72 years 
(range 21 to 95), there was a male predominance (67%) and the most common 
diagnosis recorded was RCMD (Table 1). In total, 774 slides were reviewed by 
the 11 raters, 45 slides (5.8%) were excluded from subsequent analyses as the 
panel members were unable to review the diagnosis due to the poor quality 
of the slide. One case was removed as only two panel members had reviewed 
it. Accordingly, in total 98 cases were included in the review, and, on average, 
each case was reviewed by eight diff erent panel members (range 3-9).  In total, 
727 diagnoses were made by the panel members. 
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Concordance of MDS diagnoses
In a first step, the concordance with regard to the diagnosis of an MDS versus 
non-MDS was analyzed. Differences were seen by reviewer in the proportion of 
cases reviewed, as can be seen in Figure 1; in addition, this Figure demonstrates 
the difference in the proportion of diagnoses queried to whether or not the 
case had MDS (‘possible MDS’). Overall, 8% of cases were classified as ‘possible’ 
MDS, but reviewer 11 classified 27% of cases to this category, all of them were 
rated to have <5% medullary blasts.  For the majority of slides a MDS diagnosis 
was made (88%). 11 slides were classified as RAEB-2 or AML, 23 as CMML, and 
58 as possible MDS cases. In Table 2 the number of possible MDS is not included 
itself, but can be deducted from the numbers of different MDS diagnosis by 
panel review and the total number of slides (Table 2). Agreement between the 
reviewers whether the diagnosis was MDS or non-MDS was strong ICC=0.85, 
(95% Confidence Intervals (95%CI): 0.80-0.89).
Figure 1. Proportion of cases reviewed by each panel member and expert diagnoses made
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Table 1.   Patient characteristics at registration to the registry
Total 
N (%)
98 (100)
Age at Diagnosis (years), Median  (Range) 72.0 (21.0 - 95.0)
Sex
Males 66 (67.3)
Females 32 (32.7)
Country
Austria 2 (2.0)
Czech Republic 7 (7.1)
Denmark 3 (3.1)
France 30 (30.6)
Germany 7 (7.1)
Greece 11 (11.2)
Italy 2 (2.0)
Netherlands 8 (8.2)
Poland 2 (2.0)
Romania 4 (4.1)
Sweden 8 (8.2)
United Kingdom 14 (14.3)
Haemoglobin (g/dL), mean (sd) 10.5 (2.0)
WBC (109/L) mean (sd) 4.9 (2.4)
Absolute Neutrophil Count (109/L) mean (sd) 3.0 (2.0)
Platelets (109/l) mean (sd) 183 (121)
WHO Diagnosis provided at time of entry into the registry1
RA 17 (17.3)
RARS 20 (20.4)
RCMD 40 (40.8)
RCMD-RS 3 (3.1)
RAEB-1 14 (14.3)
5q-Syndrome 4 (4.1)
IPSS Score 
Low 344 (47.3)
Intermediate-1 345 (47.5)
Not Known 38 (5.2)
1Refractory anaemia (RA), Refractory anaemia with ringed sideroblasts (RARS), Refractory cytopenia with 
multilineage dysplasia (RCMD), Refractory cytopenia with multilineage dysplasia & ringed sideroblasts 
(RCMD-RS), Refractory anaemia with excess blasts-1 (RAEB-1), 5q-Syndrome.
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Concordance of WHO 2001 diagnoses
In the next step the concordance of WHO 2001 subtypes were analyzed (Figure 
2). The agreement by WHO 2001 diagnoses was almost identical; ICC=0.83, 
(95%CI: 0.77-0.87).  Table 2 describes the review panel diagnoses made versus 
the original diagnosis recorded in the Registry. We also assessed the medullary 
blast categories by separating patients with <5%, 5-9%, 10-19% and >20% 
medullary blasts. 88.4% of the slides were scored as less than 5% medullary 
blasts, 10% as RAEB-1, 0.9% as RAEB-2 and 0.5% as AML. The inter-observer 
variability for this categorization was very low, as only 6% of the slides were 
described differently by at least one panel member. 
Concordance of assessment of dysplasia
In addition, we analyzed the concordance of the assessment of dysplastic 
lineages (Table 3). The number of slides in which either dyserythropoiesis 
(9.9%), dysmyelopoiesis (7.5%) or dysmegakaryopoiesis (21.1%) could not 
be assessed properly was relatively high, especially in the slides that were 
described as possible MDS. Looking at the dysplastic lineages in the different 
WHO types it became obvious that in the unilineage dysplastic types (RA/RARS), 
in 23.8% and 9.4% of the slides dysmyelopoiesis and dysmegakaryopoiesis was 
described respectively, whereas in the RCMD/RCMD-RS group theses number 
were higher (49.5% and 54.9%). Dyserythropoiesis was described to be less 
frequent in the RA/RARS and 5q-Syndrome groups as compared to the RCMD/
RCMD-RS group. As expected, the highest percentage of dysmegakaryopoiesis 
was described in the 5q-Syndrome group. In cases that were labeled “possible 
MDS” the percentage of dyserythropoiesis was lower compared to definite 
MDS cases, and only a very small proportion showed dysmyelopoiesis 
with none showing dysmegakaryopoiesis. The agreement of the reviewers 
with regard to the assessment of dysmegakaryopoiesis (0.60; 95% CI: 0.48, 
0.71) and dysmyelopoiesis (0.72; 95% CI: 0.64, 0.80) was substantial and for 
dyserythropoiesis was moderate, close to substantial (0.591; 95% CI: 0.464, 0.699). 
Comparison of original diagnoses and panel diagnoses
In a last step, we compared the diagnoses made by the centres that entered the 
patients into the lower-risk EUMDS registry. We identified 6 cases (6.1%) that did 
not fulfil the entry criteria. Four patients were described to have CMML by all panel 
members who assessed the slides of blood and marrow with 100% agreement. 
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Both patients were originally entered into the registry as RA and RAEB-1. Two 
patients were diagnosed as RAEB-2 or AML by the panel members with 100% 
agreement. These patients were entered into the registry as RCMD and RAEB-1.
Figure 2.   Original diagnoses by local cytologists versus expert diagnoses
Table 2.   Expert diagnoses (review panel) by original diagnoses by local cytologists (clinical) 
Review panel 
diagnosis
    Original diagnosis by local cytologists
RA/RARS
   (n=37 pts)
RCMD/RCMD-RS
(43 pts)
RAEB-1
(n=14 pts)
5q-Syndrome
(n=4 pts)
Total
(n=98 pts)
Total 265 (100.0) 326 (100.0) 106 (100.0) 30 (100.0) 727 (100.0)
RA/RARS 50 (18.9) 36 (11.0) 4 (3.8) - 90 (12.4)
RCMD/RCMD-RS 155 (58.5) 232 (71.2) 51 (48.1) - 438 (60.2)
RAEB-1 21 (7.9) 27 (8.3) 21 (19.8) - 69 (9.5)
RAEB-2/AML - 4 (1.2) 7 (6.6) - 11 (1.5)
5q-Syndrome - - 8 (7.5) 30 (100.0) 38 (5.2)
CMML 9 (3.4) - 14 (13.2) - 23 (3.2)
1Refractory anaemia (RA), Refractory anaemia with ringed sideroblasts (RARS), Refractory cytopenia with 
multilineage dysplasia (RCMD), Refractory cytopenia with multilineage dysplasia & ringed sideroblast 
(RCMD-RS), Refractory anaemia with excess blasts-1 (RAEB-1), Refractory anaemia with excess blasts 
(RAEB-2), Acute Myeloid Leukaemia (AML), 5q-Syndrome, Chronic myelomonocytic leukaemia (CMML), 
pts: patients
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Discussion
Diagnosis of Myelodysplastic syndromes is still based primarily on 
cytomorphology of blood and marrow, accompanied by histomorphology, 
cytogenetics, molecular fi ndings and fl ow cytometry. The European 
LeukemiaNet MDS (EUMDS) registry is collecting data of newly diagnosed 
lower-risk MDS patients. Eligibility for entry into the registry is based on the 
local assessment of cytomorphology at the participating centers in 14 diff erent 
countries and 118 sites. In order to assess the quality and accuracy of the MDS 
diagnoses in the registry we organized a working group reviewing 10% of the 
fi rst 1000 patients that were included into the registry. In our cytomorphologic 
review of 100 newly diagnosed lower-risk MDS patients we could clearly 
demonstrate a high accuracy of the original diagnoses at entry into the registry 
and a high inter-observer concordance of the panel members with regard to 
diagnosis of MDS and assessment of the lineage involvement of dysplasia.
An important prerequisite for cytology is satisfactory quality stained slides, 
in our case well prepared blood and marrow fi lms and ‘bone marrow aspirate 
squash’ slides without many preparation artefacts. Only 6% of the slides were 
of poor quality and could not be assessed properly, whereas 94% could be 
validated. Cytomorphology in MDS can be challenging, even for experienced 
morphologists and sometimes a defi nite diagnosis is not possible or only 
based on genetic fi ndings [11]. Minimal diagnostic criteria for the diagnosis of 
an MDS cannot be based on morphology only, as no single sign of dysplasia 
is MDS specifi c [12].  The slides that were evaluated during our microscope 
session were blinded, and the panel member did not have information on 
the clinical course of the patients and were not biased in their judgment. 
We assembled a very heterogeneous panel of cytologists in terms of the 
morphological experience of the members and therefore we were prepared 
to be faced with discrepancies in the assessment the diagnosis. Surprisingly, 
most disagreements were not signifi cant. First of all, a small number of slides 
were detected as CMML and RAEB-2 and AML cases. This task was the easiest 
for the panel members as there was no disagreement. As a result, only 6% of 
the patients entered into the registry were misdiagnosed by the centres. This 
confi rms that the data quality of the registry is high and that subsequent 
analyses based on diagnosis by the local cytomorphologists are likely to be 
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valid. The assessment of medullary blast counts was also extremely uniform, 
as only 6% of the cases were differently categorized (<5% blasts versus 5-9% 
blasts). 
The assessment of lineage involvement of dysplasia was less concordant. Inter-
observer variability with regard to description of dysplasia was reported by 
several groups [13, 14, 15]. Our data show that our Panel team had substantial 
agreement on the assessment of dysmyelopoiesis and dysmegakaryopoiesis, 
whereas the assessment of dyserythropoiesis was less concordant. This finding 
is plausible, as some signs of dysplasia in myelo- and megakaryopoiesis 
are more specific for myeloid malignancies like micromegakaryocytes, 
mononuclear megakaryocytes, pseudo-pelger cells and degranulated myeloid 
precursors. These signs of dysplasia are usually not described in the marrow 
with reactive changes due to inflammation, toxic effects and others [12]. 
Morphological erythroid dysplasia can be evident in benign disorders like 
hemolysis, megaloblastic anemias and others. As a result, the panel members 
differed moderately in the categorization of uni- versus multilineage dysplasia. 
There is growing evidence that flow cytometry with regard to properly describe 
dysplasia of erythropoiesis can be utilized if performed in a sophisticated way 
[3, 16, 17]. The separation of lower-risk MDS cases, namely distinguishing 
uni- and multlineage dysplasia, ring sideroblastic phenotype, and deletion of 
chromosome 5 is of great prognostic value, as shown by different groups [18, 
19, 20, 21].  As our data show, knowledge of cytomorphology is necessary to 
properly describe dysplasia and to use the classification systems accordingly. 
Therefore, skills in cytomorphology are still mandatory in centres where 
patients with MDS are diagnosed and treated accordingly [22, 23].
The WHO 2001 proposals for the classification of myelodysplastic syndromes 
took into account the separation of uni- and multilineage dysplasia within the 
non blastic MDS cases with ring sideroblasts. This feature was omitted by the 
WHO 2008 [24] proposals but was reintroduced in the WHO 2016 classification 
[21]. As a result, our data generally reflect the WHO 2016 classification with 
the exception of minor changes of the definition of MDS del(5q) and MDS 
unclassified and the introduction of SF3B1 mutations as classifying elements. 
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The slides that were evaluated during our microscope sessions were blinded 
and the panel members did not have information on the clinical course of the 
disease. The only bias was the information that slides has been  diagnosed as 
lower-risk MDS by the local cytologists.
Limitations of the project were some missing iron stains, not primarily aff ecting 
the morphological results with regard to eligibility of the patients into the 
registry. An even better assessment of morphology could have been reached by 
adding histomorphology for all cases. Although the impact of histomorphology 
in lower-risk MDS is limited as compared with cytomorphology, it can be 
helpful in cases with poor cytologic material and can help to properly assess 
the cellularity and fi brosis [25]. Therefore, another Panel review, including 
Histopathologists, could be of added value.
In summary, there was a high inter-observer agreement after the elimination of 
poor quality slides within our very heterogeneous panel of 11 morphologists. 
As a result, the inclusion of the patients into the EUMDS registry could be shown 
to be correct in the vast majority of the patients. The 6 patients originally not 
diagnosed correctly by the local cytologists have not been withdrawn from the 
registry. The registry is assessing patients who were diagnosed in the real world 
as lower-risk MDS and managed as such. Therefore, a central morphology 
review is not mandatory for this particular registry.  
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Abstract
Conventional karyotype is one of the most relevant prognostic factors in MDS. 
However, about 50% of patients with MDS have a normal karyotype. Usually, 
20 to 25 normal metaphases (nMP) are considered to be optimal to exclude 
small abnormal clones which might be associated with poor prognosis. This 
study evaluated the impact of examining a suboptimal number of metaphases 
in patients recruited to the EUMDS Registry with low and intermediate-1 risk 
according to IPSS. Only 179/1,049 (17%) of patients with a normal karyotype 
had a suboptimal number of nMP, defi ned as less than 20 metaphases analyzed. 
The outcome (overall survival and progression-free survival) of patients with 
suboptimal nMP was not inferior to those with higher numbers of analyzed 
MP both in univariate and multivariate analyses. For patients with an abnormal 
karyotype, 224/649 (35%) had a suboptimal number of MP assessed, but this did 
not impact on outcome. For patients with a normal karyotype and suboptimal 
numbers of analyzable metaphases standard evaluation might be acceptable 
for general practice, but we recommend additional FISH-analyses or molecular 
techniques, especially in candidates for intensive interventions. 
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Introduction
Myelodysplastic syndromes (MDS) are a heterogeneous group of clonal myeloid 
disorders characterized by peripheral blood cytopenias and increased risk of 
transformation to acute myelogenous leukemia (AML).[1] Classical karyotype 
analyses detect clonal chromosome abnormalities in about 50% of patients 
with MDS.[2] The karyotype is one of the strongest prognostic parameters in 
the currently applied prognostic models, including the revised International 
Prognostic Scoring System (IPSS-R).[3] In general, the aim is to analyze 20 or 
more metaphases (MP) before a karyotype is considered to lack specific clonal 
abnormalities. A lower number of MP analyzed (<20) is associated with a higher 
chance of missing small clones.[2] The prognostic relevance of these smaller 
clones remains to be elucidated in lower-risk MDS.[4]  
The primary aim of the present study was to assess whether the number of MP 
examined in patients with normal karyotype provide any additional prognostic 
information about overall survival (OS) and progression-free survival (PFS) in 
patients with lower-risk MDS participating in the European MDS Registry Study.
[5] The secondary aim was to assess the impact of the number of analyzed 
metaphases on outcome in patients with an abnormal karyotype. To the best of 
our knowledge, this is the first prospective study in this field. We hypothesized 
that a higher number of analyzed nMP does have a positive impact on survival 
in patients with lower-risk MDS.
Design and Methods
Eligibility
Patients were eligible for inclusion if they were newly diagnosed with MDS 
according to the WHO 2001 classification[6] and had a low or intermediate-1 
risk score according to the IPSS.[7] Patients with post-cytotoxic MDS have 
been excluded from this Registry. The ethics committees of all participating 
countries and centers have approved the EUMDS registry (trial number 
NCT00600860). Patient-specific (including bone marrow morphology, histology 
and cytogenetics), intervention and outcome data were collected at baseline 
and at each 6-monthly out-patient follow-up visit for the routine clinical care 
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of patients with MDS. All subjects were prospectively followed until death, 
progression to higher-risk MDS or leukemia, loss to follow-up or withdrawal of 
informed consent. 
Assignment of IPSS(-R) score
Both the IPSS cytogenetic score and the IPSS-R cytogenetic score were 
determined from the diagnostic cytogenetic reports at registration. The local 
investigator assigned the IPSS cytogenetic scores. The IPSS-R cytogenetic scores 
were retrospectively assigned by one of the investigators of the EUMDS registry 
and verifi ed by an independent expert of the international IPSS working group 
(D. Haase). IPSS and IPSS-R scores were calculated and the IPSS-R cytogenetic 
risk category of patients with only nMP was assigned as good-risk. In these cases 
no abnormal MP were reported. Patients with abnormal MP were categorized 
to the IPSS-R cytogenetic risk score: very good, good, intermediate, poor and 
very poor risk category.[8] 
Statistical analysis
Standard descriptive techniques were used to assess the distribution of 
baseline patient characteristics including chi squared test and Wilcoxon rank 
sum test. Overall survival (OS) was defi ned as the time from date of diagnosis 
to death, or for subjects still alive at the date of the last follow-up visit. Time 
to disease progression (TDP) was measured from date of diagnosis to date 
of disease progression to either higher-risk MDS or acute leukemia. Patients 
without disease progression were censored at date of death or date of last 
follow-up visit. Standard methods were used to assess time to event, namely 
Cox proportional hazards regression models and Kaplan–Meier survival curves. 
Hazard ratios (HR) and 95% confi dence intervals (95% CI) are reported for 
univariate analyses, unadjusted and adjusted for sex and age at diagnosis. All 
analyses were undertaken in Stata 14 (StataCorp, College Station, TX).
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Results
In total 2,196 patients were registered to the study between 1st April, 2008 to 31st 
March, 2017 and patients were followed-up to the 1st June, 2017. The majority 
of patients had conventional cytogenetics performed (95%) and 1,999 had a 
karyotype recorded. Sixty-one percent had a normal karyotype (1,225/1,999) 
at diagnosis and 39% an abnormal karyotype (774/1,999). Patients were 
subdivided into six categories based on the number of reported MP (Table 
1). The median number of MP examined was 20 for patients with normal and 
abnormal karyotypes, however, the distributions were very different as can be 
seen in Figure 1 (p=0.01).  Whilst some patients with an abnormal karyotype 
had over 40 MP assessed, 35% had less than 20 MP assessed (suboptimal), this 
is in contrast to those with a normal karyotype where only 17.1% had less than 
20 MP assessed (p<0.0001). Patients with an abnormal karyotype were, on 
average, older (75 vs 73 years, p=0.03), and in terms of cytopenias they lower 
hemoglobin values than those with a normal karyotype (p<0.0001).  However, 
there were no differences in hemoglobin, platelets or neutrophil counts by 
number of metaphases examined (Table 1). 
Figure 1 Distribution of number metaphases by abnormal vs normal karyotype
The p-value (=0.01) shows a significant difference in median number of analyzed metaphases in the normal 
and abnormal karyotype groups. The aim in assigning an abnormal karyotype is not to analyze 20 or more 
metaphases (MP) compared to a normal karyotype where the aim is to analyze 20 or more metaphases (MP).
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Table 1 Number of metaphases by age at diagnosis and cytopenias for subjects with a normal karyotype 
only or an abnormal karyotype
Normal karyotype
Metaphase 
category (n)
N (%) Median age 
years
(range)
Median (25-75 percentile)
Hemoglobin 
(g/dL)
Platelets (109/L) Absolute Neutrophil 
Count  (109/L)
Total 1225 (100) 73 (18 - 93) 10.3 (9.2 - 11.6) 171 (96 - 263) 2.4 (1.3 - 3.8)
1-9 42 (3.4) 72 (47 - 89) 10.3 (9.2 - 11.6) 179 (88 - 264) 2.6 (1.2 - 4.1)
10-19 137 (11.2) 72 (21 - 90) 9.8 (8.8 - 11.4) 169 (97 - 263) 2.4 (1.4 - 3.7)
20-24 634 (51.8) 74 (21 - 93) 10.2 (9.1 - 11.4) 173 (96 - 270) 2.4 (1.3 - 3.8)
25-29 164 (13.4) 73 (42 - 93) 10.6 (9.7 - 11.7) 160.5 (94 - 270) 2.2 (1.2 - 3.6)
30+ 72 (5.9) 74 (57 - 90) 10.8 (9.8 - 12.1) 181.5 (99 - 253) 2.4 (1.4 - 4.1)
Not recorded 176 (14.4) 74 (18 - 93) 10.6 (9.4 - 11.8) 169 (101 - 257) 2.4 (1.4 - 3.9)
Abnormal karyotype
Total 774 (100) 75 (21 - 97) 10 (9 - 11.1) 177.5 (103 - 283) 2.4 (1.4 - 3.8)
1-9 44 (5.7) 70 (39 - 93) 9.8 (8.9 - 10.9) 162 (67.5 - 236) 1.8 (1.2 - 3.3)
10-19 180 (23.3) 75 (21 - 93) 10 (9 - 11.1) 197 (114 - 296) 2.2 (1.4 - 3.5)
20-24 276 (35.7) 77 (33 - 93) 9.9 (9 - 11.1) 168 (103 - 290) 2.6 (1.5 - 4)
25-29 104 (13.4) 74 (34 - 89) 10.2 (9.1 - 11.4) 181 (106 - 292) 2.8 (1.5 - 4.4)
30+ 45 (5.8) 77 (27 - 91) 10.3 (9 - 11.2) 189 (98 - 258) 2.2 (1.4 - 3.7)
Not recorded 125 (16.1) 73 (46 - 97) 9.7 (8.5 - 10.9) 172 (102 - 275) 2.1 (1.4 - 3.6)
Table 2 shows the number of normal MP were evenly distributed within the 
various categories with the exception of the participating countries. The 
median number of analyzed MP was signifi cantly higher (p<0.0001) in the two 
Scandinavian countries compared to the number of MP in Israel, Italy, Serbia, 
Croatia and Romania. As expected, there were diff erences between the normal 
and abnormal karyotypes groups in terms of WHO diagnosis and IPSS-R score; 
patients with an abnormal karyotype were more likely to have been transfused 
at diagnosis compared to those with a normal karyotype. 
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Table 2 Demographic parameters and impact on median number of metaphases  
Normal karyotype Abnormal karyotype
Category No. of patients No. of nMP
Median (range)
No. of patients No. of MP
Median (range)
Total 1049 (100) 20 (1 - 42) 649 (100) 20 (1 - 60)
Age
<60 years 130 (12.4) 20 (4 - 34) 50 (7.7) 20 (4 - 47)
60-70 247 (23.5) 20 (2 - 42) 138 (21.3) 20 (1 - 52)
70+ 672 (64.1) 20 (1 - 38) 461 (71) 20 (1 - 60)
WHO-diagnosis
RA 164 (15.6) 20 (3 - 42) 101 (15.6) 20 (6 - 52)
RARS 190 (18.1) 20 (1 - 34) 78 (12) 20 (9 - 34)
RCMD 429 (40.9) 20 (2 - 38) 245 (37.8) 20 (1 - 60)
RCMD-RS 73 (7) 20 (3 - 38) 33 (5.1) 21 (7 - 40)
RAEB-1 143 (13.6) 20 (2 - 35) 60 (9.2) 20 (1 - 47)
RAEB-2 6 (0.6) 20 (10 - 23) - -
MDS-U 44 (4.2) 20 (8 - 34) 29 (4.5) 14 (1 - 30)
5q-Syndrome - 103 (15.9) 20 (3 - 37)
Country
Austria 65 (6.2) 22 (4 - 34) 41 (6.3) 20 (1 - 31)
Croatia 2 (0.2) 20 (20 - 20) 5 (0.8) 16 (7 - 21)
Czech Republic 50 (4.8) 22 (2 - 25) 42 (6.5) 22 (8 - 40)
Denmark 36 (3.4) 25 (10 - 26) 20 (3.1) 25 (25 - 28)
France 291 (27.7) 20 (8 - 36) 162 (25) 21 (4 - 49)
Germany 27 (2.6) 22 (2 - 29) 21 (3.2) 22 (5 - 34)
Greece 70 (6.7) 20 (2 - 29) 58 (8.9) 20 (5 - 52)
Israel 60 (5.7) 10 (3 - 21) 37 (5.7) 10 (2 - 28)
Italy 40 (3.8) 17 (1 - 25) 22 (3.4) 14 (3 - 25)
Netherlands 45 (4.3) 20 (10 - 20) 22 (3.4) 10.5 (10 - 30)
Poland 29 (2.8) 22 (5 - 27) 26 (4) 21 (18 - 30)
Portugal 17 (1.6) 20 (20 - 30) 16 (2.5) 10 (6 - 29)
Romania 12 (1.1) 15 (8 - 24) 9 (1.4) 16 (9 - 22)
Serbia 8 (0.8) 15 (1 - 15) 8 (1.2) 30 (5 - 30)
Spain 80 (7.6) 20 (5 - 42) 37 (5.7) 20 (3 - 47)
Sweden 54 (5.1) 26 (20 - 38) 38 (5.9) 25 (20 - 30)
United Kingdom 163 (15.5) 20 (3 - 30) 85 (13.1) 10 (1 - 60)
IPSS-R* Cytogenetics
Very Good - - 156 (24.0) 20 (1 - 60)
Good 1049 (100) 20 (1 - 42) 250 (38.5) 20 (1 - 39)
Intermediate - - 206 (31.7) 20 (1 - 49)
Poor - - 21 (3.2) 20 (1 - 60)
Very Poor - - 16 (2.5) 20 (4 - 28)
IPSS-R* Overall 986 (100) 20 (1 - 42) 610 (100) 20.0 (1 - 60)
Very low 309 (31.3) 20 (1 - 42) 166 (27.2) 20 (2 - 39)
Low 480 (48.7) 20 (1 - 38) 245 (40.2) 20 (1 - 60)
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Table 2 continued 
Normal karyotype Abnormal karyotype
Category No. of patients No. of nMP
Median (range)
No. of patients No. of MP
Median (range)
Intermediate 161 (16.3) 20 (2 - 35) 152 (24.9) 20 (1 - 40)
High 35 (3.5) 20 (10 - 32) 42 (6.9) 20 (1 - 30)
Very high 1 (0.1) 20 5 (0.8) 20 (5 - 20)
Transfused at registration
No 761 (72.5) 20 (1 - 35) 427 (65.8) 20 (1 - 60)
Yes 288 (27.5) 20 (1 - 42) 222 (34.2) 20 (1 - 39)
Transfused >1 unit/month
No 886 (84.5) 20 (1 - 42) 504 (77.7) 20.0 (1 - 60)
Yes 163 (15.5) 20 (2 - 38) 145 (22.3) 20.0 (1 - 39)
*IPSS-R: Revised International Prognostic Scoring System
Overall Survival and progression-free survival
Median follow-up was 2.1 years (range of 0.1 to 8.7 years) and 33% (669 of 
1999) of patients had died during the observation period; median survival 
for patients with a normal karyotype was 5.2 years (95% Confi dence Intervals 
(95%CI): 3.3-4.5) and abnormal karyotype (4.0 years (95% CI: 4.0 (4.8-5.9) log 
rank test = 15.63, p=0.0001. The univariate overall survival (fi gure 2AB) and 
progression-free survival estimates, as depicted in fi gure 3AB, showed a similar 
outcome in the six categories throughout the whole observation period. 
Multivariate analyses were performed to adjust for the various relevant 
prognostic components: age at diagnosis, MDS WHO category, blast count, 
hemoglobin levels, platelets and neutrophil count, RBCT- dependency (>1 
unit/month for 6 months) and country. IPSS-R cytogenetic risk category was 
also included in the model in patients with an abnormal karyotype. The largest 
category of MP (20 to 24 MP) was used as the reference category. The number 
of MP, analyzed both as a continuous variable or as a categorical variable did 
not signifi cantly infl uence survival nor progression-free survival. The group 
with MP not recorded in the database were included in all analyses (table 3 and 
fi gures 2, 3).
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Figure 2 Overall Survival 
Overall survival from date of diagnosis by the six analyzed categories based on the number of reported 
metaphases; normal karyotype 2A, and abnormal karyotype 2B. The columns under the figures 
represent the number of patients in each of the categories at that specific time point.
Figure 3 Progression-free survival
Progression-free survival from date of diagnosis by the six analyzed categories based on the number 
of reported metaphases; normal karyotype 2A, and abnormal karyotype 2B. The columns under the 
figures represent the number of patients in each of the categories at that specific time point.
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Discussion
The analyses of this study were focused on the impact of analyzable metaphases 
in patients with a normal karyotype on outcome, including estimated overall 
survival and progression-free survival. Our recently published study on the first 
1,000 patients within the EUMDS registry confirmed established prognostic 
factors, such as age, gender and World Health Organization 2001 classification 
[5] in addition, with low health-related quality of life (EQ-5D visual analogue 
scale score) and a high co-morbidity index predicted poor outcome. The IPSS-R 
was superior to the original IPSS for predicting both disease progression and 
survival.[5] We identified 1225 patients with normal conventional karyotype 
in the EUMDS Registry, representing 61% of this lower-risk MDS patient 
population. The great majority of patients with normal karyotype had 20 or 
more MP analyzed, while 14% of the patients were registered with a normal 
karyotype, based on less than 20 analyzed MP. Estimated overall survival as 
well as the estimated progression-free survival of the patients with a normal 
karyotype and a suboptimal number of analyzed MP (<20) was not inferior 
when compared with 20 or more analyzed MP. In our study, we found a complete 
absence of a trend towards an impaired prognostic risk when comparing the 
varying cohorts. This is not surprising, since the chance of missing a small 
abnormal clone increases by 25% if only 5 normal MP have been analyzed and 
between 10 and 15% in patients with 10 to 15 nMP analyzed.[2] This means that 
the majority of patients with a suboptimal number of analyzed MP (<20) are 
expected to have a conventionally normal karyotype associated with a low risk 
MDS. In contrast, the size of abnormal clones may play a role in the prognosis.
[9] In the study by Mallo et al. the outcome of patients with abnormal clones 
<100%, assessed by FISH, was better when compared to patients with 100% 
abnormal clones[9]. Unfortunately, the impact of smaller clone sizes was not 
assessed in that study, similar to a large important study, performed by Schanz, 
et al.[10] A study of 101 MDS patients with normal karyotype revealed small 
clones (ranging 15% to 32%) using FISH techniques in 18 patients.[4] FISH 
abnormalities were predictive for worse prognosis, but the majority of these 18 
patients had higher-risk MDS and all three patients with refractory anemia were 
surviving at time of evaluation. It is also possible to apply FISH on circulating 
CD34-positive cells, in order to avoid another BM aspiration to obtain sufficient 
material for standard banding techniques.[11]
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Additionally, we analyzed the patients with abnormal karyotypes. As expected 
the number of analyzed metaphases is lower in this group of patients because 
the defi nition of clonality in patients with abnormal karyotype requires a lower 
number of analyzed metaphases. Also in this group of patients the number 
of analyzed metaphases does not infl uence the outcome after adjustment for 
relevant variables.
Currently, it is possible to detect MDS-specifi c mutations in more than 90% 
of patients with MDS.[12] These mutations will allow a better prognostication 
of all MDS cases with normal karyotype. Therefore, molecular testing should 
be seriously considered in all fi t patients with MDS who are candidates for 
allogeneic stem cell transplantation or patients in investigational studies, in 
absence of poor-risk cytogenetic characteristics, as is the case in all patients 
with MDS, characterized by normal karyotype.[13]
In summary: patients with lower-risk MDS with a normal karyotype and 
suboptimal numbers of analyzable metaphases (<20) have a similar outcome 
when compared to patients with optimal numbers of analyzed metaphases 
(≥20). However, it should be a general aim to reach at least a complete analysis 
of 20 metaphases to be able to exclude clonal cytogenetic abnormalities, 
especially in patients who are eligible for intensive interventions. If this is not 
possible, we recommend to use complementary FISH-analyses covering the 
most frequent cytogenetic changes such as del(5q), monosomy 7/del(7q), 
trisomy 8, del(17p)/loss of TP53-alleles and del(20q), or additional or molecular 
techniques.[13]
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Abstract 
Non-transferrin bound iron (NTBI) and its labile (redox active) plasma iron 
component (LPI) are thought to be potentially toxic forms of iron originally 
identifi ed in the serum of patients with iron overload. We compared 10 
worldwide leading assays (6 NTBI and 4 LPI) as part of an international inter-
laboratory study. Serum samples from 60 patients with 4 diff erent iron-overload 
disorders in various trea tment phases were coded and sent in duplicate for 
analysis to 5 diff erent laboratories worldwide. Some laboratories provided 
multiple assays. Overall, highest assay levels were observed for patients 
with untreated hereditary hemochromatosis and β-thalassemia intermedia, 
patients with transfusion-dependent myelodysplastic syndromes and patients 
with transfusion-dependent and chelated β-thalassemia major. Absolute 
levels diff ered considerably between assays and were lower for LPI than for 
NTBI.  Four assays also reported negative values. Assays were reproducible with 
high between-sample and low within-sample variation. Assays correlate and 
correlations were highest within the group of NTBI assays and within that of LPI 
assays. Increased transferrin saturation, but not ferritin, was a good indicator 
for the presence of circulating NTBI iron forms. The possibility of using NTBI and 
LPI measures as clinical indicators of overt iron overload and/or of treatment 
effi  cacy would largely depend on the rigorous validation and standardization 
of assays. 
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Introduction 
The predominant forms of iron present in living entities are associated with 
proteins such as transferrin in the major circulating fluid and hemoglobin and 
ferritin in cells. However, the iron binding capacity of the iron transport protein 
transferrin can be surpassed when a substantial amount of iron enters the 
circulation due to excessive iron absorption from the diet or an outpour of iron 
from cell stores due to enhanced blood cell recycling. In these conditions non-
transferrin-bound-iron (NTBI; circulating iron not bound to transferrin, ferritin, 
or haem) appears in the plasma.(1-4) Iron complexes assumed to represent 
NTBI have been shown experimentally to be taken up by susceptible cell 
types, including hepatocytes, cardiomyocytes and pancreatic islet cells, with 
consequent oxidant injury.(4) Plasma NTBI is apparently comprised of several 
subspecies, which may be classified either by their chemical composition, 
chemical reactivity and susceptibility to chelation.(5-15) The fraction of plasma 
NTBI that is redox-active and chelatable is designated labile plasma iron (LPI).
(11,13)   
Imbalances in iron homeostasis are responsible for a variety of disorders. Excess 
iron accumulates in the circulation and tissues of patients with hereditary 
hemochromatosis (HH), iron-loading anemias (β-thalassemia (Thal) major and 
intermedia), myelodysplastic syndromes (MDS) and sickle-cell disease (SCD) 
after transfusion.(1,2,4,13) To prevent iron-induced tissue damage, detection of 
impending iron toxicity is needed before complications develop and become 
irreversible.
Currently, the most widely adopted method for the detection of iron overload 
is the measurement of serum ferritin, occasionally combined with transferrin 
saturation (TSAT). However, it is well known that as an acute phase protein, 
serum ferritin levels are influenced by factors like inflammation, liver disease 
and malignancy and therefore they are not universally representative of hepatic 
iron overload.  Moreover, with the introduction of MRI T2* for the assessment 
of tissue iron overload, (16) it became also clear that organs such as heart and 
endocrine glands iron load differently than the liver and non-commensurately 
with serum ferritin. Studies of plasma NTBI in Thal major patients suggest that 
NTBI may be an important early indicator of extra-hepatic iron toxicity.(17) 
Studies in patients with various iron-loading disorders have shown a reduction 
in NTBI and LPI upon phlebotomy and chelation therapy that is associated with 
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an improved prognosis.(1,2,18-21) Therefore, NTBI and LPI assays are promising 
for the evaluation of iron overload and the effi  cacy and compliance of iron-
chelation therapy. (4,12,22)
Due to the complexity and potential clinical importance of NTBI, several 
assays have been developed for its detection.(5,9-11,15,23-27) In our previous 
Round Robin 1 (RR1) we found that NTBI values of patients with HFE-related 
hemochromatosis diff ered considerably between the various assays.(28) 
We concluded that NTBI assays were insuffi  ciently standardized and the 
most pertinent assay for clinical applications remained uncertain. Since 
this RR1 for NTBI, novel assays have been published and brought to market.
(11,15,27) Therefore, the aims of our study were to update RR1 and increase 
our understanding of the various NTBI and LPI levels measured by the 
current leading analytical assays in four diff erent groups of iron overloaded 
patients (HH, Thal, MDS, SCD) undergoing various treatments (phlebotomy, 
iron chelation, red blood cell transfusion). More specifi cally, in these patient 
populations, we aim to 1) establish correlations between assays, 2) establish 
levels of reproducibility of each of the assays, 3) assess levels of the NTBI 
fraction consisting of iron citrate, and 4) correlate assays with other established 
parameters of iron overload (e.g., TSAT and serum ferritin).
Materials and methods
Study design and participants
We compared 10 diff erent assays (5 NTBI, 1 NTBI isoform-specifi c and 4 LPI) 
performed in 5 diff erent laboratories worldwide. A total of 60 serum samples 
were split into two aliquots, coded, stored at -80°C and shipped for analysis 
on dry ice to the laboratories in May 2013. Laboratories performed duplicate 
measurements in a blinded fashion, on each aliquot of a serum sample on 2 
diff erent days, resulting in a total of 4 measurements for each sample. Some 
laboratories provided multiple assays. The participants reported their results 
within 5 weeks after receiving the samples.  
Collection of samples and laboratory analysis 
Serum samples (n=60) were collected from patients with 4 iron overload 
disorders in various treatment phases (TD, transfusion dependent; CH, receiving 
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iron chelation) making a total of 10 different patient and treatment groups.  
Hemoglobin concentration (Hb), mean corpuscular volume (MCV), and all 
serum parameters were determined by routine methods (supplemental 
information). Transferrin was measured using immunochemistry and total iron 
binding capacity (TIBC) was calculated as: TIBC (μmol/L) = 25.0 x transferrin 
(g/L). TSAT was calculated as: TSAT (%) = (serum iron (μmol/L) / TIBC (μmol/L)) 
x 100%. For all samples, TSAT was also determined by urea gel electrophoresis, 
separating the four forms of transferrin by polyacrylamide gel electrophoresis 
in the presence of 6M urea.(29) This latter TSAT methodology is not affected by 
the presence of residual chelator or chelates. 
NTBI and LPI assays
The participating NTBI/LPI assays were divided into 3 different assay groups: i) 
5 NTBI assays (N1-N5) ii) 1 NTBI isoform-specific assay (N6) and iii) 4 LPI assays 
(L1-L4) (supplemental table 1). The test principles of the NTBI assays can be 
divided into two subgroups. The first subgroup (N2-4) consists of the chelation-
ultrafiltration-detection approach based on the prior mobilization of serum 
NTBI by weak iron-mobilizing chelators such as nitrilotriacetate (NTA) at 80 mM. 
The chelated NTBI is separated from transferrin-bound iron by ultrafiltration 
and detected by colorimetry or HPLC.(24-26)  The second subgroup of NTBI 
assays (N1 and N5) comprises the measurement of directly chelatable iron 
(DCI). In these assays NTBI is mobilized and detected in the same reaction 
mixture by iron-binding probes such as fluorescently-labeled desferrioxamine 
and the hexadentate pyridinone chelator (CP851) attached to a fluorescent 
probe.(5,9,15) In the latter assay the CP851 was bound to beads and the 
fluorescent signal from the bead-bound chelator was differentiated from the 
non-specific plasma signals by flow cytometry.(5,15) None of the NTBI assays 
used a cobalt compound to block unsaturated transferrin. The NTBI isoform-
specific method N6 measures the sum of the oligomeric and monomeric 
iron (III)-citrate complexes of NTBI. This methodology consists of gel filtration 
chromatography by HPLC to separate the individual components of NTBI by 
mass, followed by quantification of iron by inductively coupled-plasma mass 
spectrometry (LC-ICP-MS).(5)
The LPI assays (L1-4) measure the redox active component of NTBI, a potentially 
toxic species. Assay L1 used bleomycin, which forms a complex with DNA and 
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redox active ferrous iron. When ascorbate is added, reactive oxygen species 
(ROS) are generated which degrade the deoxyribose moieties of the DNA in a 
site-specifi c reaction. These degradation products bind to thiobarbituric acid 
(TBA) to give a pink chromogen for quantifi cation.(23) The assays L2, L3 and 
L4 used a reducing agent (ascorbate) and an oxidizing agent (atmospheric 
O2) to generate Reactive Oxygen Species (ROS) from endogenous oxidants 
and labile catalytic iron. ROS were detected by an oxidation-sensitive probe 
(dihydrorhodamine (DHR)). Comparison of the generated fl uorescence in the 
presence and absence of an iron chelator (deferiprone or deferrioxamine) 
makes the assay specifi c for iron, which can then be measured from a standard 
curve generated from known iron concentrations.(11,27) For the extraction of 
iron from NTBI, assay L4 used 0.1 mM NTA to capture the mobilizer-dependent 
form of LPI (enhanced or eLPI).(10,27)
Statistical methods
The study was designed to compare NTBI levels as well as the repeatability 
of the methods. With respect to the repeatability, the magnitude of variation 
that exists between samples and between measurements of the same sample 
relative to the total variation is of interest. Accordingly, we partitioned 
the total variance of each method into the following components: i) the 
between-sample variance and ii) the analytical variance. Our design allowed 
us to divide the latter into three subcomponents: the between-day variance, 
the between-duplicate variance and the residual analytical variance, i.e. the 
part of the analytical variance that cannot be attributed to the other two. A 
linear mixed model was used to estimate these variance components of each 
method separately. The dependent variable was the NTBI outcome, and the 
independent random variables were: sample (60 levels), day (two levels) and 
repeated measurement (two levels). The standard deviation   (absolute error) 
and the percentage variance relative to the total variance are presented for 
each method separately.
For statistical calculations, for assays N3 and N4, results below the LLOD of 0.60 
and 0.87 were included as 0.30 and 0.40 µmol/L, respectively; for assays L3 and 
L4, results above the ULOD of 2.2 were included as 2.4 µmol/L.
Louise de Swart van idml.indd   105 04-05-19   13:47
Chapter 5
106
Results
Patient characteristics 
Patient characteristics by disease and treatment groups are shown in table 1. 
Serum ferritin levels were most elevated in Thal major TD&CH, MDS TD and 
SCD TD and in HH patients at presentation (HH naive). The ferritin levels in 
HH patients decrease after phlebotomy. TSAT levels were similar for the two 
different TSAT methodologies used and were highest in Thal major TD&CH 
(median 100%). Median TSAT was also very high (>94%) in patients with naive 
HH, MDS TD and Thal intermedia naive, and less increased (>51%) in Thal major 
naive, in the depletion phase of phlebotomies in HH patients, in MDS, refractory 
anemia with ringed sideroblasts (RARS)/refractory cytopenia with multilineage 
dysplasia (RCMD)-RS and in SCD TD, and within reference range (<45%) for 
most patients with naive SCD and HH patients in the maintenance phase. 
Assay levels and limits of detection 
Absolute NTBI and LPI levels differed considerably between assays (table 2). 
Overall, the NTBI assays (N1-N4, N6) measured ~2-30 times higher concentrations 
compared to the LPI assays (L1-L4), in agreement with the concept that NTBI 
assays measure total circulating NTBI, whereas LPI assays specifically measure 
the redox active fraction. Nonetheless, major differences in absolute values 
were found within the group of NTBI and LPI assays. For example, both N1 and 
N5 measure DCI but levels are much higher for N1 than for N5. In fact, N5 levels 
were greater than the cut-off of zero in only 8% of the samples (n=5). This assay 
was therefore excluded for further analysis.   
As expected, levels of assay L4 that measures the forms of LPI that are detectable 
in the presence of NTA (designated “eLPI”), are higher than those obtained by 
assay L3 that uses a methodology that is identical to L4 except that NTA is not 
added. 
Assays differed widely in the use of predefined detection limits (supplemental 
table 1). Four out of 10 participating methods reported negative values: i.e. 
N1, N2, L1 and L2 in 20%, 60%, 53% and 25% of the samples, respectively. For 
assays N5, L3 and L4, 92%, 70%, and 28% of the samples, respectively, were 
measured as ≤ 0 but were reported as 0 (zero) NTBI or LPI. For 2 of these assays, 
L3 and L4, also an upper limit of detection (ULOD) of 2.2 µmol/L was employed 
since the assay is non-linear above this concentration. Three assays (N3, N4, N6) 
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measured positive values only. Two of them (N3 and N4) applied a lower limit of 
detection (LLOD) of 0.60 µmol/L and 0.87 µmol/L with reported results < LLOD 
in 42% and 32% of the samples, respectively.
Reproducibility 
Assays showed a high contribution of the between-sample variance to the 
total variance indicating that the assays are able to identify diff erent NTBI/LPI 
concentrations in the various patient groups (table 3). 
The relatively low between-sample variance of assay N4 could be attributed to 
the relatively high residual variance (33%) due to some outliers.
For all assays, the contribution of the within-sample variance (within day and 
between-day) to the total variance was relatively low (0-2.2%), indicating good 
reproducibility. 
Comparison between assays 
Overall, assays correlate well and correlations were highest within the same 
group of NTBI or LPI assays (table 4). The NTBI and LPI assays with the highest 
mutual Spearman’s correlation were N2 and N3 (rs=0.88), N3 and N4 (rs=0.86), 
N2 and N4 (rs=0.85), L3 and L4 (rs=0.77), and L2 and L3 (rs=0.74). Spearman 
correlations of N6 with the other assays were all <0.10. 
Remarkably, the Spearman correlation of LPI assay L1, using bleomycin, with 
NTBI assays was higher compared to the LPI assays. In contrast, NTBI assay N1 
showed a better Spearman correlation with LPI assays than with NTBI assays 
(table 4). 
In Figure 1 the Bland –Altman plots are shown of a selection of 9 graphs with 
the highest mutual correlation or a specifi c correlation of interest. Some 
obvious line patterns can be attributed to the use of cut-off  values in one of 
the two assays. 
Louise de Swart van idml.indd   107 04-05-19   13:47
Chapter 5
108
Table 1. Median (range) of patient characteristics by disease and treatment groups. Assay ID: a random 
numbering is used within assay group. Median (range) are given for 5-7 measurements in each disease 
and treatment group. Naive, before start of any therapy; Depletion, during the depletion phase of 
phlebotomy treatment; Maintenance, during maintenance phase of phlebotomy. TD, transfusion-
dependent; CH, receiving iron chelation therapy;  RARS, refractory anemia with ringed sideroblasts; 
RCMD, refractory cytopenia with multilineage dysplasia;  Hb; Hemoglobin; MCV, Mean Corpuscular 
Volume; CRP, C- reactive protein; LDH, lactate dehydrogenase; Iron, serum iron; Ferritin, serum ferritin; 
TSAT immuno, transferrin saturation, transferrin measured immunochemically and iron with a 
colorimetric method, both on an automated analyzer; TSAT gel, transferrin saturation measured with 
gel electrophoresis; NA, not available; Hb and MCV in Thal patients were from the first sampling due to 
pooling afterwards. 
a,Hb (g/dL) = mmol/L x 1.6206; b, chelation consisted of Deferiprone (Ferriprox, DFP, n=2) and Deferasirox 
(Exjade, DFX, n=4);  c, the disease groups have been given numbers as IDs; d, including 5 patients on iron 
chelation therapy that consisted of DFP (n=3) and DFX (=2); e, the hemolytic index (reflecting in vivo 
and ex vivo hemolysis) levels were within the reference range (<20 mg/dL) for all samples (data not 
shown). Patients with Sickle Cell Disease were of African descent (African-Dutch) and the patients with 
β-Thalassemiawere all Italian-Caucasian (Italians). All other patients were Dutch-Caucasian.
Age Hb MCV CRP LDHe Iron Ferritin TSAT immuno TSAT gel
Diseasec N years mmol/La fL mg/L U/L µmol/L µg/L % % 
Hemochromatosis
1. Naive 6 58 (42-66) 9.5 (8.4-10.0) 91 (82-96) 0 (0-0) 157 (128-238) 37 (33-44) 1389 (948-2049) 97 (76-100) 100 (80-100)
2. Depletion 6 59 (42-66) 8.5 (7.9-9.0) 93 (85-104) 0 (0-0) 121 (105-140) 31 (18-39) 631 (570-786) 66 (35-89) 58 (31-95)
3. Maintenance 6 59 (43-67) 9.2 (8.3-9.6) 90 (82-97) 0 (0-0) 126 (112-144) 23 (10-36) 58 (30-166) 44 (21-95) 43 (24-100)
β-Thalassemia
4. Major Naive 6 1 (0.5-2) 5.7 (4.6-6.6) 81 (73-84) 0 (0-5) 252 (233-478) 24 (17-29) 912 (639-2060) 52 (43-94) 52 (46-100)
5. Major TD & CHb 6 31 (28-35) 6.0 (5.4-6.3) 84 (82-86) 0 (0-0) 127 (91-141) 38 (17-46) 2507 (623-5451) 100 (45-103) 100 (47-100)
6. Intermedia Naive 7 39 (22-60) 5.5 (4.7-6.3) 85 (64-94) 0 (0-6) 228 (150-550) 35 (16-42) 487 (306-940) 95 (42-103) 100 (48-100)
MDS
7. RARS/RCMD-RS 6 69 (26-77) 6.7 (5.4-7.4) 97 (79-99) 0 (0-0) 190 (105-292) 35 (17-39) 474 (289-826) 71 (31-90) 52 (31-88)
8. TD 5 71 (68-85) 4.6 (4.0-5.6) 92 (87-97) 20 (0-275) 181 (161-290) 30 (19-45) 2633 (1379-11834) 94 (93-106) 100 (92-100)
Sickle Cell Disease
9. Naive 6 34 (18-57) 5.2 (4.1-7.1) 87 (76-114) 0 (0-6) 437 (290-864) 19 (11-27) 164 (79-996) 37 (18-58) 37 (28-48)
10. TDd 6 23 (19-41) 5.9 (4.2-6.5) 85 (81-90) 3 (0-30) 448 (231-649) 25 (7-38) 2091 (1451-5353) 62 (19-95) 51 (17-100)
Reference range
- Male - - 8.5-11.0 80-100 <10 <250 14-35 25-250 <45 <45
- Female - - 7.5-10.0 80-100 <10 <250 10-25 20-250 <45 <45
Discrimination of disorder and treatment groups by the assays 
Table 2 shows the results obtained by the 9 assays in the 10 different disease and 
treatment groups. Using a linear mixed model, we found that all methods were 
suitable to discriminate, at least on a group level, between some different types 
of iron overload disease (p<0.05), except for the NTBI isoform-specific assay N6 
(p=0.268) (supplementary table 2).  Overall, assays were best in discriminating 
LPI and NTBI from patients with highest TSAT levels (Thal major TD&CH, Thal 
intermedia, MDS TD and untreated HH) from those of the diseases with lower 
TSAT (SCD naive, SCD TD and HH maintenance, Table 2 and Supplemental Table 
2). 
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Table 1. Median (range) of patient characteristics by disease and treatment groups. Assay ID: a random 
numbering is used within assay group. Median (range) are given for 5-7 measurements in each disease 
and treatment group. Naive, before start of any therapy; Depletion, during the depletion phase of 
phlebotomy treatment; Maintenance, during maintenance phase of phlebotomy. TD, transfusion-
dependent; CH, receiving iron chelation therapy;  RARS, refractory anemia with ringed sideroblasts; 
RCMD, refractory cytopenia with multilineage dysplasia;  Hb; Hemoglobin; MCV, Mean Corpuscular 
Volume; CRP, C- reactive protein; LDH, lactate dehydrogenase; Iron, serum iron; Ferritin, serum ferritin; 
TSAT immuno, transferrin saturation, transferrin measured immunochemically and iron with a 
colorimetric method, both on an automated analyzer; TSAT gel, transferrin saturation measured with 
gel electrophoresis; NA, not available; Hb and MCV inThal patients were from the fi rst sampling due to 
pooling afterwards. 
a,Hb (g/dL) = mmol/L x 1.6206; b, chelation consisted of Deferiprone (Ferriprox, DFP, n=2) and Deferasirox 
(Exjade, DFX, n=4);  c, the disease groups have been given numbers as IDs; d, including 5 patients on iron 
chelation therapy that consisted of DFP (n=3) and DFX (=2); e, the hemolytic index (refl ecting in vivo 
and ex vivo hemolysis) levels were within the reference range (<20 mg/dL) for all samples (data not 
shown). Patients with Sickle Cell Disease were of African descent (African-Dutch) and the patients with 
β-Thalassemiawere all Italian-Caucasian (Italians). All other patients were Dutch-Caucasian.
Age Hb MCV CRP LDHe Iron Ferritin TSAT immuno TSAT gel
Diseasec N years mmol/La fL mg/L U/L µmol/L µg/L % % 
Hemochromatosis
1. Naive 6 58 (42-66) 9.5 (8.4-10.0) 91 (82-96) 0 (0-0) 157 (128-238) 37 (33-44) 1389 (948-2049) 97 (76-100) 100 (80-100)
2. Depletion 6 59 (42-66) 8.5 (7.9-9.0) 93 (85-104) 0 (0-0) 121 (105-140) 31 (18-39) 631 (570-786) 66 (35-89) 58 (31-95)
3. Maintenance 6 59 (43-67) 9.2 (8.3-9.6) 90 (82-97) 0 (0-0) 126 (112-144) 23 (10-36) 58 (30-166) 44 (21-95) 43 (24-100)
β-Thalassemia
4. Major Naive 6 1 (0.5-2) 5.7 (4.6-6.6) 81 (73-84) 0 (0-5) 252 (233-478) 24 (17-29) 912 (639-2060) 52 (43-94) 52 (46-100)
5. Major TD & CHb 6 31 (28-35) 6.0 (5.4-6.3) 84 (82-86) 0 (0-0) 127 (91-141) 38 (17-46) 2507 (623-5451) 100 (45-103) 100 (47-100)
6. Intermedia Naive 7 39 (22-60) 5.5 (4.7-6.3) 85 (64-94) 0 (0-6) 228 (150-550) 35 (16-42) 487 (306-940) 95 (42-103) 100 (48-100)
MDS
7. RARS/RCMD-RS 6 69 (26-77) 6.7 (5.4-7.4) 97 (79-99) 0 (0-0) 190 (105-292) 35 (17-39) 474 (289-826) 71 (31-90) 52 (31-88)
8. TD 5 71 (68-85) 4.6 (4.0-5.6) 92 (87-97) 20 (0-275) 181 (161-290) 30 (19-45) 2633 (1379-11834) 94 (93-106) 100 (92-100)
Sickle Cell Disease
9. Naive 6 34 (18-57) 5.2 (4.1-7.1) 87 (76-114) 0 (0-6) 437 (290-864) 19 (11-27) 164 (79-996) 37 (18-58) 37 (28-48)
10. TDd 6 23 (19-41) 5.9 (4.2-6.5) 85 (81-90) 3 (0-30) 448 (231-649) 25 (7-38) 2091 (1451-5353) 62 (19-95) 51 (17-100)
Reference range
- Male - - 8.5-11.0 80-100 <10 <250 14-35 25-250 <45 <45
- Female - - 7.5-10.0 80-100 <10 <250 10-25 20-250 <45 <45
Comparison of assays with TSAT and ferritin
The assays show a hyperbolic relationship with TSAT, regardless of the underlying 
etiological condition (fi gure 2), NTBI concentrations increase sharply when 
TSAT levels exceeded 70%, NTBI is sporadically observed in samples with TSAT 
lower than 70% and LPI is found essentially when TSAT exceeds 90%. There is 
no relationship between serum ferritin and either LPI or NTBI measured in any 
of the assays (data not shown). 
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Table 2. Mean (SD, in µmol/L) of the NTBI and LPI values by assay, disease and treatment. Each mean 
was calculated as the outcome of the means of a total of 4 NTBI or LPI measurements (2 days, 2 
measurements with exception of two methods, one which performed assays over 4 days, 1 measurement 
and one which performed 1 day, 2 measurements), according to the number of patients in each disease 
category (N=5-7). NTBI assays, measurement of total NTBI using chelators like NTA or desferrioxamine 
as scavenging agent; LPI assays, measurement of redox active fraction of NTBI using reducing agents 
like ascorbate or bleomycin to induce redox cycling and generate reactive oxygen species (ROS); NTBI 
isoform-specific, measurement of the iron-citrate fraction in the serum samples; DCI, direct chelatable 
iron; eLPI, enhanced LPI. Method N5 (DCI) has been omitted from this table since NTBI was only present 
in 8 % of the samples (N=5: 3 Thal major TD & CH, 1 Thal intermedia naive, 1 MDS TD); 
a,b, for statistical calculations, results below the LLOD of 0.60 and 0.87 were included as 0.30 and 0.40, 
respectively; c, results were recommended to be interpreted as follows: X <0.1 =negative, 0.1 ≥ X <0.2 
= undetermined, X ≥0.2 = positive; d, for statistical calculations, results above the ULOD of 2.2 were 
included as 2.4 µmol/L;  e, range of levels assessed in healthy individuals (23-61 yrs, 50% men; TSAT 
16-56%): -2.29 to 0.35 µmol/L.
N NTBI assays LPI assays 
Assay ID N1 N2e N3a N4b N6 L1 L2 L3c,d L4c,d
Assay subgroup DCI NTBI NTBI       NTBI      Isoform LPI LPI LPI eLPI
Disease/Total 60 1.60  (.37) -0.73 (.20) 1.32 (.14) 2.19 (.64) 1.10 (.15) 0.09   (.07) 0.24 (.17) 0.14  (.04) 0.46  (.11)
Hemochromatosis
1. Naive 6 2.61 (.43) 0.42 (.19) 2.08 (.16) 3.25 (.73) 1.58 (.22) 0.21 (.11) 0.39 (.13) 0.10 (.06) 1.34 (.31)
2. Phlebotomy 6 0.36 (.30) -1.32 (.20) 0.66 (.13) 1.15 (.20) 1.36 (.15) -0.04 (.05) -0.09 (.14) 0.00 (.00) 0.03 (.04)
3. Maintenance 6 0.25 (.26) -1.52 (.15) 0.57 (.02) 0.91 (.35) 1.19 (.19) -0.07 (.03) 0.02 (.15) 0.00 (.00) 0.05 (.03)
β-Thalassemia
4. Major Naive 6 0.61 (.25) -1.19 (.17) 0.76 (.05) 1.68 (1.07) 1.08 (.36) -0.01 (.04) 0.08 (.09) 0.01 (.01) 0.17 (.05)
5. Major TD & CH 6 5.79 (.65) 0.38 (.27) 2.46 (.12) 4.00 (.67) 0.87 (.11) 0.43 (.12) 0.68 (.24) 0.54 (.15) 1.43 (.17)
6. Intermedia Naive 7 3.32 (.44) 0.04 (.17) 2.46 (.17) 3.74 (2.25) 1.51 (.06) 0.28 (.10) 0.64 (.25) 0.52 (.06) 0.83 (.14)
MDS
7. RARS/RCMD-RS 6 0.14 (.16) -1.38 (.25) 0.61 (.03) 1.37 (.20) 1.11 (.05) -0.05 (.02) 0.04 (.17) 0.00 (.00) 0.02 (.03)
8. TD 5 2.97 (.81) 0.53 (.15) 2.33 (.43) 3.65 (.31) 0.60 (.04) 0.22 (.10) 0.62 (.23) 0.20 (.11) 0.66 (.29)
Sickle Cell Disease
9. Naive 6 -0.10 (.24) -2.01 (.15) 0.44 (.22) 0.49 (.12) 0.94 (.06) -0.06 (.04) -0.01 (.12) 0.00 (.00) 0.01 (.01)
10. TD & CH 6 -0.05 (.19) -1.12 (.32) 0.86 (.14) 1.69 (.20) 0.57 (.21) 0.00 (.04) -0.01 (.15) 0.00 (.00) 0.06 (.06)
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Table 2. Mean (SD, in µmol/L) of the NTBI and LPI values by assay, disease and treatment. Each mean 
was calculated as the outcome of the means of a total of 4 NTBI or LPI measurements (2 days, 2 
measurements with exception of two methods, one which performed assays over 4 days, 1 measurement 
and one which performed 1 day, 2 measurements), according to the number of patients in each disease 
category (N=5-7). NTBI assays, measurement of total NTBI using chelators like NTA or desferrioxamine 
as scavenging agent; LPI assays, measurement of redox active fraction of NTBI using reducing agents 
like ascorbate or bleomycin to induce redox cycling and generate reactive oxygen species (ROS); NTBI 
isoform-specifi c, measurement of the iron-citrate fraction in the serum samples; DCI, direct chelatable 
iron; eLPI, enhanced LPI. Method N5 (DCI) has been omitted from this table since NTBI was only present 
in 8 % of the samples (N=5: 3 Thal major TD & CH, 1 Thal intermedia naive, 1 MDS TD); 
a,b, for statistical calculations, results below the LLOD of 0.60 and 0.87 were included as 0.30 and 0.40, 
respectively; c, results were recommended to be interpreted as follows: X <0.1 =negative, 0.1 ≥ X <0.2 
= undetermined, X ≥0.2 = positive; d, for statistical calculations, results above the ULOD of 2.2 were 
included as 2.4 µmol/L;  e, range of levels assessed in healthy individuals (23-61 yrs, 50% men; TSAT 
16-56%): -2.29 to 0.35 µmol/L.
N NTBI assays LPI assays 
Assay ID N1 N2e N3a N4b N6 L1 L2 L3c,d L4c,d
Assay subgroup DCI NTBI NTBI       NTBI      Isoform LPI LPI LPI eLPI
Disease/Total 60 1.60  (.37) -0.73 (.20) 1.32 (.14) 2.19 (.64) 1.10 (.15) 0.09   (.07) 0.24 (.17) 0.14  (.04) 0.46  (.11)
Hemochromatosis
1. Naive 6 2.61 (.43) 0.42 (.19) 2.08 (.16) 3.25 (.73) 1.58 (.22) 0.21 (.11) 0.39 (.13) 0.10 (.06) 1.34 (.31)
2. Phlebotomy 6 0.36 (.30) -1.32 (.20) 0.66 (.13) 1.15 (.20) 1.36 (.15) -0.04 (.05) -0.09 (.14) 0.00 (.00) 0.03 (.04)
3. Maintenance 6 0.25 (.26) -1.52 (.15) 0.57 (.02) 0.91 (.35) 1.19 (.19) -0.07 (.03) 0.02 (.15) 0.00 (.00) 0.05 (.03)
β-Thalassemia
4. Major Naive 6 0.61 (.25) -1.19 (.17) 0.76 (.05) 1.68 (1.07) 1.08 (.36) -0.01 (.04) 0.08 (.09) 0.01 (.01) 0.17 (.05)
5. Major TD & CH 6 5.79 (.65) 0.38 (.27) 2.46 (.12) 4.00 (.67) 0.87 (.11) 0.43 (.12) 0.68 (.24) 0.54 (.15) 1.43 (.17)
6. Intermedia Naive 7 3.32 (.44) 0.04 (.17) 2.46 (.17) 3.74 (2.25) 1.51 (.06) 0.28 (.10) 0.64 (.25) 0.52 (.06) 0.83 (.14)
MDS
7. RARS/RCMD-RS 6 0.14 (.16) -1.38 (.25) 0.61 (.03) 1.37 (.20) 1.11 (.05) -0.05 (.02) 0.04 (.17) 0.00 (.00) 0.02 (.03)
8. TD 5 2.97 (.81) 0.53 (.15) 2.33 (.43) 3.65 (.31) 0.60 (.04) 0.22 (.10) 0.62 (.23) 0.20 (.11) 0.66 (.29)
Sickle Cell Disease
9. Naive 6 -0.10 (.24) -2.01 (.15) 0.44 (.22) 0.49 (.12) 0.94 (.06) -0.06 (.04) -0.01 (.12) 0.00 (.00) 0.01 (.01)
10. TD & CH 6 -0.05 (.19) -1.12 (.32) 0.86 (.14) 1.69 (.20) 0.57 (.21) 0.00 (.04) -0.01 (.15) 0.00 (.00) 0.06 (.06)
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Table 3.  The between-sample and within-sample variation of the assay concentrations by method. SD, 
standard deviation, absolute error; Between-sample SD, segment due to variation between samples; 
Within-sample within-day, segment due to variation in repeated measurements on the same day; 
Within-sample between-day, segment due to variation in repeated measurements on two different 
days.  NA= not available, measurements were on four different days instead of twice on two different 
days. For N6 only a duplicate measurement on day 2 is available because of iron contamination issues on 
day 1.
SD (µmol/L) Variance (%)
Method Total Between-
sample
Within-sample Residual Between-
sample
Within-sample Residual
Within-
day
Between-
day
Within-
day
Between-
day
N1 3.20 3.15 0.00 0.15 0.51 97.2 0.0 0.2 2.6
N2 1.23 1.19 0.00 0.18 0.21 94.8 0.0 2.2 3.0
N3 1.18 1.15 NA 0.06 0.25 95.3 NA 0.2 4.5
N4 2.07 1.70 0.07 0.00 1.19 67.1 0.1 0.0 32.8
N6 1.08 1.05 0.00 0.00 0.26 94.3 0.0 0.0 5.8
L1 0.26 0.24 0.00 0.03 0.08 87.7 0.0 1.3 11.0
L2 0.51 0.47 0.00 0.00 0.21 83.5 0.0 0.0 16.5
L3 0.40 0.38 0.00 0.00 0.10 94.0 0.0 0.0 6.0
L4 0.69 0.67 0.00 0.00 0.18 93.5 0.0 0.0 6.5
Table 4.  Spearman’s correlation coefficients between the assays, using the mean of the duplicate 
measurements on day two. Bland-Altman plots of the shaded cells are presented in Figure 1. Correlation 
plots of all cells are provided in supplemental figure 1. 
N1 N2 N3 N4 N6 L1 L2 L3
N2 0.60 -
N3 0.57 0.88 -
N4 0.57 0.85 0.86 - -
N6 -0.06 -0.06 -0.06 -0.11
L1 0.50 0.89 0.85 0.83 0.05 -
L2 0.59 0.54 0.48 0.44 0.05 0.54 -
L3 0.75 0.73 0.69 0.62 0.03 0.72 0.74 -
L4 0.62 0.71 0.63 0.58 0.13 0.67 0.57 0.77
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Figure 1. Bland-Altman plots, showing diff erences in mean NTBI or LPI levels (µmol/L) between 2 
methods versus the average of the mean values of these two methods. Solid lines represent the mean 
diff erence between the 2 methods. Thick dashed lines represent the 95% confi dence interval. Thin 
dashed lines at 0 refer to no diff erence between methods. Dots represent the means of duplicates on 
day 2. Note that absolute values on both axis diff er between plots. 
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Figure 2. Relationship between the assay concentrations and transferrin saturation (TSAT). Assay results 
are given for day 2 as duplicate measurements (circle and triangle).   
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Discussion
This second international Round Robin for the quantifi cation of serum NTBI 
and LPI concentrations compared the performance of ten diff erent analytical 
assays in patients with 4 diff erent iron-overload diseases in various treatment 
phases. Nine out of 10 assays reported an assay value above zero in ≥30% of 
the samples. These 9 methods exhibited a high between-sample variation and 
low within-sample variation indicating their suitability to identify diff erent 
serum NTBI and LPI concentrations in patients with iron-overload. Overall, 
results correlated both within the group of fi ve NTBI assays and in the group 
of the four LPI assays, but between group correlations were also present. 
Nonetheless, absolute assay levels diff ered considerably between assays, with 
lowest levels for LPI methods. Overall, assay levels correlated with TSAT but not 
with ferritin concentrations and iron-overload diseases with the highest TSAT 
also had the highest levels of NTBI and LPI. 
Some of the diff erences in absolute values between the assays can be 
attributed to diff erences in the assay principles that result in the measurement 
of diff erent NTBI entities, e.g. NTBI, DCI, NTBI-iron citrate, LPI and eLPI.(2,10) In 
addition, minor variations in analytical procedures between methods aiming 
at the measurement of the same entities (N2-N4 or N1 and N5 or L2 and L3) 
may also have contributed to between-assay variation in absolute values. 
For instance, it has recently been shown that for NTA based assays that use 
fi ltration, centrifugation at extremely high speed can lead to overestimation 
of the NTBI concentration due to passage of transferrin-bound iron through 
the fi lter membrane. Conversely, when centrifuging at lower speed, iron-NTA 
complexes do not pass the membrane, leading to underestimation.(30) The LPI 
assays also mutually diff er in reagents and buff ers. The presence of residual 
chelator or chelates could contribute to higher values in some assays, such as 
the bleomycin-based LPI (L1) assay and the NTA-fi ltration assays (N2-N4), but 
not in others.(10) 
Furthermore, since assays diff ered in the use of acid-treated glassware and 
iron-free plastics and reagents, iron-contamination may also be an important 
source of variation in absolute assay concentrations.(31) Importantly, iron-
contamination could contribute to the reported negative values by mimicking 
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free circulating iron. Rather than registering as an increase in NTBI, this 
contaminant free iron can shuttle from the iron chelator NTA to vacant binding 
sites on transferrin.(25,30,32) Thus samples containing unsaturated transferrin 
may have lower NTBI values compared to standards where no transferrin is 
present. In principle, this can result in underestimation of NTBI and negative 
values. This iron shuttling can be prevented by saturating transferrin with 
cobalt(III) prior to addition of the NTA.(5,33) Still, others have reported that the 
addition of cobalt (III) may result in substantial iron-contamination that could 
account for the rise in NTBI even in normal individuals.(31) Finally, for the iron 
chelator NTA applied in 3 NTBI assays, the use of 80 mM was shown by some 
authors to remove 1-8% of the iron bound to transferrin in case of elevated 
transferrin saturation, thus leading to overestimation of NTBI measurements.
(25,30) By contrast, at physiological concentrations of serum iron in control 
subjects others report no mobilization of iron from transferrin under these 
conditions.(26) 
NTBI is heterogeneous and thought to consist of Fe(III) bound to albumin and 
citrate and potentially to acetate, malate and phosphate.(5-7,14) Of these, 
citrate has the highest affinity for Fe(III).(7) Citrate forms a range of Fe(III) 
complexes, but under the physiological conditions two forms dominate, 
monomeric and an oligomeric form.(7,34) Since the iron citrate forms are likely 
to be the most prevalent in most conditions, a LC-ICP-MS assay for the sum of 
these iron (III)-citrate complexes of NTBI was developed and included as N6 
in the current Round Robin.(5) The assay was reproducible and discriminated 
between samples, but assay levels did not correlate with other assays and 
could not discriminate between any of the disorders. Clearly, this method may 
need optimization, but if successful, we anticipate that quantification of NTBI 
subspecies could provide the basis for further studies on their toxicity. Different 
methods may not be equivalent at measuring these subspecies. It has been 
postulated that the abundance of each subspecies varies with the type and 
degree of iron-overload disease.(6,10) Although this possibility is still under 
investigation, it implies that specific assays might be required for different 
chemical species of NTBI.(5,6,10,12,13)
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Overall the assays correlated well. Mutual correlations between the assays were 
found to be highest in methods based on a similar principle (i.e. in the group 
of NTBI assays and the group of LPI assays). We observed two unexpected 
correlations: fi rst, despite the chelator-based principle of N1, correlation of 
N1 with LPI assays exceeded its correlation with other NTBI assays. A possible 
explanation could be the kinetics of access of CP851 to redox active NTBI.
(5,11,15,25) Secondly, even though assay L1 is based on binding of the antibiotic 
bleomycin to redox-active iron and DNA, its results correlated slightly better 
with most NTBI assays than with LPI assays. Bleomycin-detectable NTBI might 
represent a larger redox active fraction of NTBI than LPI, in equilibrium with a 
larger, still uncharacterized pool of NTBI. 
Diff erences in the range of reported values as well as in absolute values, have 
highlighted the urgent need for thorough method-validation protocols, 
standardization and consensus on how to best report before introduction for 
clinical use. Four out of 10 assays report negative values and as such provide 
information on the residual iron-binding capacity of transferrin. Other assays 
report 0 (zero) for results ≤0, or <LLOD for results that do not signifi cantly diff er 
from 0. It remains to be determined which reporting strategy is clinically more 
useful.
Importantly, both LPI and NTBI assays showed a relationship with TSAT, 
irrespective of the type of iron-overload disease. NTBI and LPI were essentially 
found above certain thresholds of TSAT, lower for NTBI (~70%) than for LPI 
(~90%). A comparable pattern was previously reported for LPI assays that 
were similar to assays L1-L3 for patients with various conditions.(1,2,35,36) 
Altogether, our fi ndings corroborate previous reports in HH and Thal patients 
that TSAT levels of around 70% can be considered as a threshold for the 
presence of  potentially toxic iron species.(1,2) Nonetheless, because a single 
measurement only refl ects the labile iron species present during the previous 
24-48 hrs, repetitive measurements are imperative to assess this potential risk 
of impending NTBI toxicity. (13)
The majority of the assays of the current RR have given useful insights into the 
effi  cacy of iron chelation in transfusional siderotic patients and of phlebotomy 
in patients with hereditary hemochromatosis.(1,2,8,12,17-20,37-40) Despite 
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this finding, in the absence of studies that assess the relation of assay levels to 
clinical outcome in these various patient categories, the clinically most relevant 
assay formats and their decision limits remain unknown. Overall, NTBI and LPI 
need to be put on a more rigorous foundation before they can be used for 
clinical prognostication.
In conclusion, several novel methods have been developed since the previous 
Round Robin for NTBI, including LPI and DCI assays and first attempts to 
specifically determine the NTBI iron-citrate isoforms. While NTBI and LPI values 
of various assays were well correlated and were reproducible, absolute values 
differed considerably. The assay(s) that best represent the clinically relevant 
species and are most relevant for diagnostic and therapeutic purposes cannot 
be determined from this study. Before NTBI and LPI assays can be introduced into 
clinical practice rigorous validation and standardization of assays, consensus 
on how the reporting of results, and clinical outcome studies to determine 
clinically relevant assay formats and their toxic thresholds are needed. 
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Online supplemental information
Collection of samples 
Serum samples (n=60) were collected from patients with 4 iron overload 
disorders in various treatment phases, making a total of 10 diff erent patient 
and treatment groups. 
The 60 serum samples were split into two aliquots, coded, stored at -80°C and 
shipped for analysis on dry ice to the laboratories in May 2013. Laboratories 
performed duplicate measurements in a blinded fashion, on each aliquot of 
a serum sample on 2 diff erent days, resulting in a total of 4 measurements for 
each sample. Some laboratories provided multiple assays. The participants 
reported their results within 5 weeks after receiving the samples.  
Samples (n=18) from HH patients were collected at the Radboudumc between 
January 2004 and March 2012 after obtaining oral informed consent and 
approval of the local ethical committee. They were from 6 diff erent patients 
with a homozygous p.Cys282Tyr mutation in the HFE-gene from 3 diff erent 
stages of phlebotomy treatment: naive (n=6), during depletion (n=6) and 
during maintenance (n=6) therapy. 
Samples from 19 diff erent patients with Thal major and intermedia were 
collected at the University of Cagliari, Italy, between July 2011 and April 2012 
and comprised residual sera from routine clinical assessment conforming to 
the code for proper secondary use of human tissue. In order to obtain suffi  cient 
volumes, samples from both Thal major and Thal intermedia patients consisted 
of 2-5 pooled aliquots of the same patient obtained within a period of 7 months. 
All patients with Thal major were homozygous for the β°39 nonsense mutation. 
Thal major naive patients received transfusions but did not receive iron chelation 
therapy (n=6); Thal major TD & CH patients were transfusion-dependent (TD) 
and received iron chelation (CH) therapy (n=6), either Deferiprone (Ferriprox, 
DFP, n=2) or Deferasirox (Exjade, DFX, n=4). Two diff erent genotypes of the 
β-globin gene were included in the Thal intermedia patients: homozygous 
for β°39 nonsense and compound heterozygous for β6 (-A)/β°39 nonsense. 
In these patients, the co-inheritance of α-thalassemia and the presence of 
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the c.158C>T mutation in the Gγ-globin gene, associated with increased 
production of γ-globin chains in adult life, are the main determinants for the 
milder phenotype. Thal intermedia naive patients were untransfused and did 
not receive iron chelation therapy (n=7). 141, 142
Samples (n=11) from patients with MDS were collected at Rijnstate hospital 
and Radboudumc, The Netherlands between January 2012 and May 2013 after 
obtaining oral informed consent and approval of the local ethical committee. 
Patients with MDS were diagnosed according to the WHO-2001 MDS 
classification system.5 Samples were collected from: i) transfusion-independent 
patients with MDS with refractory anemia with ringed sideroblasts (RARS, n=4) 
or refractory cytopenia with multilineage dysplasia with ringed sideroblasts 
(RCMD-RS, n=2); ii) transfusion-dependent patients with MDS RCMD (n=1), 
MDS RAEB-1 (n=2), MDS RAEB-2 (n=1), MDS therapy related (n=1), where 
transfusion-dependency was defined as serum ferritin ≥1000µg/L or a 
transfusion intensity of ≥1 red blood cell unit/8 weeks (MDS TD). 
Samples (n=12) from patients with sickle cell disease (SCD) were collected, after 
obtaining oral informed consent and approval of the local ethical committee, 
in the Academic Medical Center (AMC) in Amsterdam, The Netherlands 
between March and May 2013. All SCD patients had homozygous sickle cell 
disease (HbSS) and were i) untransfused and without iron chelation therapy 
(SCD naive; n=6) and ii) transfusion-dependent, with serum ferritin ≥1000µg/L, 
including 5 patients on iron chelation therapy that consisted of DFP (n=3) 
and DFX (=2) (SCD TD; n=6). All patients were requested to abstain from iron 
chelation therapy for 24 hours before blood withdrawal. 
Laboratory analysis 
Hemoglobin and mean corpuscular volume (MCV) measurements were 
performed on automated hematology analyzers at the hospital of sample 
collection:  MDS on a Sysmex XE-2100, Thalassemia samples on a Beckman 
Coulter LH750, Hemochromatosis samples on an ADVIA TM120, Sysmex 
XE-2100 or Sysmex XE-5000; SCD samples on a Sysmex XE-5000. C-reactive 
protein (CRP), lactate dehydrogenase (LDH), Hemolytic Index (HI) and all iron 
parameters were all determined at Radboudumc on an Architect c16000 
(Abbott Diagnostics, Lake Forest, USA) or on an Immulite 2000 (Siemens 
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healthcare Diagnostics, Deerfi eld, USA). Only LDH of the SCD and MDS patients 
(P800, Roche diagnostics) and ferritin for SCD patients (E170 Roche Diagnostics) 
were measured on automated analyzers at the hospital of sample selection. 
Reference ranges are from the clinical laboratory of Radboudumc.
Transferrin was measured using immunochemistry and total iron binding 
capacity (TIBC) was calculated as: TIBC (μmol/L) = 25.0 x transferrin (g/L). TSAT 
was calculated as: TSAT (%) = (serum iron (μmol/L) / TIBC (μmol/L)) x 100%. For 
all samples, TSAT was also determined by urea gel electrophoresis, separating 
the four forms of transferrin (apotransferrin, monoferric transferrin with iron 
bound to either the N-terminus or the C-terminus and holotransferrin) by 
polyacrylamide gel electrophoresis in the presence of 6M urea. 143 This latter 
TSAT methodology is not aff ected by the presence of residual chelator or 
chelates.
Statistical methods
The study was designed to compare NTBI levels as well as the repeatability 
of the methods. With respect to the repeatability, the magnitude of variation 
that exists between samples and between measurements of the same sample 
relative to the total variation is of interest. Accordingly, we partitioned 
the total variance of each method into the following components: i) the 
between-sample variance and ii) the analytical variance. Our design allowed 
us to divide the latter into three subcomponents: the between-day variance, 
the between-duplicate variance and the residual analytical variance, i.e. the 
part of the analytical variance that cannot be attributed to the other two. A 
linear mixed model was used to estimate these variance components of each 
method separately. The dependent variable was the NTBI outcome, and the 
independent random variables were: sample (60 levels), day (two levels) and 
repeated measurement (two levels). The standard deviation   (absolute error) 
and the percentage variance relative to the total variance are presented for 
each method separately.
For statistical calculations, for assays N3 and N4, results below the LLOD of 0.60 
and 0.87 were included as 0.30 and 0.40 µmol/L, respectively; for assays L3 and 
L4, results above the ULOD of 2.2 were included as 2.4 µmol/L.
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Supplemental Figure 1. Correlation plots between assays, using the mean of the duplicate measurements 
on day two.  
A, B and C match the upper left, lower left and lower right quadrant of table 4 of the article, respectively. 
The Spearman correlation coefficients of each plotted combination of two assays can be found in the 
respective cell in table 4. 
Absolute values on both axis are expressed in µmol/L and differ between plots. 
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Abstract 
Red blood cell transfusions remain one of the cornerstones in supportive care 
of lower-risk patients with myelodysplastic syndromes. We hypothesized that 
patients develop oxidant mediated tissue injury through the formation of 
toxic iron species, caused either by red blood cell transfusions or by ineff ective 
erythropoiesis. We analyzed serum samples from 100 lower-risk patients with 
myelodysplastic syndromes at six-month intervals for transferrin saturation, 
hepcidin-25, growth diff erentiation factor 15, soluble transferrin receptor, non-
transferrin bound iron and labile plasma iron in order to evaluate temporal 
changes in iron metabolism and presence of potentially toxic iron species and 
their impact on  survival. Hepcidin levels were low in 34 patients with ringed 
sideroblasts compared to 66 patients without. Increases of hepcidin and non-
transferrin bound iron levels were visible early in follow-up of all transfusion 
dependent patient groups. Hepcidin levels signifi cantly decreased over time 
in transfusion independent patients with ringed sideroblasts. Increased 
soluble transferrin receptor levels in transfusion-independent patients with 
ringed sideroblasts confi rmed the presence of ineff ective erythropoiesis and 
suppression of hepcidin production in these patients. Detectable labile plasma 
iron levels in combination with high transferrin saturation levels occurred almost 
exclusively in patients with ringed sideroblasts and all transfusion dependent 
patient groups. Detectable labile plasma iron levels in transfusion dependent 
patients without ringed sideroblasts were associated with decreased survival. 
In conclusion: toxic iron species occurred in all transfusion dependent patients 
and in transfusion independent patients with ringed sideroblasts. Labile plasma 
iron appeared to be a clinically relevant measure for potential iron toxicity and 
a prognostic factor for survival in transfusion dependent patients. This trial was 
registered at www.clinicaltrials.gov as #NCT00600860.
Louise de Swart van idml.indd   133 04-05-19   13:47
Chapter 6
134
Introduction 
Myelodysplastic syndromes (MDS) are a heterogeneous group of acquired 
clonal hematopoietic stem cell disorders that are characterized by abnormal 
differentiation and maturation of hematopoietic cells, bone marrow failure 
and genetic instability with an enhanced risk of progression to acute myeloid 
leukemia.1 The EUMDS registry is a prospective, observational registry 
established in 2007 to collect data on low and intermediate-1 risk MDS patients, 
which represents the lower-risk MDS population comprising approximately 
seventy percent of the overall MDS population.2,3 The majority of lower-risk MDS 
patients (51% in the EUMDS Registry)3 become transfusion dependent, usually 
early after diagnosis. With an expected median survival of 2.4 to 11.8 years, these 
patients are prone to long-term accumulation of iron due to red blood cell (RBC) 
transfusions.4-8 Iron overload may also occur in MDS patients who do not receive 
RBC transfusions, due to the stimulation of intestinal iron absorption, mediated 
through suppression of hepcidin production in patients with ineffective 
erythropoiesis9. Patients with ringed sideroblasts (MDS-RS) are of special interest 
in this context, considering their pronounced ineffective erythropoiesis.6,7,10,11
The toxic effects of iron overload in other iron loading diseases, such as 
hereditary hemochromatosis11 and the thalassemia syndromes12, are well 
known, but the consequences in MDS remain to be elucidated. MDS patients 
are generally older than patients with other iron loading disorders13. Their 
exposure may not be long enough to develop classical tissue damage due to 
iron overload, but they may suffer from oxidative stress caused by toxic iron 
molecules. Moreover, iron toxicity might be restricted to specific subgroups of 
MDS patients: patients receiving RBC transfusions and a subgroup of patients 
with MDS-RS and increased ineffective erythropoiesis.5,13
A greater insight into the pathophysiology of iron metabolism in MDS, might be 
obtained through an optimized diagnostic work-up and monitoring by specific 
iron metabolism markers, including hepcidin, growth differentiation factor 15 
(GDF15), soluble transferrin receptor (sTfR),  and the recently introduced serum 
toxic iron species, namely  non-transferrin bound iron (NTBI) and labile plasma 
iron (LPI).14-18 The most important regulator of systemic iron metabolism is 
hepcidin, a 25-aminoacid peptide hormone, produced predominantly by the 
hepatocytes. Hepcidin triggers internalization and lysosomal degradation of 
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ferroportin, a membrane bound cellular iron exporter present on macrophages 
and the basolateral site of enterocytes that releases iron into the circulation.19,20
Hepcidin is suppressed in hypoxia and with increased erythropoietic iron 
demand and is upregulated in case of infl ammation and increased circulating 
iron levels and elevated body iron stores.5,20,21
GDF15 is a protein produced by erythroid precursors and has been reported to 
be involved in the communication between bone marrow and liver in case of an 
increased erythroid demand, functioning as a suppressor of hepcidin synthesis, 
as shown for  β-thalassemia.5,9,22 However, its role in MDS is still a matter of 
debate because of confl icting results.5,11,22-25 Twisted gastrulation factor 1 
(TWSG1) and Erythroferrone (ERFE) are also reported to have a suppressive 
function in hepatic hepcidin production, but validated human assays are 
not available.9 Of additional interest in iron homeostasis is sTfR. The serum 
concentration of sTfR is proportional to the quantity of the Transferrin Receptors 
1 (TfR1) on cellular membranes, especially on erythroid precursors, and is a 
valuable parameter of erythroid mass and iron supplies.26,27 Among others, 
sTfR levels are elevated in case of high erythroid proliferation rates especially 
in combination with adequate iron supply,27 as in diseases characterized by 
ineff ective erythropoiesis such as β-thalassemia syndromes, and suppressed in 
case of decreased erythropoietic activity as in anemia of chronic disease, and 
diseases with erythroid hypoplasia.20,25,28  Earlier studies showed that sTfR levels 
are increased in MDS-RS5, including SF3B1-positive MDS, patients.11
NTBI concentrations are only sporadically present with transferrin saturations 
(TSAT) <70% and increase sharply when saturation of transferrin with iron 
exceeds 70%.29 Chemically, NTBI consists of iron that is rather loosely bound 
to albumin or low molecular weight metal complexing groups.30,31 The NTBI 
complexes may be taken up by specifi c NTBI transporters in liver, pancreas, and 
heart and contribute to oxidant-mediated cellular injury in these tissues.17,32 LPI 
is thought to be the NTBI fraction that is mostly responsible for tissue injury, 
since it is readily available to participate in redox cycling causing oxidative 
damage to cellular membranes, proteins and DNA.15,33 It has been proposed 
that plasma NTBI is an important early indicator of extra-hepatic iron toxicity in 
β-thalassemia major.34,35
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Improved insights in levels and roles of key players of iron metabolism during 
treatment with transfusions in the various MDS subtypes may provide leads for 
novel diagnostic and iron reducing treatment strategies. The prospective study 
of the EUMDS registry has been initiated to provide a better understanding of 
the pathophysiology and prognostic value of iron overload and iron mediated 
oxidative stress as well as possibly important markers in iron homeostasis 
over time in MDS. To this end, we evaluated serum ferritin, iron, transferrin 
saturation, hepcidin-25, GDF15, sTfR, NTBI and LPI levels over time in lower-
risk MDS patients and their relation with WHO 2001 subtype and transfusion 
history. We identified detectable LPI levels as a new important prognostic 
factor for survival in patients with MDS-RS or lower-risk MDS patients treated 
with regular RBC transfusions.
Methods 
Study design and participants 
Patients were eligible to be included in the EUMDS registry if they were newly 
diagnosed with MDS according to the WHO 2001 classification and a low or 
intermediate-1 score according to the IPSS prognostic system.2 Patients with 
IPSS intermediate-2 or high risk, patients with secondary or therapy-related 
MDS were excluded from this registry. The ethics committees of all participating 
countries and centers have approved the protocol (ClinicalTrials.gov Identifier: 
NCT00600860). Patients were required to provide written informed consent. 
Serum samples were collected prospectively, at registration and at 6-month 
intervals, from 109 patients included in six countries participating in this study 
from April 2008 to December 2010, but samples from nine patients had to be 
excluded due to technical reasons, see online supplemental information for 
details. The total number of analyzed serum samples was 454.
Biochemical assays
The iron parameters in this sub study were analyzed centrally at the department 
of Laboratory Medicine of the Radboudumc, Nijmegen, Netherlands. Detailed 
information these iron parameters is described in the online supplemental 
information.
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Measurement of serum NTBI consisted of the chelation-ultrafi ltration-
detection approach based on the prior mobilization of serum NTBI by weak 
iron-mobilizing chelators such as nitrilotriacetate (NTA) at 80 mM. The chelated 
NTBI is separated from transferrin-bound iron by ultrafi ltration and detected 
by colorimetry.36 The lower limit of detection (LLOD) of the NTBI assay is 0.47 
μmol/L. The LPI measurement was based on the measurement of the redox-
active and readily chelatable fraction of NTBI. This assay measures iron-
catalyzed radical generation in the presence of a low ascorbate concentration. 
Radical generation was measured with the fl uorogenic redox sensitive probe 
dihydrorhodamine (DHR) 123, and iron-catalyzed radical generation was 
calculated by subtracting the radical generation in the presence of 50 μmol/L 
of the bidendate iron chelator deferiprone (DFO, the LPI DHR oxidation that is 
NOT iron dependent).37 The LLOD of the LPI assay is 0.24 μmol/L.
Statistical analysis
Standard descriptive techniques were used to assess the association between 
the iron parameters including Spearman’s rank correlation coeffi  cients. Where 
NTBI or LPI was below LLOD, values were randomly drawn from a univariate 
distribution in the range from zero to the LLOD. Overall survival (OS) was defi ned 
as the time from date of diagnosis to death or for subjects still alive censored 
at the date of the last visit a sample was available. Cox proportional hazards 
regression models and Kaplan–Meier survival curves with time-dependent 
covariates38 were used in time-to-event analyses to assess the impact of 
LPI level, NTBI and TSAT by transfusion status on survival. All variables were 
treated as time-varying covariates in the model by assessing the levels of the 
parameters (LPI, NTBI: <LLOD vs elevated, TSAT <80% vs ≥80%) and transfusion 
status (transfused vs. not transfused) at each visit. LPI and NTBI levels >LLOD 
were considered abnormal. Once a subject had received a transfusion, they 
were classifi ed as transfused for the remaining time. Hazard ratios (HR) and 95% 
confi dence intervals (95% CI) are reported for both univariate and multivariate 
models. In the case of the multivariate analyses, the additional covariates 
included were age at diagnosis, IPPS-R category and usage of Erythroid 
Stimulating Agents (ESA).  All analyses were undertaken in Stata 14 (StataCorp, 
College Station, TX). 
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Results
Patient Characteristics 
The median age of all patients at registration was 73 years (range 43-95 years). 
The majority of the patients were male: 64% (n=64). The IPSS risk groups of 
the 100 patients in the study were low 47%, intermediate-1 41% and unknown 
12% and the IPSS-R risk groups were very low 32%, low 41%, intermediate 8%, 
high 3% and unknown 16%. WHO2001 MDS-subtypes were RCMD (37%), RARS 
(30%), RA (18%), RAEB (7%), 5q-syndrome (4%) and RCMD-RS (4%).  Fourteen 
percent of the patients were transfusion dependent (defined as any time after 
starting transfusions) at registration (n=14). No patients received iron chelation 
therapy at time of registration. Six patients received iron chelation therapy 
during this observation period (Table S1). The median number of samples 
available per patient is five samples (range 1-7), and median follow-up was 5.8 
years. Overall survival and progression free survival in our study population 
were 4.8 and 4.6 years, respectively. Nineteen patients have died, including 5 
patients after progression and 9 patients from causes possibly related to MDS 
(hemorrhage 2, infection 5, and cardiovascular 2 patients) (table S4).
  
Iron parameters 
Median ferritin levels were elevated (>250 µg/l) at registration in all patient 
groups, but the highest median levels were observed in the transfusion 
dependent (TD) groups (Table 1). Median serum iron levels were within reference 
range (12-30 µmol/L) in all patient groups at registration. Overall, median TSAT 
was within reference range (<45%) at registration with the exception of TD 
MDS-RS patients (Table 2). Median hepcidin levels were within reference range 
in all patient groups at registration, but TD patients had significantly higher 
hepcidin levels compared to transfusion independent (TI) patients (p<0.001). 
Ferritin levels correlated significantly with hepcidin levels (r=0.55, p<0.001). 
The median GDF15 levels were elevated in the RS subgroup only. NTBI levels 
above LLOD (>0.47 µmol/L) occurred in all patient groups at registration with 
highest levels in MDS-RS patients. STfR levels were within reference range (0.8-
1.8 mg/L) at registration, and the highest levels were observed in TI MDS-RS 
patients (Table 2). The median LPI levels were below LLOD in all patient groups 
at registration (<0.24 mol/L), except in TD MDS-RS patients. Median CRP levels 
were below the upper limit of the reference range (<10 mg/L) in all groups 
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Table 2 Frequency, median and quartiles of iron parameters by transfusion status per MDS subtype at 
registration, 1 year and 2 years follow-up
Registration 1 year follow-up 2 years follow-up
N Median(p10-p90) N Median(p10-p90) N Median(p10-p90)
Transferrin 
saturation (%) 
100 35.6 (19.0 - 87.4) 78 34.4 (16.4 - 92.9) 64 37.5 (22.2 - 94.3)
MDS non-RS: TI 56 32.8 (17.1 - 55.6) 32 28.4 (17.4 - 59.1) 26 30.1 (18.8 - 54.2)
MDS non-RS: TD 10 28.7 (8.5 - 77.9) 21 36.8 (14.0 - 89.1) 17 39.3 (20.4 - 97.7)
MDS-RS: TI 29 48.8 (24.6 - 92.5) 16 36.4 (20.8 - 86.4) 9 35.6 (23.9 - 92.6)
MDS-RS: TD 5 90.0 (53.1 - 120.4) 9 93.6 (42.1 - 110.6) 12 93.1 (71.7 - 97.6)
Hepcidin (nmol/L) 99 4.5 (1.1 - 21.7) 78 5.6 (1.2 - 19.6) 65 5.2 (1.0 - 19.6)
MDS non-RS: TI 56 4.5 (1.7 - 22.1) 32 4.3 (1.5 - 11.8) 26 4.6 (0.9 - 13.6)
MDS non-RS: TD 10 4.9 (0.5 - 75.9) 21 17.3 (0.5 - 29.2) 17 9.2 (1.3 - 28.4)
MDS-RS: TI 28 3.8 (1.0 - 8.7) 16 3.4 (0.5 - 5.8) 9 2.9 (0.8 - 12.2)
MDS-RS: TD 5 10.3 (3.8 - 15.9) 9 9.2 (3.8 - 14.4) 13 5.2 (1.0 - 14.6)
Growth differentiation 
factor 15 (ng/L)
100 2193 (952 - 5663) 77 2479 (1016 - 7982) 63 2576 (1045 - 7746)
MDS non-RS: TI 56 1777 (731 - 4658) 32 1653 (615 - 5684) 26 1685 (633 - 5736)
MDS non-RS: TD 10 2306 (1218 - 4927) 20 2583 (1725 - 7166) 17 2998 (1398 - 8037)
MDS-RS: TI 29 2619 (996 - 11083) 16 2694 (1223 - 10303) 8 2780 (1331 - 9554)
MDS-RS: TD 5 2893 (2113 - 5370) 9 3866 (830 - 15167) 12 5361 (1053 - 8399)
Soluble transferrin 
receptor (mg/L)
100 1.3 (0.7 - 2.8) 78 1.4 (0.7 - 3.0) 62 1.3 (0.8 - 2.7)
MDS non-RS: TI 56 1.2 (0.8 - 2.7) 32 1.4 (0.9 - 2.8) 26 1.2 (0.9 - 2.7)
MDS non-RS: TD 10 1.0 (0.6 - 2.8) 21 1.1 (0.4 - 3.1) 16 1.2 (0.6 - 2.2)
MDS-RS: TI 29 1.6 (0.8 - 3.3) 16 2.0 (1.1 - 2.8) 8 2.2 (1.0 - 2.8)
MDS-RS: TD 5 0.9 (0.4 - 3.1) 9 1.2 (0.6 - 3.1) 12 1.4 (0.4 - 3.6)
Non transferrin 
bound iron (µmol/L)
100 0.65 (0.14 - 3.03) 77 0.59 (0.15 - 3.64) 65 0.64 (0.14 - 5.42)
MDS non-RS: TI 56 0.41 (0.10 - 1.51) 31 0.42 (0.03 - 0.91) 26 0.50 (0.18 - 1.78)
MDS non-RS: TD 10 0.80 (0.05 - 2.73) 21 0.69 (0.16 - 3.64) 17 1.00 (0.12 - 7.25)
MDS-RS: TI 29 0.88 (0.26 - 3.99) 16 0.70 (0.16 - 3.52) 9 0.52 (0.05 - 5.42)
MDS-RS: TD 5 3.03 (1.90 - 3.40) 9 3.60 (0.15 - 8.64) 13 2.86 (0.46 - 7.57)
Labile plasma 
iron (µmol/L)
100 0.09 (0.02 - 0.22) 77 0.13 (0.03 - 0.38) 65 0.13 (0.02 - 0.38)
MDS non-RS: TI 56 0.10 (0.03 - 0.19) 31 0.10 (0.02 - 0.17) 26 0.11 (0.01 - 0.30)
MDS non-RS: TD 10 0.06 (0.01 - 0.18) 21 0.17 (0.06 - 0.38) 17 0.14 (0.02 - 1.08)
MDS-RS: TI 29 0.10 (0.02 - 0.32) 16 0.09 (0.05 - 0.24) 9 0.10 (0.03 - 0.17)
MDS-RS: TD 5 0.08 (0.00 - 0.35) 9 0.47 (0.06 - 1.26) 13 0.19 (0.08 - 1.39)
RS: ring sideroblastic; TI = Transfusion Independent, TD = Transfusion Dependent
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at all time-points (Table 1) and the majority of patients with CRP levels above 
50 mg/L were transfusion-dependent. CRP levels correlated positively with 
hepcidin levels (r = 0.30, p<0.001) and ferritin levels (r=0.22, p<0.001). 
Impact of MDS subtype and transfusions on iron parameters over time 
The impact of transfusions and MDS subtype (RS versus nonRS) on TSAT, 
hepcidin, GDF15, NTBI and LPI levels over time is shown in Table 2. Both serum 
ferritin and serum iron levels increased signifi cantly (r=0.59, p<0.001 and r=0.32, 
p<0.001, respectively) with cumulative number of transfused units over time in 
transfusion dependent patients (Table S2) as well as in RS patients (Table S3). 
TSAT remained stable and within reference range in the TI patients with the 
exception of a minority of RS patients (Figure S2) and increased over time in the 
TD patients up to 94.9% in patients with >10 RBC units transfused (Table S2). 
Hepcidin levels increased with the number of units transfused, but in contrast, 
hepcidin levels signifi cantly decreased over time in transfusion independent 
MDS-RS patients. (Table S3). GDF15 levels were not associated with transfusion 
status alone, but did increase over time in TD MDS-RS patients with a median of 
2893 ng/L at registration compared to 5361 ng/L at two years follow up. 
STfR levels increased signifi cantly (p<0.001) over time both in TI- and TD MDS-
RS patients (p=0.01) (Table 2). STfR levels did not change over time in non-
RS MDS patients. The lowest sTfR levels were observed in patients who had 
received more than 10 units (Table S2). TD MDS-RS patients had the most 
elevated levels of NTBI and LPI over time (Table S2, S3). 
Correlation between markers of iron overload 
Both elevated NTBI and LPI levels (>LLOD) showed a threshold eff ect with TSAT 
of >70% and >80%, respectively (Figure 1A-B). Detectable LPI levels occurred 
almost exclusively in patients with MDS-RS and/or patients who had received 
transfusions. NTBI and LPI levels above the LLOD were mutually positively 
correlated (r = 0.46; p<0.001). Both NTBI and LPI showed a linear relationship 
(P<0.001) with ferritin, but no threshold levels could be detected (Figure 1C-
D). The highest values were observed in transfusion dependent MDS patients; 
and subgroup analyses showed mainly a positive correlation in the transfusion 
dependent and/or RS subgroup (Figure 1C-D).
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Figure 1 LPI and NTBI correlated to TSAT and Ferritin in different patient groups. A) Relation between LPI 
and TSAT. B) Relation between NTBI and TSAT C) relation between LPI and ferritin. D) Relation between 
NTBI and ferritin. Each dot represents one sample (median: 5 samples/patient).
RS = ring sideroblastic, TI = Transfusion Independent, TD = Transfusion Dependent
Prognostic impact of iron overload markers 
Time-dependent, multivariate analysis of overall survival, adjusted for age and 
IPSS-R risk groups revealed no significant effect on overall survival for NTBI 
(HR=0.56, 95%CI=0.21-1.52; p=0.26) and for TSAT (HR=0.91, 95%CI=0.29-2.86; 
p=0.88) (table 3, figure 2B and Figure S1).  
Ten out of 19 patients who died during this study had detectable LPI. The 
majority (7 patients) died from progression or MDS-related causes (table S4). 
Kaplan-Meier curves demonstrate prognostic impact on survival of detectable 
LPI levels by transfusion status (Figure 2), but no significant effect in the 
multivariate analysis adjusted for age and IPSS-R risk (HR=2.1, 95%CI 0.7-6.2; 
table 3). Once LPI is increased in both transfusion dependent and independent 
patients, survival time decreases, with greatest impact in patients who are 
transfusion dependent and have increased LPI levels (adjusted HR=3.0, 95%CI= 
0.7-13.3). Since 41 patients were also treated with erythropoietin stimulating 
agents (ESA), we repeated the analyses adjusted for whether or not the patient 
had been treated with erythropoietin stimulating agents (ESA) at each visit 
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(Figure 3). These adjustments did not signifi cantly alter the magnitude of the 
risk estimates on overall survival (HR=3.0, 95%CI= 0.7-13.5) (Table 3).
Because the survival of patients with RS-MDS is usually considered better than 
in the nonRS MDS population, we repeated the analyses in the largest group of 
66 nonRS patients (table 4). Detectable LPI levels had a remarkable impact on 
survival in the whole nonRS group, but the impact was only signifi cant in the 
TD subgroup (HR=17.0, 95%CI 2.0-146.6). TSAT levels had a borderline impact 
on survival in TI patients.
Six patients received iron chelation in this study (Table S3). LPI levels during 
treatment with deferasirox decreased below LLOD (four patients), even 
in patients with high TSAT.  Only three patients have been treated with 
lenalidomide.
Ferritin levels and elevated CRP are time dependent variables, which correlate 
closely with transfusion burden/transfusion intensity, and presumably with 
infections (detailed data not available). Ferritin levels and elevated CRP predict 
survival when adjusted for age and IPSS-R group only, but the prognostic impact 
is less clear when transfusion intensity was added to the model (data not shown).
Louise de Swart van idml.indd   143 04-05-19   13:47
Chapter 6
144
Figure 2 Survival according to LPI (2A) or NTBI (2B) and transfusion status. LPI, NTBI and transfusion 
status were analyzed as time dependent factors, implicating that patients may switch groups over time 
according to the LPI/NTBI and transfusion status at each specific time point.
LLOD = Lower Limit of detection, TI = Transfusion Independent, TD = Transfusion Dependent 
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Figure 3 Flow diagram of patients treated with transfusions and erythropoietin stimulating agents 
(ESAs). In total, 10 patients became transfusion independent after starting ESA treatment
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Table 4 Cox model of overall survival by labile plasma iron, non-transferrin bound iron and transferrin 
saturation along with transfusion status as time varying variable for non-ring sideroblast patients only 
(n=66)
Unadjusted Adjusted1 Adjusted2
Hazard ratio
(95% CI)
p Hazard ratio
(95% CI)
p Hazard ratio
(95% CI)
P
LPI (µmol/L) 
<LLOD1
1 - 1 - 1 -
Elevated 4.9 (1.4 – 16.8) 0.01 5.4 (1.5 – 19.6) 0.01 9.3 (2.0 – 43.3) 0.004
LPI<LLOD, TI 1 - 1 - 1 -
LPI≥LLOD, TI 10.2 (0.9 – 115.4) 0.06 5.3 (0.4 – 68.9) 0.20 5.9 (0.4 – 86.2) 0.19
LPI <LLOD, TD 4.6 (0.9 – 23.5) 0.07 2.0 (0.3 – 12.0) 0.47 1.4 (0.2 – 8.9) 0.70
LPI ≥LLOD, TD 11.8 (1.9 – 74.0) 0.008 10.3 (1.3 – 79.5) 0.03 17.0 (2.0 – 146.6) 0.01
NTBI (µmol/L) 
<LLOD1
1 - 1 - 1 -
Elevated 0.6 (0.2 – 1.9) 0.37 0.6 (0.2 – 2.0) 0.38 0.6 (0.2 – 2.2) 0.46
NTBI<LLOD, TI 1 - 1 - 1 -
NTBI≥LLOD, TI 0.6 (0.1 – 6.9) 0.70 1.1 (0.1 – 14.4) 0.92 1.1 (0.09 – 14.3) 0.92
NTBI<LLOD, TD 5.7 (1.1 – 30.3) 0.04 5.7 (0.8 – 42.2) 0.09 5.4 (0.7 – 43.7) 0.11
NTBI≥LLOD, TD 2.1 (0.4 – 12.3) 0.39 1.4 (0.2 – 8.2) 0.74 1.4 (0.2 – 8.2) 0.74
TSAT <80 1 - 1 - 1 -
Elevated 2.1 (0.6 – 7.8) 0.28 1.1 (0.2 – 5.4) 0.90 1.5 (0.3 – 8.6) 0.63
TSAT <80, TI 1 - 1 - 1 -
TSAT≥80, TI 3.8 (1.1 – 12.7) 0.03 3.7 (0.98 – 13.8) 0.053 3.7 (0.99 – 14.1) 0.052
TSAT <80, TD 1.9 (1.1 – 3.2) 0.02 1.7 (0.9 – 3.2) 0.13 1.6 (0.8 – 3.2) 0.21
TSAT≥80, TD 1.5 (0.9 – 2.5) 0.12 1.1 (0.6 – 1.9) 0.80 1.1 (0.6 – 1.9) 0.77
LLOD = lowest level of detection, LPI = Labile Plasma Iron, TI = Transfusion Independent, TD = Transfusion 
Dependent
1 Adjusted for age at diagnosis and IPSS-R; 2 Adjusted for age at diagnosis, IPSS-R and ESA treatment 
status at each visit
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Figure 4 Proposed pathogenesis of iron toxicity in lower-risk MDS: the impact of ineffective erythropoiesis 
(4a) and of transfusions (4b)
Ineffective erythropoiesis (IE), especially in ring sideroblastic MDS, results in increased bone marrow 
production of GDF15 and possibly twisted gastrulation 1(TWSG1) and erythroferrone (ERFE). These 
factors inhibit hepcidin production by the hepatocytes. Low hepcidin levels increase iron absorption 
from intestinal mucosa and increase iron release from the macrophages. Finally, this may lead to 
toxic levels of NTBI and LPI causing damage in solid organs, immune system and the marrow. During 
transfusions hepcidin levels increase, despite higher GDF15 levels, leading to lower iron absorption in 
the gut. However, transfusions cause massive iron loading of RES-macrophages leading to elevated 
circulating, stored iron levels and toxic iron species - despite elevated hepcidin levels - and subsequent 
toxicities. Figure adapted from M. Cuijpers, et al 144
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Discussion 
This study among 100 European lower-risk MDS patients showed that both 
red blood cell transfusions and presence of RS increased the occurrence of the 
toxic iron species NTBI and LPI in serum. Our data on iron parameters over time 
suggest that body  iron accumulation and toxic iron species (NTBI and LPI)  in RS-
MDS patients occur along the axis of ineff ective erythropoiesis, characterized 
by elevated sTfR, increased GDF15, low hepcidin, and increased circulating and 
parenchymal iron levels (Figure 4a). Interestingly, we found detectable LPI, but 
not NTBI, to be associated with a signifi cantly decreased overall survival in the 
nonsideroblastic MDS patients. 
Hepcidin levels were signifi cantly elevated in all transfusion dependent (TD) 
patient categories, immediately after initiation of transfusions and remained 
elevated during transfusion dependency, confi rming recent studies in 
transfused MDS patients and illustrated in Figure 4b.5,7 However, the elevated 
hepcidin levels showed a tendency to decrease during continued exposure 
to transfusions. In addition, sTfR levels decreased over time in TD patients, 
compatible with previously reported suppression of erythropoiesis by 
continued transfusions.20,25 Interestingly, GDF15 increased over time in TD MDS 
patients and especially in TD RS-MDS patients. Increased GDF15 has previously 
been associated with ineff ective erythropoiesis, but not with TD-mediated 
suppression of erythropoiesis.5 This suggests that TD-mediated suppression of 
ineff ective erythropoiesis may be less eff ective during prolonged transfusions. 
This is supported by the gradual decline over time of the initially elevated 
hepcidin levels during prolonged transfusions. These data show that previous 
confl icting observations on the relationship of GDF15 and hepcidin can 
be explained by the impact of transfusions on GDF15 and hepcidin levels, 
especially in RS-MDS patients.5
Hepcidin levels decreased over time in TI patients of the RS subtype. An earlier 
study in 107 untransfused patients observed generally elevated hepcidin 
levels in MDS, but they observed low hepcidin/ferritin ratios in the RS subtypes, 
compatible with the low hepcidin levels in the RS patients of our study.39 In 
addition, RS patients showed elevated sTfR levels and decreased hepcidin 
levels compared to TI non-RS at all time points. These observations confi rm the 
previously reported association between sTfR and ineff ective erythropoiesis, 
resulting in increased uptake of dietary iron and iron release by macrophages, 
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subsequently leading to increased circulating iron levels, elevated parenchymal 
iron stores and toxic iron species.7 Interestingly, recently developed hepcidin 
agonists prevented low-hepcidin induced toxicity pre-clinically showing the 
potential of these compounds to prevent iron loading erythropoietic activity 
in MDS, especially in RS-MDS.25,40 Altogether, our data suggest worsening over 
time of the ineffective erythropoiesis in RS patients and lower hepcidin levels 
in these patients.41,42 
Elevated NTBI levels could be demonstrated in our study early in follow up of all 
patient groups. In iron loading anemias, such as thalassemia syndromes, iron 
species, like NTBI and LPI, have been suggested to serve as early indicators of 
iron toxicity and as measures for the effectiveness of iron chelation therapy 
in reducing potentially toxic iron molecules in the plasma.7,43 Excess toxic iron 
species catalyze the cellular generation of ROS. Oxidative stress, and high TSAT, 
as in combination with subsequent decrease in cellular antioxidants, may lead 
to oxidation of lipids, proteins and DNA causing cell and tissue damage.44,45 
Biomarkers of oxidative stress have been found to be increased in patients with 
MDS and iron overload.3,46-49 The combination of high serum ferritin levels as 
well as the presence of NTBI and LPI, was noted more frequently in RS patients 
compared to non-RS patients in our study. Here, it is important to realize 
that in general practice, including our study, serum samples are collected 
immediately prior to transfusions. LPI levels are usually elevated for a few days 
after transfusion (except when transferrin is highly saturated) in contrast to the 
more stable NTBI which have been reported to have a longer half-life.50,51  These 
free iron molecules are easily translocated intracellularly and cause oxidative 
stress as shown in thalassemia.33 Oxidative stress may explain why elevated LPI 
levels are associated with an increased risk of dying prematurely, too early to 
die from causes related to classical iron overload in lungs, liver and heart as 
observed in young thalassemia patients after long-term transfusions. 
Less is known about pathophysiology and tissue toxicity of iron overload 
caused by ineffective erythropoiesis in MDS. We observed that high NTBI and 
LPI levels also occurred in RS patients not receiving transfusions, indicating that 
iron toxicity (oxidative stress) may also occur in this category of MDS patients 
(Figure 4), similar to transfusion independent β-thalassemia intermedia, 
α-thalassemia (Hb-H disease), and X-linked sideroblastic anemia.52,53 
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Previously, we reported that detectable LPI occurred almost exclusively in 
samples with TSAT >80%.29 Interestingly, in the current study survival of patients 
with TSAT >80% was not diff erent from the survival of patients with a TSAT 
below this level (Figure S1). The lowest hepcidin levels have been observed 
in RS patients,5 similar to our observations. Elevation of LPI in TI patients 
occurred exclusively in RS patients as expected in view of the low hepcidin 
levels leading to increased serum iron levels, through increased intestinal iron 
absorption and increased iron release from macrophages. Non-RS patients 
with SF3B1 mutations may show a similar iron pathophysiology since they 
appear to have a similar outcome compared to RS-MDS patients with SF3B1 
mutations.54 In addition, signifi cant relationships were found between SF3B1
mutations and marrow erythroblasts (P=0.001) or soluble transferrin receptor 
factor 15 (P=0.033).11 Our data show that elevated LPI levels - in contrast to 
elevated NTBI levels and TSAT - associate with decreased survival. The risk of 
dying prematurely  in patients with detectable LPI levels occurred too early in 
this study to explain this risk by classical iron overload due to organ toxicity 
(lungs, liver and heart) after long term transfusions, but this indicates a direct 
eff ect associated with elevated LPI levels. The impact of detectable LPI was only 
signifi cant in the large nonRS group, but the same tendency was observed in 
the smaller RS subpopulation. This eff ect was independent of ESA treatment 
indicating that the eff ect of LPI on outcome is not simply an eff ect of the 
interaction of LPI with ESA - as a previously described outcome modifi er.55,56 The 
widely used parameter TSAT cannot serve as a parameter to predict survival. 
However, TSAT can be used as a pre-screening method to identify patients who 
are at risk to develop detectable LPI levels and associated poor prognosis. This 
approach may reduce the number of LPI determinations considerably. 
Ferritin levels have been reported as a prognostic indicator in MDS, but ferritin 
as a marker of iron toxicity may be compromised by the stage of MDS, the 
cumulative transfusional load and its properties as an acute phase protein.57,58,59
Moreover, the level of ferritin does not indicate whether iron is stored in 
parenchymal cells or in the reticulo-endothelial system (RES), of which the 
former is considered to be a more toxic form of iron overload. The foregoing is 
refl ected by the weaker correlation of ferritin levels with LPI when compared 
with the correlation between TSAT and LPI levels. The positive correlation 
between CRP and hepcidin in our study suggests that infl ammation also 
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influences iron homeostasis in some MDS patients, as reported for patients with 
other inflammatory diseases.4 Similar to ferritin, CRP has a significant impact 
on survival, potentially reflecting the impact of infections and autoimmune 
diseases on survival in this patient group. Finally, we could show in the limited 
number of patients treated with iron chelators in this study that LPI levels 
decreased below LLOD, even in patients with high TSAT during treatment 
with deferasirox. These data corroborate with the post-hoc data from a large 
chelation study in MDS.43
In conclusion, we demonstrated a disturbed iron homeostasis both in 
transfusion dependent MDS patients and in the subgroup of transfusion 
independent RS patients. This is the first clinical study that identifies LPI as a 
relevant marker for the potentially toxic fraction of iron species and its impact 
on overall survival.  Increased LPI levels were restricted to patients with TSAT 
percentages exceeding 80%. However, TSAT exceeding 80% alone was not 
prognostic for survival. Therefore, we propose TSAT as a screening parameter 
to assess risk for detectable LPI.  Additional studies are warranted to show that 
intervention with iron chelation improves survival, co-morbidities and quality 
of life in lower-risk MDS patients by lowering LPI levels. 
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Online supplemental information
Methods 
Study design and participants 
Serum samples were collected just prior to transfusion in transfusion dependent 
patients, stored at -80C and shipped on dry ice to the central Laboratory in 
Nijmegen, the Netherlands.  The overall analyses had to be restricted to 100 
patients, since samples from three centers showed consistently elevated NTBI/
LPI levels (even in samples with low transferrin saturation), due to technical 
issues. Clinical Information was collected at registration and 6-monthly 
intervals thereafter via a bespoke web-based database on: concomitant 
diseases, detailed red cell transfusion history, other treatment modalities, 
peripheral blood values, bone marrow pathology, progression of MDS or 
acute myeloid leukemia (AML), and loss to follow-up. Additionally analyzed 
parameters included the conventional iron parameters ferritin, serum iron, 
TSAT, the less standard iron parameters: hepcidin, GDF15, sTfR, NTBI, LPI and 
the inflammation parameter CRP. 
Biochemical assays
Serum ferritin, iron, transferrin, and CRP were measured with routine 
methodologies. The serum hepcidin-25 assay was based on a combination of 
weak cation exchange chromatography and time-of-flight mass spectrometry 
using an stable hepcidin-25 isotope for quantification at nM level as previously 
reported164 (www.hepcidinanalysis.com). The lower limit of detection of this 
method was 0.5 nM. The median reference value  of serum hepcidin-25 (Dutch 
population) is 4.5 nM for men, 2.0 nM for premenopausal women, and 4.9 nM 
for postmenopausal women (www.hepcidinanalysis.com).165
GDF15 levels were measured with DuoSet (R&D Systems, Minneapolis, 
MN) enzyme-linked immunosorbent assay for human GDF15 following 
the manufacturer’s protocol. Serum concentration of sTfR was measured 
immunonephelometrically with the use of polystyrene particles coated with 
monoclonal antibody specific to human sTfR on a BN II System (Dade Behring 
Marburg GmbH, Marburg, Germany). 
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Table S1 Treatment with iron chelation and corresponding LPI and follow-up
Patient 
nr
Nr 
Visits
Max LPI 
levels
First visit 
LPI>LLOD
Max 
TSAT
Max 
Ferritin
Chelation/months Survival (years)/
AML
1 5 0.38 1 96 1954 Deferasirox/7.5 5.2+
2 4 - - >100 3560 Deferoxamine/6.5 1.8
3 7 0.24 1 >100 1237 Deferasirox/26 6.1+
4 7 0.92 3 100 2563 Deferasirox/10+ 3.5/AML
5 6 0.81 1 >100 1840 Deferasirox/36 5.0+
6 10 1.25 8 98 4857 Deferoxamine/14 4.7/AML
1. Good response; LPI low all the time with the exception of visit 1 
before start of chelation. 
2. No LPI levels available
3. LPI levels low all the time with the exception of one determination
4. Only first LPI positive
5. Only visit 6 LPI positive, the starting date of chelation.  No LPI 
levels measured after this date.
6. LPI levels became positive during treatment (last visit).
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Table S2 Frequency, median and percentiles of parameters by transfusion status at registration, 1-year 
follow up and 2-years follow up
At registration 1-yr follow-up(3) 2-yr follow-up(5)
N Median 
(p10-p90)
N Median 
(p10-p90)
N Median 
(p10-p90)
Serum Iron (µmol/L) 100 20.0 (12.0 - 37.5) 78 18.5 (8.0 - 41.0) 64 21.5 (11.1 - 43.0)
0 units 88 20.0 (12.0 - 36.0) 52 17.0 (11.0 - 32.0) 40 17.0 (11.1 - 40.0)
<=10 units 11 23.0 (4.0 - 45.0) 12 22.0 (7.0 - 43.0) 15 22.0 (11.0 - 47.0)
>10 units 1 16.0 (16.0 - 16.0) 14 38.0 (5.0 - 47.0) 9 38.0 (18.0 - 47.5)
Ferritin (µg/L) 100 287 (48 - 982) 78 285 (57 - 1573) 64 341 (59 - 2387)
0 units 88 272 (49 - 819) 52 207 (56 - 662) 40 237 (51 - 777)
<=10 units 11 408 (20 - 1897) 12 593 (192 - 901) 15 590 (61 - 870)
>10 units 1 1885 (1885 - 1885) 14 1528 (829 - 2217) 9 2085 (591 - 7904)
Transferrin 
saturation (%)
100 35.6 (19.0 - 87.4) 78 34.4 (16.4 - 92.9) 64 37.5 (22.2 - 94.3)
0 units 88 36.1 (19.0 - 85.7) 52 31.8 (17.4 - 73.3) 40 31.6 (21.0 - 93.0)
<=10 units 11 29.8 (12.9 - 90.0) 12 37.4 (14.0 - 93.5) 15 59.5 (22.2 - 92.9)
>10 units 1 32.0 (32.0 - 32.0) 14 87.6 (11.1 - 102.3) 9 94.1 (31.6 - 102.2)
Hepcidin (nmol/L) 99 4.5 (1.1 - 21.7) 78 5.6 (1.2 - 19.6) 65 5.2 (1.0 - 19.6)
0 units 87 4.2 (1.2 - 13.8) 52 4.3 (1.2 - 10.4) 41 3.9 (0.9 - 13.6)
<=10 units 11 5.1 (0.5 - 53.7) 12 9.3 (3.8 - 19.6) 15 5.2 (1.0 - 19.6)
>10 units 1 39.1 (39.1 - 39.1) 14 15.9 (4.9 - 39.4) 9 10.5 (2.9 - 48.5)
GDF15 (ng/L) 100 2193 (952 - 5663) 77 2479 (1016 - 7982) 63 2576 (1045 - 7746)
0 units 88 2165 (921 - 6084) 52 2268 (1014 - 5909) 39 1986 (664 - 6737)
<=10 units 11 2823 (1232 - 4987) 12 2417 (1923 - 11543) 16 3235 (1053 - 7488)
>10 units 1 1856 (1856 - 1856) 13 3210 (1765 - 7071) 8 3780 (1247 - 9474)
Soluble transferrin 
receptor (mg/L)
100 1.3 (0.7 - 2.8) 78 1.4 (0.7 - 3.0) 62 1.3 (0.8 - 2.7)
0 units 88 1.3 (0.8 - 2.8) 52 1.5 (0.9 - 3.0) 39 1.3 (0.9 - 2.8)
<=10 units 11 1.1 (0.6 - 2.6) 12 1.3 (1.0 - 2.6) 15 1.4 (0.7 - 2.3)
>10 units 1 0.6 (0.6 - 0.6) 14 0.9 (0.4 - 1.7) 8 1.1 (0.4 - 5.4)
Non transferrin 
bound iron (µmol/L)
100 0.65 (0.14 - 3.03) 77 0.59 (0.15 - 3.64) 65 0.64 (0.14 - 5.42)
0 units 88 0.63 (0.14 - 2.97) 51 0.54 (0.16 - 2.62) 41 0.52 (0.18 - 2.86)
<=10 units 11 0.97 (0.05 - 3.36) 12 0.71 (0.20 - 4.01) 15 1.00 (0.09 - 2.91)
>10 units 1 0.81 (0.81 - 0.81) 14 3.21 (0.08 - 5.03) 9 3.78 (0.12 - 8.42)
Labile plasma 
iron (µmol/L)
100 0.09 (0.02 - 0.22) 77 0.13 (0.03 - 0.38) 65 0.13 (0.02 - 0.38)
0 units 88 0.09 (0.02 - 0.21) 51 0.10 (0.02 - 0.27) 41 0.11 (0.01 - 0.30)
<=10 units 11 0.09 (0.01 - 0.32) 12 0.16 (0.06 - 1.14) 15 0.13 (0.07 - 0.20)
>10 units 1 0.02 (0.02 - 0.02) 14 0.17 (0.06 - 0.47) 9 0.18 (0.02 - 1.39)
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Table S3 Frequency, median and percentiles of parameters by ring sideroblast status at registration, 1 
year follow-up and 2 years follow-up
Registration 1-yr follow-up 2-yr follow-up
N Median 
(p10-p90)
N Median 
(p10-p90)
N Median 
(p10-p90)
Serum Iron 
(µmol/L)
100 20.0 (12.0 - 37.5) 78 18.5 (8.0 - 41.0) 64 21.5 (11.1 - 43.0)
Non-RS 66 17.0 (10.0 - 26.0) 53 16.0 (7.0 - 35.0) 43 18.0 (11.0 - 38.0)
RARS/RCMD-RS 34 29.5 (16.0 - 45.0) 25 30.0 (12.0 - 44.0) 21 33.0 (13.0 - 47.0)
Ferritin (µg/L) 100 287 (48 - 982) 78 285 (57 - 1573) 64 341 (59 - 2387)
Non-RS 66 246 (36 - 665) 53 279 (56 - 1367) 43 283 (54 - 1970)
RARS/RCMD-RS 34 376 (127 - 1242) 25 287 (149 - 2217) 21 590 (215 - 2560)
Transferrin 
saturation (%)
100 35.6 (19.0 - 87.4) 78 34.4 (16.4 - 92.9) 64 37.5 (22.2 - 94.3)
Non-RS 66 31.2 (17.1 - 61.2) 53 30.2 (14.0 - 76.1) 43 31.7 (20.4 - 92.7)
RARS/RCMD-RS 34 58.5 (25.0 - 93.0) 25 46.2 (22.2 - 95.1) 21 85.0 (26.2 - 95.5)
Hepcidin (nmol/L) 99 4.5 (1.1 - 21.7) 78 5.6 (1.2 - 19.6) 65 5.2 (1.0 - 19.6)
Non-RS 66 4.7 (1.1 - 24.2) 53 7.4 (1.2 - 23.7) 43 6.3 (1.0 - 22.4)
RARS/RCMD-RS 33 4.2 (1.2 - 10.3) 25 4.9 (1.4 - 9.8) 22 3.4 (1.0 - 14.2)
Growth 
differentiation 
factor 15 (ng/L)
100 2193 (952 - 5663) 77 2479 (1016 - 7982) 63 2576 (1045 - 7746)
Non-RS 66 1844 (921 - 4828) 52 2195 (1016 - 5909) 43 2113 (982 - 5995)
RARS/RCMD-RS 34 2888 (1026 - 10361) 25 3148 (1223 - 10303) 20 3661 (1192 - 8977)
Soluble transferrin 
receptor (mg/L)
100 1.3 (0.7 - 2.8) 78 1.4 (0.7 - 3.0) 62 1.3 (0.8 - 2.7)
Non-RS 66 1.2 (0.7 - 2.7) 53 1.3 (0.5 - 3.0) 42 1.2 (0.8 - 2.2)
RARS/RCMD-RS 34 1.5 (0.8 - 3.1) 25 1.8 (0.9 - 2.8) 20 1.5 (0.5 - 3.2)
Non transferrin 
bound iron 
(µmol/L)
100 0.65 (0.14 - 3.03) 77 0.59 (0.15 - 3.64) 65 0.64 (0.14 - 5.42)
Non-RS 66 0.46 (0.08 - 1.75) 52 0.51 (0.08 - 2.78) 43 0.52 (0.14 - 3.31)
RARS/RCMD-RS 34 1.22 (0.30 - 3.85) 25 1.61 (0.16 - 5.20) 22 2.02 (0.16 - 6.00)
Labile plasma iron 
(mg/L)
100 0.09 (0.02 - 0.22) 77 0.13 (0.03 - 0.38) 65 0.13 (0.02 - 0.38)
Non-RS 66 0.09 (0.02 - 0.19) 52 0.12 (0.02 - 0.31) 43 0.12 (0.01 - 0.30)
RARS/RCMD-RS 34 0.09 (0.02 - 0.32) 25 0.16 (0.06 - 0.87) 22 0.14 (0.04 - 0.94)
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Table S4 Cause of death by LPI status
Total 
n (%)
LPI status 
N (%)
LPI<LLOD LPI≥LLOD
Total 19 9 10
AML 3 (15.8) 2 (22.2) 1 (10.0)
Cardiovascular 2 (10.5) 1 (11.1) 1 (10.0)
Hemorrhage 2 (10.5) - 2 (20.0)
Infection 5 (26.3) 2 (22.2) 3 (30.0)
Myelodysplastic 2 (10.5) 2 (22.2) -
Not Known 2 (10.5) - 2 (20.0)
Other 2 (10.5) 1 (11.1) 1 (10.0)
Pulmonary 1 (5.3) 1 (11.1) -
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Figure S1 Survival according to transferrin saturation (TSAT) and transfusion status.  
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Abstract
Progression-free survival of lower-risk myelodysplastic syndromes patients 
treated with red blood cell transfusions is usually reduced, but it is unclear 
whether transfusion dose density is an independent prognostic factor. The 
European MDS Registry collects prospective data at 6-monthly intervals of 
newly diagnosed lower-risk myelodysplastic syndromes patients from 16 
European countries and Israel. Data on the transfusion dose density - the 
cumulative dose received at the end of each interval divided by the time since 
the beginning of the interval in which the fi rst transfusion was received - were 
analyzed using proportional hazards regression with time-varying co-variates, 
with death and progression to higher-risk myelodysplastic syndromes /acute 
myeloid leukemia as events. Of the 1267 patients included in the analyses, 317 
patients died without progression, in 162 patients the disease had progressed. 
Progression-free survival was signifi cantly associated with age, EQ-5D index, 
baseline WHO classifi cation, bone marrow blast count, cytogenetic risk 
category, number of cytopenias, and country. Transfusion dose density was 
inversely associated with progression-free survival (p<1x10-4): dose density 
had an increasing eff ect on hazard until a dose density of about 3 units per 16 
weeks. The transfusion dose density eff ect continued to increase beyond 8 units 
per 16 weeks after correction for the impact of treatment with erythropoietin 
agents, lenalidomide and/or iron chelators. Conclusion: the negative eff ect 
of transfusion treatment on progression-free survival already occurs at low 
transfusion densities below 3 units per 16 weeks. This indicates that transfusion 
dependency, even at relatively low dose densities, may be considered as an 
indicator of inferior progression-free survival.  
This trial was registered at www.clinicaltrials.gov as #NCT00600860.
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Introduction 
Red blood cell transfusions (RBCT) are the major component of the supportive 
care of patients with myelodysplastic syndromes (MDS). The life expectancy of 
MDS patients treated with RBCT is usually reduced compared with untransfused 
patients,1,2 but whether the impaired outcome is a result of intrinsic 
deterioration of the underlying disease or a result of external factors related to 
transfusion per se (for example the iron toxicity induced by RBCT) remains an 
open question. The EUMDS registry has prospectively collected observational 
data on patients with low and intermediate-1 risk MDS according to IPSS3, 
defined as lower-risk MDS (LR-MDS), since December 2007.4 The majority of LR-
MDS patients become transfusion dependent (51% in the EUMDS Registry)4, 
usually within 6 months after diagnosis. With an expected median survival of 
2.4 to 11.8 years, these patients might be prone to long-term accumulation 
of iron due to RBCT.3,5-8 The toxic effects of iron overload in other iron 
loading diseases, such as hereditary hemochromatosis9 and the thalassemia 
syndromes10, are well known, but the consequences in MDS patients require 
further clarification. MDS patients are generally older than patients with other 
iron loading disorders11. Their exposure to RBCT may not be long enough to 
develop classical tissue damage due to iron overload, but they may suffer from 
oxidative stress caused by toxic iron species, including non-transferrin bound 
iron (NTBI) and labile plasma iron (LPI), which have been suggested to serve 
as early indicators of iron toxicity in iron loading anemias, such as thalassemia 
syndromes.8,12 Biomarkers of oxidative stress have been found to be increased 
in patients with MDS and iron overload.4,13-16 Data from a recently completed 
study of the EUMDS Registry17 showed that elevated LPI levels - in contrast to 
elevated NTBI levels and TSAT - are associated with decreased survival. The risk 
of dying prematurely in patients with detectable LPI levels occurred too early 
in this study to explain this risk by classical iron overload due to organ toxicity 
(lungs, liver and heart) after long term transfusions, and this may suggest a 
direct effect associated with elevated LPI levels.
The aim of this analysis was to assess the effect of RBCT dose density on 
progression-free survival (PFS) of patients with LR-MDS. The hypothesis is that 
transfusional iron may be toxic and associated with oxidative stress, which may 
lead to BM failure, genetic damage, increased risk for progression or premature 
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death. Two countervailing forces may play a role in this analysis: fi rstly, patients 
with symptomatic anemia are more likely to receive more frequent RBCT. 
Secondly, higher RBCT doses may lead to faster deterioration of LR-MDS or to a 
higher risk of complications by co-morbidities.
Methods
Lower-risk (IPSS risk low or intermediate-1)3 patients from 16 European countries 
and Israel were included in the EUMDS registry, after signed informed consent 
within 100 days of the initial diagnosis of a MDS according to WHO 2001 criteria18. 
Patients with an IPSS risk intermediate-2 or high, or with therapy-related MDS 
were excluded, but MDS-specifi c treatment, started before registration within 
100 days after diagnosis, was not a reason for exclusion. Data were collected 
at baseline and at each 6-monthly outpatient routine follow-up visit. Clinical 
information was collected on: demographics, anthropometrics, co-morbidities, 
performance status, quality of life (EQ-5D), concomitant medication, laboratory 
parameters, diagnostics including information on bone marrow morphology, 
histology, cytogenetics, red blood cell transfusion episodes, total number of 
transfused units and simultaneous therapeutic interventions. All subjects were 
followed prospectively by full reports every 6 months until death, progression 
to high risk MDS or leukemia, loss to follow-up or withdrawal of informed 
consent. The registry was approved by each institution’s ethics committee 
according to countries legislations.
Transfusion data available in the EUMDS Registry consists of the number of units 
received between each reported visit, usually at 6 months intervals. In order 
to assess the association between transfusions received and progression free 
survival (PFS), proportional hazards regression with time-varying covariates 
was employed, adjusting the eff ect of transfusions by appropriate baseline and 
time varying variables. For the purposes of the time-to-event analyses, time is 
measured from date of diagnosis with MDS to date of disease progression or 
date of death. Progression is defi ned as increase to either RAEB-2 or to acute 
leukemia. Patients without disease progression and still alive at time of the 
analyses were censored at their date of their last visit.
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In order to avoid problems with simultaneity of cause and effect assumed 
by the proportional hazards approach to survival analysis a “dose density” 
variable was defined for blood transfusions received, in the following way. The 
cumulative total of units of blood received at the end of each inter-visit time 
interval was calculated. This was then divided by the time since the beginning 
of the time interval in which the first post-diagnosis transfusion was received, 
giving a dose-density measurement. This dose-density was then assigned to 
each time interval. The value of this variable at each point in time represents 
the average rate at which the patient has been receiving units of blood since 
they started transfusions.
Adjusted baseline variables included: age at diagnosis, number of cytopenias 
and number of units of blood received before diagnosis. Adjusted time-varying 
variables (with the intention of adjusting for the condition of the patient 
over time) were: bone marrow blast count, EQ5D-index, IPSS-R cytogenetic 
category, platelet and neutrophil counts. Additional analyses were adjusted for 
the effect of ESA treatment, iron chelation therapy and lenalidomide, taking 
these treatments to be confounding factors. Finally, a sensitivity analysis was 
performed in the survival regressions to take into account that the population 
is not homogeneous but distributed over different centers in several countries, 
using a random effects frailty term. The random effect, called “frailty”, is the 
term that describes the common risk or the individual heterogeneity, acting 
as a factor on the hazard function. Missing values in adjustment variables were 
imputed with last observation carried forward or next observation carried 
backward.
Results
Patient characteristics
The EUMDS Registry contained data from 2,192 patients diagnosed between 
December 3rd, 2007 to March 14th, 2017 of which 1,504 patients had three or 
more visits recorded (visit 3 = landmark at 1 year follow-up). Two patients with 
RAEB-2 were excluded resulting in the inclusion of 1,502 patients. An additional 
235 patients were excluded, as one or more of the following variables had 
never been measured or the test failed throughout the study: cytogenetics 
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(n=112), EQ-5D (n=101), blast count (n=60), platelets count (n=1) neutrophil 
count (n=2). The fi nal cohort consisted of 1267 patients, unselected for any 
type of treatment. In 162 patients the disease had progressed to higher-risk 
MDS or acute myeloid leukemia (AML) and 317 patients had died without 
progression. Median survival after disease progression was 5.3 months (95%CI 
3.2- 9.8 months). For full details of the exclusions, see the supplementary data. 
Table 1 and supplementary table 1 show the baseline demographics. For the 
landmark analysis patients were defi ned as untransfused if they had never 
received a transfusion from diagnosis until the end of the study period (death 
or progression), or if they had received transfusion only once (n=751). Patients 
were defi ned as transfused if they had received multiple transfusions (n=516) 
within the fi rst year of follow-up (visit 3 = landmark). Regular transfusions 
were initiated usually during the fi rst 6 months. Using visit 3 as the landmark 
ensured that the majority of patients who received more than one transfusion 
were correctly identifi ed.
Distribution of transfusion dose density
The distribution of non-zero dose densities at the third visit (the landmark visit) 
is shown in fi gure 1. Mean dose density amongst those who had received a 
transfusion at one year of follow-up was 1.24 units per month, with a median 
of 0.88 units per month (IQR 0.31 – 1.85). Dose densities of the transfused 
patients declined on approach to the fi nal recorded interval, if patient died or 
progressed to higher-risk MDS during the last interval (supplementary fi gure 1). 
This implies that patients received fewer transfusions per month in the interval 
during which death occurred, than in the preceding intervals. Presumably, the 
treatment focus switches to palliative care at home on the approach to death. 
Patients alive at the last recorded visit and no signs of progression did not show 
an increase of the transfusion density over time (supplementary fi gure 1).
Outcome of patients stratifi ed according to transfusion status at landmark 
one year after registration
Characteristics at time of landmark visit 3 stratifi ed according the transfusions 
status are shown in supplementary table 2. 145 Subjects untransfused at visit 3, 
went on to have transfusions after the landmark visit. Out of 516 transfused by 
the time of the landmark 288 subjects were not reported to have received any 
further transfusions, but out of these 288, 125 subjects did not have any further 
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visits and a further 91 had only one additional visit. Of the 163 who had an 
additional visit (91+72), 73 received treatment with ESA, 19 lenalidomide, 10 
hypomethylating agents, 2 hydroxycarbamide, 3 iron chelators. Unadjusted 
PFS stratified by transfusion status (transfused n=516, untransfused n=751) at 
the third visit is presented in figure 2A. The overall PFS of the untransfused 
patients at visit 3 was significantly better (p <0.0001) compared to the 
transfused patients. 
Figure 1: Distribution of Dose Densities of all transfused patients in the interval preceding the landmark of 
one year
Legend figure 1: Frequency: number of patients in each dose dose density ranging from >0-0.2 units per 
month to >6 units per month
Transfused patients were divided into those receiving above (high density) or 
below (low density) the median value (0.87 units per month) of non-zero dose 
densities. Unadjusted PFS stratified by transfusion status and dose density 
(untransfused n=751, low dose density n=258, high dose density=258) at 
the third visit is presented in figure 2B. The overall PFS of the three groups of 
patients, stratified according to the dose density at visit 3, was significantly 
different (p <0.0001). We evaluated the time to progression in the three groups 
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of patients by censoring those who died before progression, see fi gure 2C. The 
Hazard ratios of the patients in the low and high density group were 1.85 (95% 
CI 1.24, 2.76), and 3.79 (95% CI 2.65, 5.42) relative to the non-transfused group. 
The recently revised IWG hematological response criteria in patients with MDS 
have refi ned the RBCT burden by dividing patients into 3 categories (non-
transfused patients, low transfusion burden (0.75-2 units per month) and high 
transfusion burden patients (> 2 units per months)19. Therefore, we repeated 
the analysis and subdivided the patients into 4 groups: no transfusions, >0 
to <0.75 (low transfusion burden), 0.75 to 1.75 (mid transfusion burden) and 
>1.75 (high transfusion burden). The results are shown in fi gure 2D. The main 
eff ect occurred for low dose densities, such that the outcome of the mid and 
high transfusion density group was similar. The low transfusion burden group 
is almost identical to the low burden group (<0.89 units per month) of fi gure 
2B. MDS-related causes of death increased from 28% in the non-transfused 
group to 39% and 48% in the mid and high transfusion burden group (data 
not shown). 
Impact of individual prognostic factors
The univariate eff ect of various covariates on the outcome was investigated 
in order to discover the appropriate functional form for the covariates (i.e. 
to discover whether a linear or non-linear form was best) and to discover 
appropriate ways of adjusting for confounding covariates. Increasing RBCT 
dose density was associated with inferior PFS (p<10-4). The functional form 
is shown in fi gure 3A. The eff ect of the dose density increases until a dose 
density of about 1 unit per month; thereafter, the eff ect is fl at. Baseline age (as 
continuous variable) was strongly associated with PFS (p<1x10-4) in univariate 
regression analyses, as well as baseline MDS diagnosis (p<1x10-4), quality of 
life measured by the EQ5D Index (p<1x10-4), country (p=0.002), bone marrow 
blast count (p<1x10-4), number of cytopenias (p<1x10-4), IPSS-R cytogenetic 
category (p<1x10-4), hemoglobin levels (p<1x10-4), neutrophil levels (p<1x10-4) 
and platelet levels (p<1x10-4). No diff erence in PFS was detected by sex (p=0.1), 
but PFS in females was superior in the multivariate analyses.
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Figure 2: Progression-free survival and risk of progression according to transfusion status at landmark 
of visit 3 (1 year after registration)
Legend figure 2: A; Kaplan-Meijer plot of progression-free survival of patients receiving transfusions by 
landmark (visit 3) versus not receiving transfusions. B; Kaplan-Meijer plot of progression-free survival of 
patients receiving transfusions at a low density (<0.87 units/month) by landmark or at a high density 
(>0.87 units/month) versus not receiving transfusions; C; Kaplan-Meijer plot of time to progression of 
patients surviving till progression subdivided according to transfusion burden or not as in figure B; D; 
Kaplan-Meijer plot of progression-free survival of patients receiving transfusions at densities according 
to the revised IWG criteria: low dose density: >0- <0.75 units/month; mid dose density: 0.75 to 1.75 units 
per months; high dose density >1.75 units per month.
Progression-free survival using time-varying covariates proportional 
hazards regression analysis
Variables used for adjustment at baseline included age at diagnosis, sex, country 
of origin, number of cytopenias (and their corresponding blood counts), 
number of units of blood received before registration. Time varying variables 
measured longitudinally included: dose density, EQ5D index, components of 
the IPSS-R, receipt of ESA, iron chelators and lenalidomide.
In multivariate analysis, not adjusting for the effects of ESA, iron chelation 
and lenalidomide therapy, all variables entered in the regression retained 
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statistical signifi cance. The functional form of the dose density eff ect (p<10-4) 
was as shown in fi gure 3B. With a frailty term added for the subject country, all 
previously signifi cant variables, including the dose density, retained statistical 
signifi cance, with a dose density p-value of <10-4.
Impact of therapeutic interventions on RBCT densities
Treatment with ESAs, lenalidomide and iron chelators may improve 
erythropoiesis and reduce the need for RBCT. Reduction of the RBCT rate 
will result in a gradual decrease of the subsequent RBCT dose densities in 
intervals during the response period. Therefore, we investigated how many 
of the transfused patients had been treated with these interventions and 
calculated the average treatment duration and the number of patients with 
reduced transfusion densities after starting the intervention. In our cohort of 
1267 patients, 679 of them received treatment with ESA and 151 had reduced 
transfusion densities in the fi rst visit after starting ESA treatment. Supplementary 
fi gure 2 gives the individual dose density over time during ESA treatment of 
the 151 responding patients. Overall, 100 patients received treatment with 
lenalidomide and of these 53 patients had a reduced transfusion density in the 
fi rst visit after starting lenalidomide treatment; Supplementary fi gure 3 shows 
the individual dose density over time during lenalidomide treatment of the 53 
responding patients. Within our study group 186 patients received treatment 
with iron chelators and 75 patients had a response leading to reduced 
transfusion densities in the fi rst interval after start of iron chelation treatmen 
(Supplementary fi gure 4). In contrast to the dose densities over time during 
ESA and lenalidomide treatment, the pattern of longer term dose densities 
during iron chelation appeared to show a more stable pattern. Subjects 
receiving a certain level of blood transfusion dose when they fi rst receive iron 
chelation appear to be maintaining that level of dose density. The decline of 
the dose density is less pronounced, but this might be a refl ection of the longer 
transfusion period before starting chelation treatment when compared with 
the other two interventions.
The observed patterns of dose density trajectories suggest that receiving ESA, 
lenalidomide and iron chelation therapy modulates the dose density and 
therefore we included these variables in the regression model. This analysis 
resulted in an eff ect for the dose density similar to the previous analyses 
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(fi gure 3B), with a p-value of <0.0001 indeed all variables entered in the 
regression retained statistical signifi cance, except for platelet count (p=0.47) 
and neutrophil count (p=0.24). However, the dose density eff ect continues to 
increase beyond 1 unit per month after correction for the three interventions 
(ESA, iron chelation and lenalidomide) up until a dose of 6 units per month 
(fi gure 3C).
Some patients received more than one intervention simultaneously, including 
25 patients who received chelation and lenalidomide and 88 patients who 
received ESA and chelation. However, no additional impact could be detected 
over and above the impact of the two individual interventions.
Figure 3: Infl uence of dose density on progression-free survival
Legend fi gure 3 A; Dose density eff ect on progression-free survival (PFS) in an univariate analysis. 
B; Dose density eff ect on PFS in a multivariate regression model unadjusted for the three treatment 
variables. C; Dose density eff ect on PFS in a multivariate regression model adjusted for treatment with 
either ESA, Iron Chelation or Lenalidomide.
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Discussion
This large prospective, observational study confi rmed the reported association 
of transfusion dose density with reduced PFS in patients with LR-MDS.20 More 
surprisingly, we showed in this study that this negative association already 
occurred at a low transfusion rate. In addition, we showed that the risk of 
progression increased both in the low and high transfusion burden group 
when compared to the non-transfused patients. We could even show that the 
deleterious eff ect of transfusions occurred at a very low transfusion burden (< 
0.75 units per month or < 3 units per 16 weeks as defi ned in the revised IWG), 
when the patients were subdivided according to the revised IWG hematological 
response criteria19. These patients with a very low transfusion burden are 
considered as untransfused patients using the revised IWG response criteria19.
The main focus of our study was to analyze the association of transfusion rate 
with outcome, assuming that regularly transfused patients may be exposed to 
the postulated toxicity of RBCT at a lower transfusion burden than generally 
accepted. Several studies have addressed this question using various defi nitions 
of transfusion rate. The initial publications describing the impact of RBCT on 
outcome in MDS compared RBCT dependent patients with RBCT independent 
patients, using RBCT dependency as a time dependent variable.1,21 These 
studies were based on various defi nitions of RBCT dependency22,23, including 
a study using a rigid criterion, which implied a RBCT rate of at least 1 unit per 
month during a period of 2 months.24 In this last study, transfusion dependency 
occurred in a minority of the patients (35% to 44%). The use of this defi nition 
implies that patients receiving regularly less 3 units per 16 weeks are defi ned as 
RBCT independent, but these patients might also be subject to the deleterious 
association with RBCT. In addition, patients may respond to therapeutic 
interventions, such as ESA, lenalidomide or iron chelators and become RBCT 
independent again. The conclusion was that the severity of anemia was the 
leading cause of impaired survival rather than RBCT dependency.24 However, 
the defi nition of severe anemia (<9 g/dL in males and <8 g/dL in females) implies 
that the majority of these patients were regularly transfused, as confi rmed in 
this study.24 This study also showed that the transfusion rate was signifi cantly 
associated with an increased risk of cardiac complications. The risk of cardiac 
complications was signifi cantly higher in patients with a RBCT intensity of >3 
units per months compared to patients transfused with <1 unit per month.24 In 
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an open forum discussion RBCT dependency was even defined much higher at 
2 units per months in a 3-month interval.25 A Spanish study in 191 transfused 
patients with MDS used the interval between each transfusion to calculate 
the transfusion intensity.26 They concluded that high transfusion intensity was 
associated with decreased survival and increased risk for development of AML 
in concordance with our study. Interestingly, the cumulative transfusion burden 
was not a prognostic factor when the transfusion intensity was included in the 
model.26
The traditional evaluation of prognostic impact of factors influencing outcome 
have used standard time-to-event methods based on variables at diagnosis, 
however, many variables in MDS may change over time. This aspect can 
be addressed by using proportional hazards regression with time-varying 
covariates. The EUMDS registry is collecting its observational data at registration 
of each new patient (within 100 days after diagnosis) and follow-up data at 
six months intervals. This practice leads to regular visit intervals of six months. 
For many patients in this dataset, the value of the recorded transfusion rate 
varies strongly over time, as shown in the supplementary files. Therefore, we 
calculated the RBC rate at each reported visit during all preceding visit intervals 
between the date of the first RBCT and the date of the last visit, leading to a 
“smoothed” variable, defined as dose density. This reflects an average rate of 
receiving transfusions during the whole observation period with transfusions. 
The relatively low number of RBCT units per months can be explained by the 
remarkable variation of the transfusion rate over time, even when using interval 
visit reports of 6 months duration.
Baseline age, bone marrow percentage category, number of cytopenias, and 
the EQ5D-index retained their significant prognostic impact in the proportional 
hazards regression with time-varying explanatory variables. Also, the non-linear 
component of the dose density effect was retained (p<10-4). The unfavorable 
effect of the dose density increased until a dose density of about two units per 
month and leveled off thereafter. A similar form and effect was observed when 
using the cumulative dose of RBCT units over time in an identical multivariate 
regression model using the same variables (data not shown). The negative 
impact of the cumulative RBCT dose already starts at time of administering 
the first transfusion and does not increase any further beyond 30 units RBCTs 
received (data not shown).
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Many patients showed a (temporary) decrease of the RBCT dose density, 
refl ecting response to ESA27, lenalidomide28, and/or iron chelators12 in 22%, 
53% and 40% of the treated patients respectively. The observed patterns of 
dose density trajectories suggest that receipt of ESA, lenalidomide and iron 
chelation modulate the dose density and therefore we included these variables 
as confounding variables in the regression model. This analysis showed that 
the impact of the dose density remained similar to the previous analyses, but in 
contrast to the previous analyses there is some evidence that the dose density 
eff ect continues to increase beyond 2 units per month after correction for the 
three interventions.
RBCT are usually administered after a certain storage time, but the survival of 
stored RBC depends on this time.29 30 Transfusion of stored RBCs leads to pro-
infl ammatory reactions, associated with a higher risk of infection and increased 
levels of circulating iron and in particular non-transferrin bound iron (NTBI) 
species, which enhance bacterial growth in vitro.31,32 Infusion of autologous 
RBC from healthy volunteers after increasing storage up to 6 weeks resulted in 
increased extravascular hemolysis, decreased RBC survival, elevated NTBI and 
ferritin levels in units transfused after 6 weeks compared to units transfused 
after shorter shortage.33 Excess toxic iron species, including NTBI and especially 
its component Labile plasma iron (LPI)34 catalyze the cellular generation 
of reactive oxygen species. Oxidative stress may lead to pro-infl ammatory 
responses and to oxidation of lipids, proteins and DNA causing cell and tissue 
damage.35,36 Elevated NTBI levels after a single unit of RBC stored for 6 weeks 
normalize within 24 hours.37 However, in multi-transfused patients (cumulative 
number of units >10) with MDS, NTBI and LPI remained elevated up to the next 
transfusion.17
Conclusion The negative association of transfusions on PFS already occurs at 
low RBCT dose densities below 3 units per 16 weeks. This indicates that the 
RBCT dependency in patients transfused at relatively low rates, who are usually 
considered as untransfused patients, may be considered as an indicator of 
poor prognosis for progression-free survival. This poor prognosis in transfusion 
dependent patients might be the result of direct toxicity by the toxic iron radicals 
resulting from the RBCT or the result of concomitant disease progression, 
including hematopoietic impairment. The data in the chelation study from 
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our group in this issue provides support for the direct toxicity of RBCT density 
on outcome, because chelated patients have a better outcome, if treated with 
chelators, which remove toxic iron radicals effectively. Future studies, including 
interventional studies, are needed to confirm our observations, which may lead 
to adaptations of the current recommendations.
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Supplementary Material
Data Handling and Exclusions
The dataset contained data from 1504 patients having three or more visits 
recorded. Within this dataset, there were 368 deaths and 181 progressions to 
high-risk MDS or AML, which were considered as events for this analysis. The 
following exclusions were made:
• 2 patients with RAEB-2 were removed leaving 1502 patients.
• 1 patient was deleted as the subject had a very long pre-diagnosis 
transfusion history.
These exclusions leave 1501 patients in the cohort.
We also removed all patients that had completely missing values for any of the 
following variables: Haemoglobin (0 patients have all observations missing), 
neutrophils (2 patients), platelets (1 patient), bone marrow blast count (60 
patients), cytogenetic risk category (112 patients), EQ5D-index (101 patients).
This left a total of 1267 patients in the analysis dataset, with 407 deaths of which 
90 had progression. 72 Patients survived until the end of the study period but 
progressed to high-risk MDS or AML.  
For the analysis dataset, missing values in these variables were imputed with 
last observation carried forward or next observation carried back.
Handling of missing transfusion data
10 remaining subjects were  agged as having received transfusions before 
diagnosis, but were missing the number of units received. Those 4 transfused 
more than a year before diagnosis were set to no transfusions received. Those 
6 transfused less than a year before diagnosis were assigned either an imputed 
2 units (a plausible  gure) or 4 units (the mean number received among those 
receiving pre-diagnosis transfusion) according to the actual length of time 
before diagnosis.
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Six additional subjects were identified as having received transfusions a very 
long time before diagnosis (more than 600 days). These patients were set to 
not having received pre-diagnosis transfusions unless they had received more 
than 7 units (3 patients). 
The Definition of Dose Density
For each patient, the transfusion data available consisted of the number of units 
received between each visit. This variable, which we call dose, is expressed as 
an average of “units received per month” in each inter-visit interval.
The analysis used is proportional hazards regression with time-varying 
covariates. The basic interval on which all variables are defined is the interval 
between visits. Therefore, covariates are assigned to be piecewise constant on 
these time intervals.
In standard survival analysis, the hazard at any instant is assumed to be modified 
by the value of the explanatory variables at that instant.  This presented three 
problems for the analysis with the dose transfusion variable:
• For many patients in this dataset, the value of the recorded 
transfusion dose variable is very “spiky”, varying strongly over 
time. It seems unlikely that the actual value of the hazard would 
follow such a form. 
• It is unlikely that the hazard will respond instantaneously to the 
transfusion dose received.
• It is observed that, in this dataset, patients receive fewer 
transfusions in the interval in which death occurs, than in the 
intervals before the interval in which death occurs (Supplement 
figure 1). Presumably, the treatment focus switches to palliative 
care on the approach to death. This would mean that the event 
of death is correlated with zero or low values of transfusion dose, 
leading to a hazard estimate that is high for low values of dose 
and which reduces as dose increases.
Rather, it seems more likely that the association between transfusions and hazard 
would be better expressed as an association with some sort of cumulative dose 
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value (refl ecting the idea that the hazard at any time is proportional to the total 
dose received) or with some other “smoothed” variable that refl ects an average 
rate of receiving transfusions. 
In order to perform this smoothing, the cumulative total dose at the end of 
each inter-visit time interval was calculated. This was then divided by the time 
(in months) since the beginning of the time interval in which the fi rst post-
diagnosis transfusion was received, giving a dose-density measurement. This 
dose-density is then assigned to each time interval. The value of this variable 
at each point in time represents the average rate at which the patient has been 
receiving units of blood since they started transfusions. This main variable of 
interest, the dose density, was modelled in regression analysis using restricted 
cubic splines with four knots.
With the dose density defi ned as such, the hazard is taken as proportional to 
the number of units received since transfusions started divided by the time 
since transfusions started. The eff ect of this is to allow the hazard to depend 
upon something that has happened in the past; but the strength of the eff ect 
will decay as time passes and no further transfusions are received. Contrast this 
with simply using the cumulative number of units received at any point in time. 
Here, again, the eff ect on the hazard is proportional to the dose received in the 
past, but there is now no decay in the size of the eff ect.
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Results
Supplementary Table 1: Baseline Characteristics from time of diagnosis & PFS, stratified according to 
transfusion status at landmark (Visit 3)
Total Hazard Ratio 
(95%CI)
Adjusted Hazard 
Ratio1 (95%CI)
(95%CI)
Transfusion Status at 
landmark
No yes
 Total 1267 (100.0) 751 (100.0) 516 (100.0)
Country: 
Austria 86 (6.8) 0.84 (0.56 - 1.27) 0.76 (0.49 - 1.18) 61 (8.1) 25 (4.8)
Czech Republic 94 (7.4) 0.82 (0.57 - 1.19) 0.89 (0.61 - 1.31) 43 (5.7) 51 (9.9)
Denmark 47 (3.7) 1.94 (1.25 - 3.02) 1.97 (1.26 - 3.07) 17 (2.3) 30 (5.8)
France 313 (24.7) 1 1 200 (26.6) 113 (21.9)
Germany 25 (2.0) 1.09 (0.62 - 1.94) 1.34 (0.75 - 2.40) 17 (2.3) 8 (1.6)
Greece 128 (10.1) 0.85 (0.60 - 1.20) 0.90 (0.63 - 1.30) 81 (10.8) 47 (9.1)
Israel 67 (5.3) 0.83 (0.46 - 1.47) 0.92 (0.51 - 1.64) 47 (6.3) 20 (3.9)
Italy 46 (3.6) 0.47 (0.23 - 0.96) 0.62 (0.30 - 1.27) 33 (4.4) 13 (2.5)
Netherlands 44 (3.5) 0.75 (0.44 - 1.29) 0.96 (0.56 - 1.65) 28 (3.7) 16 (3.1)
Poland 31 (2.4) 1.96 (1.19 - 3.22) 1.45 (0.85 - 2.47) 13 (1.7) 18 (3.5)
Portugal 2 (0.2) - - 0 (0.0) 2 (0.4)
Romania 17 (1.3) 0.28 (0.09 - 0.87) 0.15 (0.05 - 0.50) 7 (0.9) 10 (1.9)
Serbia 14 (1.1) 2.02 (0.94 - 4.33) 1.32 (0.61 - 2.87) 5 (0.7) 9 (1.7)
Spain 85 (6.7) 1.01 (0.67 - 1.53) 1.18 (0.77 - 1.79) 54 (7.2) 31 (6.0)
Sweden 88 (6.9) 0.87 (0.61 - 1.24) 0.99 (0.68 - 1.43) 45 (6.0) 43 (8.3)
United Kingdom 180 (14.2) 0.99 (0.75 - 1.32) 1.07 (0.80 - 1.44) 100 (13.3) 80 (15.5)
Ring  Sideroblasts:
No 967 (76.3) 1 1 581 (77.4) 386 (74.8)
Yes 300 (23.7) 0.83 (0.68 - 1.03) 0.78 (0.63 - 0.98) 170 (22.6) 130 (25.2)
IPSS cytogenetic score 
Good 1052 (83.0) 1 1 655 (87.2) 397 (76.9)
Intermediate 170 (13.4) 1.87 (1.49 - 2.35) 1.92 (1.52 - 2.43) 73 (9.7) 97 (18.8)
Poor 15 (1.2) 2.30 (1.18 - 4.46) 2.36 (1.21 - 4.60) 6 (0.8) 9 (1.7)
Cytogenetics 
not done
30 (2.4) 0.68 (0.35 - 1.32) 0.68 (0.35 - 1.32) 17 (2.3) 13 (2.5)
Revised IPSS cytogenetic score
Very good 121 (9.6) 0.94 (0.66 - 1.33) 0.86 (0.60 - 1.23) 87 (11.6) 34 (6.6)
Good 963 (76.0) 1 1 594 (79.1) 369 (71.5)
Intermediate 141 (11.1) 2.56 (2.02 - 3.25) 2.47 (1.93 - 3.15) 55 (7.3) 86 (16.7)
Poor/ Very Poor 23 (1.8) 1.41 (0.75 - 2.65) 1.26 (0.67 - 2.38) 9 (1.2) 14 (2.7)
Not known 19 (1.5) 1.81 (0.99 - 3.29) 1.63 (0.89 - 3.00) 6 (0.8) 13 (2.5)
Legend: Baseline characteristics of the included patients from time of diagnosis and progression-free 
survival, stratified according to transfusion status at landmark (Visit 3). 
1Hazard Ratios (HR) & 95% Confidence Intervals (CI) adjusted for all other variables, as described in Table 
1 in the manuscript,
Louise de Swart van idml.indd   186 04-05-19   13:48
 Transfusion dose density in lower-risk MDS
187
7
Supplementary Table 2 Characteristics at time of landmark Visit 3 stratifi ed according to transfusion 
status at landmark (Visit 3)
Total Transfusion Status at landmark
No Yes
 Total 1267 (100.0) 751 (100.0) 516 (100.0)
Median age at visit 3 
(years) range
74.5 (20.1 - 96.3) 74.2 (20.1 - 92.9) 74.8 (22.2 - 96.3)
WHO Diagnosis2:
RA 130 (10.3) 82 (10.9) 48 (9.3)
RARS 166 (13.1) 91 (12.1) 75 (14.5)
RCMD 328 (25.9) 190 (25.3) 138 (26.7)
RCMD-RS 46 (3.6) 23 (3.1) 23 (4.5)
RAEB-1 103 (8.1) 57 (7.6) 46 (8.9)
RAEB-2 30 (2.4) 5 (0.7) 25 (4.8)
MDS-U 27 (2.1) 21 (2.8) 6 (1.2)
Deletion 5q 70 (5.5) 31 (4.1) 39 (7.6)
Bone Marrow not done 367 (29.0) 251 (33.4) 116 (22.5)
MDS-CI3: 
Low 928 (73.2) 583 (77.6) 345 (66.9)
Intermediate 293 (23.1) 154 (20.5) 139 (26.9)
High 35 (2.8) 10 (1.3) 25 (4.8)
Not known 11 (0.9) 4 (0.5) 7 (1.4)
Karnofsky Status:
80-100 738 (58.2) 496 (66.0) 242 (46.9)
50-70 205 (16.2) 74 (9.9) 131 (25.4)
10-40 25 (2.0) 11 (1.5) 14 (2.7)
Not known 299 (23.6) 170 (22.6) 129 (25.0)
Quality of life 
Visual analogue score, mean  
(sd)
69.7 (19.0) 73.6 (18.5) 64.1 (18.2)
Revised IPSS category  
Very low 384 (30.3) 305 (40.6) 79 (15.3)
Low 576 (45.5) 314 (41.8) 262 (50.8)
Intermediate 203 (16.0) 88 (11.7) 115 (22.3)
High 45 (3.6) 16 (2.1) 29 (5.6)
Very high 4 (0.3) 1 (0.1) 3 (0.6)
Not known 55 (4.3) 27 (3.6) 28 (5.4)
2Refractory anemia (RA), Refractory anemia with ring  sideroblasts (RARS), Refractory cytopenia with 
multilineage dysplasia (RCMD), Refractory cytopenia with multilineage dysplasia & ring  sideroblasts 
(RARS), Refractory anemia with excess blasts‐1 (RAEB‐I),  Refractory anemia with excess blasts‐2 (RAEB‐
II), Refractory anemia with excess blasts‐2 (RAEB‐II), Myelodysplastic syndrome, unclassifi able (MDS‐U).
3Myelodysplastic syndrome‐specifi c comorbidity index (MDS‐CI). 
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Supplementary figure 1: Mean number of transfused units per month, counting back from the final interval 
before death, transformation or censoring.
Supplementary figure 2 Dose Density Trajectories for Subjects with Initial Response to ESA.
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Supplementary fi gure 3 Dose Density Trajectories for Subjects with Initial Response to Lenalidomide.
Supplementary fi gure 4 Dose Density Trajectories for Subjects with Initial Response to Iron Chelation.
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Summary & future perspectives
General introduction
Myelodysplastic syndromes (MDS) are predominantly a disease of elderly 
patients (median age 75 years) who are usually not candidates for participation 
in clinical studies due to impaired mobility, increased frailty or co-morbidities. 
These patients are generally managed in community hospitals with treatment 
mainly consisting of supportive care, including red blood cell transfusions 
and hematopoietic growth factors. The majority of MDS patients (71%) have 
lower-risk MDS (LR-MDS) defi ned as either low or intermediate-1 risk according 
to the International Risk Scoring System (IPSS).1 Diagnosis of MDS remains 
a challenge, as well as the right time to start appropriate treatment. The 
European LeukemiaNet MDS (EUMDS) registry is an international prospective, 
observational registry for newly diagnosed LR-MDS patients, which has been 
established to obtain a detailed and accurate prospective data set on diagnosis 
and disease management. Patients are included in 16 diff erent European 
countries and Israel from both secondary and tertiary care centres. The majority 
of the studies within this thesis have been executed within the framework of 
the European LeukemiaNet MDS (EUMDS) registry.  
In this thesis we evaluated the demographic data of the fi rst 1,000 patients 
within the EUMDS LR-MDS population. We reviewed the quality and accuracy 
of the MDS diagnoses in the registry, including the prognostic impact of a 
suboptimal number of analyzed metaphases (MP), we assessed the added 
value of the most recent risk stratifi cation tool: the revised IPSS (IPSS-R).2 We 
evaluated the applied disease management in daily practice as well as iron 
related complications both in patients receiving regular blood transfusions 
to treat their anemia and in untransfused MDS patients with ineff ective 
erythropoiesis, a characteristic in a subgroup of patients with LR-MDS. We 
aimed to provide an overview of the current knowledge on iron homeostasis 
in MDS during an early stage of the disease, in order to establish new leads for 
diagnosis and accurate iron reducing measures. In this context it is important 
to identify the relevant markers of iron overload and iron mediated oxidative 
stress, among which are the toxic iron species non-transferrin-bound iron 
(NTBI) and labile plasma iron (LPI) and to assess their prognostic value.
Louise de Swart van idml.indd   193 04-05-19   13:48
Chapter 8
194
A new risk score in the EUMDS registry
In Chapter 2 we described the baseline characteristics (demographic, clinical 
and laboratory parameters) of the first 1000 patients included in the EUMDS 
registry, the disease management of these patients and we validated the 
prognostic discrimination of the original IPSS and the more recently developed 
IPSS-R. Accurate risk stratification using reliable prognostic scoring systems is 
important to predict patient outcome and is a valuable tool for clinical decision-
making. At the start of the EUMDS registry the first international prognostic risk 
score was used (IPSS), but it became clear over time that cytogenetics plays a 
more prominent role, leading to the IPSS-R international risk score.
Patients were eligible to be included if they were newly diagnosed with MDS 
according to the WHO 2001 classification and had a low or intermediate-1 risk 
score according to the IPSS. To ensure that patients were newly diagnosed 
they had to be enrolled within 100 days from the date of the diagnostic bone 
marrow aspirate. Patients with IPSS intermediate-2, high-risk MDS, or with 
secondary or therapy-related MDS were originally excluded from this registry. 
Using IPSS-R we were able to distinguish four different prognostic risk groups 
in our LR-MDS population, including a combined group of high and very high 
risk patients, compared to two risk groups by using the IPSS. Almost all IPSS 
low risk patients were reclassified as IPSS-R low and very low risk patients, while 
the intermediate-1 group (estimated median survival 3.6 years) appeared to 
be more heterogeneous: more than 50% of these patients were reclassified as 
(very) low risk (median survival 5.3-8.8 years) and 10% as (very) high risk (median 
survival 0.8-1.6 years), while 40% of the patients remained in the intermediate 
risk group.2 Especially in the group of patients with a (very) high IPSS-R risk 
score specific early intervention with hypomethylating agents, intensive 
chemotherapy or allogeneic stem cell transplantation might be considered.3 
Reproducibility of the morphological diagnosis of a multicentre European 
registry
Chapter 3 describes the results of a cytomorphology review of 100 newly 
diagnosed LR-MDS patients in the EUMDS Registry. The WHO 2001 classification 
system was the most widely used classification system at start of the registry in 
2001.4  This study aimed primarily at reproducibility of the WHO 2001 criteria 
for MDS by an international panel, and correct diagnostic inclusion into the 
registry. A total of 105 cases, representing all participating countries, were 
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randomly selected and reviewed by a panel comprising 11 morphologists 
during a 3 day meeting.
In our review we demonstrated a high accuracy of the original diagnoses at 
entry into the registry and a high inter-observer concordance of the panel 
members with regard to diagnosis of MDS and agreement by WHO 2001 
classifi cation. The interpretation of the panel members diff ered moderately in 
the categorization of unilineage versus multilineage dysplasia. The WHO 2001 
proposals for the classifi cation of myelodysplastic syndromes took into account 
the separation between unilineage and multilineage dysplasia (RA versus 
RCMD), including MDS patients with ring sideroblasts. Our data are generally 
compatible with  the most recent WHO 2016 classifi cation with the exception of 
minor changes of the defi nition of MDS del(5q) and MDS unclassifi ed, and the 
introduction of SF3B1 mutations as classifying elements based on advancing 
molecular techniques in MDS (next-generation-sequencing).5-7
Our data show that in general the inter-observer agreement was high and 
a low percentage of misdiagnosed cases had been entered into the EUMDS 
registry. This is an important fi nding since the golden standard to diagnose 
MDS remains cytomorphology.
Th e importance of the evaluated number of metaphases in karyotyping
In Chapter 4 we investigated the prognostic impact of a suboptimal number 
of analyzed metaphases (MP) in LR-MDS patients with a normal karyotype. 
Karyotyping continues to be the most widely used method to identify genetic 
abnormalities. 
Both the IPSS cytogenetic score and the IPSS-R cytogenetic score were 
determined from the diagnostic cytogenetic reports at registration. Twenty MP 
remains the strongly recommended number of MP for analysis.
We identifi ed 1225 patients with a normal karyotype representing 61% of this 
LR-MDS patient population. Only 14% of these patients were registered with 
a normal karyotype, based on less than 20 analyzed MP. Estimated overall 
survival as well as the estimated progression-free survival of the patients with 
suboptimal numbers of analyzed MP (<20) were not inferior when compared 
with 20 or more analyzed MP in patients with a normal karyotype. 
Additionally, we analyzed patients with abnormal karyotypes (774). As 
expected, in this group the percentage of patients with less than 20 analyzed 
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MP was higher: 29%, because of the definition of clonality in patients with an 
abnormal karyotype requires a lower number of analyzed MP. Also in this group 
of patients the number of analyzed metaphases did not influence the outcome 
after adjustment for relevant variables. 
These observations indicate that the majority of patients with a LR-MDS for 
whom a suboptimal number of MP (<20) have been analyzed have a normal 
karyotype. Despite these findings, we recommend to reach at least a complete 
analysis of 20 MP to enable the full exclusion of clonal cytogenetic abnormalities, 
especially in patients who are eligible for intensive interventions. In cases where 
this is not possible, mostly due to the methodological impairment of obtaining 
20 evaluable MP, we recommend to use complementary fluorescent in situ 
hybridization (FISH) analyses or consider additional molecular techniques 
(next-generation sequencing) since genetic abnormalities may influence the 
prognosis of a patient. DNA sequencing mutations of EZH2, RUNX1, TP53, NRAS 
and ASXL1 are associated with shorter overall survival, while SF3B1 mutations 
are associated with more favourable outcomes.8-11
International evaluation of techniques to evaluate NTBI and LPI
Chapter 5 describes the results of an international round robin, or 
interlaboratory sample sent out, for the quantification of the toxic iron species 
NTBI and LPI in patients with iron overload disorders, such as hemochromatosis, 
β-thalassemia, sickle cell disease and MDS in different treatment phases. These 
iron species constitute less stable moieties when compared to iron bound to 
its physiological transport protein: transferrin. Therefore, iron in NTBI and LPI is 
more accessible for micro-organisms and interacts more easily with susceptible 
cell types, including hepatocytes, cardiomyocytes and pancreatic islet cells, 
with consequent oxidant injury. We compared ten worldwide accepted assays 
(6 for NTBI and 4 for LPI). 
We found mutual correlations of the levels of NTBI and LPI obtained within the 
same group of NTBI or LPI assays. However, absolute levels differed considerably 
between assays and were lower for LPI than for NTBI. Overall, highest assay 
levels were observed for patients with untreated hereditary hemochromatosis 
and β-thalassemia intermedia, patients with transfusion-dependent (TD) 
myelodysplastic syndromes and patients with TD and chelated β-thalassemia 
major. Differences in the range of reported values as well as in absolute values, 
have highlighted the urgent need for thorough method-validation protocols, 
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standardization and consensus on how to best report before introduction for 
clinical use.
Importantly, both LPI and NTBI assays showed a relationship with transferrin 
saturation (TSAT), irrespective of the type of iron overload disease. Based on 
our observations, TSAT levels of around 70% can be considered as a clinical 
threshold for the presence of potentially toxic iron species and iron loading in 
parenchymal cells. Despite this fi nding, in the absence of studies that assess the 
relation of assay levels to clinical outcome in these various patient categories, 
the clinically most relevant assay formats and their decision limits remain 
unknown. Overall, before NTBI and LPI assays can be introduced into clinical 
practice rigorous validation and standardization of assays, consensus on how 
the reporting of results, and clinical outcome studies to determine clinically 
relevant assay formats and their toxic thresholds are needed. 
Th e prognostic impact of transfusions in low-risk MDS patients
In Chapter 6 we identifi ed LPI as a relevant marker for the potentially toxic 
fraction of iron species and its impact on overall survival. We analyzed serum 
samples from 100 LR-MDS patients included in the EUMDS registry at six-
month intervals for several serum iron parameters and temporal changes in 
iron metabolism and presence of potentially toxic iron species and their impact 
on survival. 
In our study population we identifi ed elevated LPI levels in combination with 
high transferrin saturation levels mainly in patients with ringed sideroblasts, 
characterized by ineff ective erythropoiesis, and all transfusion dependent 
patient groups. Interestingly, detectable LPI, but not NTBI, was associated with 
a signifi cantly decreased overall survival in MDS patients receiving red blood 
cell transfusions (RBCT). 
We demonstrated a disturbed iron homeostasis both in transfusion dependent 
MDS patients and in the subgroup of transfusion independent RS patients. The 
risk of premature death in patients with detectable LPI levels occurred too early 
in this study to explain this risk by classical iron overload due to organ toxicity 
(lungs, liver and heart) after long term transfusions. This observation suggests 
a short term eff ect by the increased numbers of the LPI species leading to 
increased oxidative stress. 
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Increased LPI levels were restricted to patients with TSAT percentages 
exceeding 80%. However, TSAT exceeding 80% alone was not prognostic for 
survival. Therefore, we recommend to use TSAT (>70%) as a useful clinical pre-
screening method, compared to the currently more widely used ferritin, to 
identify patients who are at risk to develop detectable LPI levels. 
Additional studies are warranted to show that intervention with iron chelation 
improves survival, co-morbidities and quality of life in lower-risk MDS patients 
by lowering LPI levels. It would also be interesting to investigate the effect 
of erythropoiesis restoring factors like Luspatercept (ACE-536) and hepcidin 
analogues on LPI levels, transfusion need, progression-free survival and quality 
of life.12, 13  
RBCT dependency as an indicator for impaired prognosis
Chapter 7 focuses on the impact of red blood cell transfusion (RBCT) dose 
density on progression-free survival (PFS) in LR-MDS patients of the EUMDS 
registry. Patients receiving RBCT less than 1 unit/month are regularly defined 
as RBCT independent, but we hypothesized that also these patients may suffer 
from deleterious effects of RBCT. We addressed several statistical challenges 
by using proportional hazards regression with time-varying covariates. We 
calculated the transfusion rate at each reported visit during all preceding 
visit intervals from the date of the first reported RCBT. This was defined as 
dose density, which reflects an average rate of receiving transfusions during 
the whole observation period with transfusions until the date of the last visit 
during the last interval at that time point. 
Of the 1267 patients included in the analyses, 317 patients had died and in 162 
patients the disease had progressed. Transfusion dose density was inversely 
associated with progression-free survival (p <1 x 10-4): dose density had an 
increasing effect on hazard until a dose density of about 1 unit per month. 
After correction for three relevant therapeutic interventions (erythropoietin 
stimulating agents, lenalidomide and iron chelation) the dose density effect 
continues to increase beyond 2 RBC units per month.
Overall, the negative impact on progression-free survival associated with RBCT 
already occurred at a low RBCT rate and before a cumulative high RBCT burden 
in this elderly LR-MDS patient population. This indicates that RBCT dependency, 
even at relatively low intensities/densities, may be considered as an indicator of 
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poor prognosis for progression-free survival. However, effi  cient iron chelation 
for a prolonged period may counterbalance the deleterious eff ect of red blood 
cell transfusions.14
Future perspectives
Systematic prospective international registries, like the EUMDS registry, 
are robust tools to collect detailed and accurate diagnostic, therapeutic 
and prognostic information in an elderly LR-MDS population. The studies 
presented in this thesis are the fi rst of many to come on diagnostic, prognostic 
and therapeutic studies in the population based EUMDS registry of LR-MDS 
patients. This extensive collection of information enables investigators to 
evaluate clinical decision making in MDS therapy, to anticipate on preventable 
side-eff ects and to develop evidence-based treatment guidelines for a 
heterogeneous disease of elderly patients. Prognostic models will be able to 
evolve by including promising candidates in DNA mutation analysis, by refi ning 
current prognostic factors or by adding new factors like transfusion dose 
density and LPI. We have expanded our knowledge on the key players of iron 
metabolism in LR-MDS. It became clear that transferrin saturation can serve as 
a more useful clinical tool compared to ferritin in identifying patients prone to 
developing toxic iron complexes like LPI. LPI and RBCT dependency, even at 
relatively low intensities, may be considered as indicators of poor prognosis for 
PFS in this elderly patient population.  
Many questions remain unanswered and new questions have risen. Future 
research within the framework of the EUMDS registry will focus on a wide 
variety of topics. 
-  (Early) Detection of MDS: it is important to diff erentiate between 
patients with non/pre-malignant hematopoietic disorders like 
ICUS (idiopathic cytopenia of undetermined signifi cance), CCUS 
(clonal cytopenia of undetermined signifi cance) and CHIP (clonal 
hematopoiesis of indeterminate potential), from patients with 
malignant causes of cytopenias like MDS. Studying several patient 
groups with unexplained anaemia in a prospective setting will 
help us to develop a diagnostic work up for these patients. 
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-  Prognosis over time: to continue learning about the behaviour of 
the disease in time. By analyzing the impact of the aggravation 
of BM failure by the decline in neutrophil and platelet counts on 
outcome in patients with LR-MDS treated with supportive care. As 
well as  exploring the impact of molecular mutations frequently 
identified in MDS (EZH2, RUNX1, TP53, NRAS, ASXL1, SF3B1) and 
the epigenetic modifications on the impaired hematopoiesis and 
the altered iron pathophysiology. 
-  Treatment interventions: to evaluate the effect of the 
interventions in our patient population it is important to identify 
specific molecular responses in mutation profiles to generally 
accepted treatment inventions including ESA, lenalidomide, RBC 
transfusions and iron chelation therapy. Ongoing prospective 
trials of the effect of iron chelation therapy will increase our 
knowledge on survival and hematological improvement, as 
well as the impact on LPI and malondialdehyde (MDA) levels in 
our lower-risk iron overloaded patient population. Additionally 
it would be interesting to compare incidence and outcome of 
allogeneic stem cell transplantation (alloHSCT) in the EUMDS 
population and patients reported to the European society for 
blood and marrow transplantation (EBMT).
Targeting specific subpopulations in MDS like patients with ringed sideroblasts 
by assessing the effect of SF3B1 modulators on SF3B1 mutations and the 
interaction with iron toxicity parameters measured by LPI, NTBI and oxidative 
stress parameters like MDA. As well as patients with auto-immune phenomena 
in MDS and the effect by treatment with hypomethylating agents (HMA). 
Another focus should be on improving treatment compliance and a more 
tailored use of existing healthcare options in order to contribute to an efficient 
and cost effective use of health care resources.
Our ultimate goal is to provide “the right care at the right time in lower-risk 
MDS patients in order to extend their life and to improve their quality of life” 
which is the topic of our ongoing Horizon 2020 project.
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Nederlandse samenvatting 
Inleiding
Myelodysplastische syndromen (MDS) zijn hoofdzakelijk een ziekte van de 
oudere medemens, met een gemiddelde leeftijd van 75 jaar. Vaak zijn deze 
patiënten uitgesloten van klinische studies vanwege verminderde mobiliteit, 
verhoogde kwetsbaarheid of co-morbiditeit. Deze patiënten worden vaak 
begeleid in perifere ziekenhuizen waarbij behandeling vooral bestaat uit 
ondersteunende maatregelen (supportive care) zoals erytrocytentransfusies 
en hematopoëtische groeifactoren (ESA of G-CSF) bij anemie. Het merendeel 
van de MDS patiënten (71%) heeft een laag-risico MDS (LR-MDS), dat wordt 
gedefi nieerd als een laag of intermediair-1 risico volgens het internationale 
prognostisch scoringssysteem (IPSS).1 De diagnose van MDS in een vroeg 
stadium blijft een uitdaging, en het is vaak onduidelijk wat een goed moment 
is om met behandeling te starten.
De Europese LeukemiaNet MDS (EUMDS) registratiestudie is een internationale 
prospectieve registratie waarin alleen nieuw gediagnosticeerde patiënten 
met LR-MDS geïncludeerd kunnen worden. Het overkoepelend doel is om 
gedetailleerde en accurate prospectieve data te verzamelen rondom het 
stellen van de diagnose, beloop van de ziekte en de behandelstrategieën in 
zowel academische als niet-academische ziekenhuizen. Deze registratiestudie 
includeert patiënten in 16 Europese landen en Israel. Het merendeel van de 
studies in dit proefschrift zijn verricht vanuit het raamwerk van de EUMDS 
registratiestudie. 
In dit proefschrift evalueren we de demografi sche data en huidige 
behandelstrategieën in onze laag-risico EUMDS populatie. We hebben de 
toegevoegde waarde getoetst van het nieuwste prognostische scoringssysteem: 
de gereviseerde IPSS score (IPSS-R).2 We hebben de kwaliteit en precisie van 
de gestelde MDS diagnoses in de registratiestudie in ogenschouw genomen, 
inclusief het eff ect op prognose wanneer een suboptimaal aantal metafasen 
(MP) tijdens karyotypering bekeken was. 
Het streven was om de huidige kennis van de ijzerhomeostase in MDS 
uit te breiden, zowel in patiënten die bloedtransfusies krijgen als in 
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ongetransfundeerde patiënten, met als doel nieuwe aanknopingspunten voor 
diagnostiek en accurate ijzerreducerende maatregelen te kunnen treffen. In 
dit kader is het belangrijk om relevante parameters van ijzerstapeling en ijzer 
gemedieerde oxidatieve stress te identificeren. Daarvoor hebben we tien 
wereldwijde assays vergeleken die niet-transferrine-gebonden ijzer (NTBI) of 
labiel plasma ijzer (LPI) hebben gemeten in vier verschillende groepen van 
patiënten met ijzerstapeling, waaronder MDS patiënten.
Een nieuwe risico score
In Hoofdstuk 2 beschrijven we de karakteristieken (demografie, kliniek, 
laboratoriumwaarden) van de eerste 1000 geïncludeerde patiënten in de 
EUMDS registratie en de therapeutische keuzes die gemaakt zijn. Daarnaast 
valideerden we de prognostische waarde van het veelgebruikte prognostisch 
scoringssysteem de IPSS en de vernieuwde IPSS-R. Betrouwbare prognostische 
scoringssystemen zijn belangrijk voor nauwkeurige inschatting van de risico's 
en het beloop van de ziekte bij de individuele patiënt. Bij aanvang van de 
EUMDS registratiestudie was de IPSS de meest gebruikte risicoscore, maar met 
de tijd werd het duidelijk dat cytogenetica een meer prominente rol speelt, 
welke heeft geleid tot de IPSS-R score.
Patiënten waren geschikt voor inclusie als ze recent gediagnosticeerd waren 
met LR-MDS volgens de WHO 2001 classificatie. Als recent werd beschouwd 
binnen 100 dagen na het diagnostische beenmergonderzoek (aspiraat voor 
cytologie). Geëxcludeerd werden patiënten met een IPSS intermediar-2 
risico, met een hoog risico score, of patiënten met secundaire of therapie-
gerelateerde MDS.
Door de IPSS-R toe te passen waren we in staat om totaal vier verschillende 
prognostische risicogroepen te onderscheiden, inclusief een gecombineerde 
groep van hoog en zeer hoog risico patiënten, in vergelijking met de 
oorspronkelijke twee risicogroepen als we de IPSS toepassen. 
Vrijwel alle laag risico IPSS patiënten werden ingedeeld als IPSS-R laag en zeer 
laag risico patiënten. De intermediair-1 groep, met een geschatte mediane 
overleving van 3.6 jaar, bleek een stuk heterogener te zijn: meer dan 50% 
van deze patiënten werd namelijk ingedeeld als laag/zeer laag IPSS-R risico 
(mediane overleving 5.3-8.8 jaar) en 10% als (zeer) hoog risico (mediane 
overleving 0.8-1.6 jaar). De overgebleven 40% van de patiënten bleef in de 
intermediair risico groep.2 Al met al heeft de IPSS-R score zich bewezen als een 
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meer verfi jnde risicoscore. Vooral in de subgroep met hoog/zeer hoog risico 
patiënten moet in een vroeg stadium behandeling middels hypomethylerende 
middelen, intensieve chemotherapie of allogene stamceltransplantatie 
overwogen worden.3
Verifi catie van de morfologische diagnose van een multicenter Europese 
registratiestudie
Hoofdstuk 3 beschrijft de cytomorfologische revisie van 100 nieuw 
gediagnosticeerde LR-MDS patiënten in de EUMD registratiestudie. Het 
uitgangspunt was de WHO 2001 classifi catie aangezien bij aanvang van de 
EUMDS registratie dit het gangbare classifi catiesysteem was.4 Het primaire 
doel van deze studie was gericht op reproduceerbaarheid van de WHO 2001 
criteria voor het stellen van de diagnose MDS door een internationaal panel 
van 11 mensen dat zich dagelijks bezighoudt met de diagnostiek van MDS. 
Tevens was het doel om te evalueren of deze patiënten op basis van hun 
morfologische diagnose inderdaad geschikt waren voor inclusie in de EUMDS. 
In totaal werden er 105 casus at random, maar wel een afspiegeling van de 
deelnemende landen, geselecteerd en beoordeeld door het panel gedurende 
een meeting van drie dagen.
Deze revisie liet een hoge precisie zien van de diagnose bij inclusie, en een 
hoge overeenstemming tussen de panelleden wat betreft MDS diagnose en de 
WHO 2001 classifi catie. Er was wel enig verschil tussen de panelleden als het 
ging om unilineaire versus multilineaire dysplasie in de cellijnen. 
Als we de huidige classifi catiesystemen op een rij zetten dan zien we dat de 
WHO 2001 classifi catie onderscheid maakte tussen unilineaire en multilineaire 
dysplasie (RA versus RCMD) en het al dan niet aanwezig zijn van ringsideroblasten 
(RS; aankleuring van ijzer in de mitochondriën). De daaropvolgende classifi catie, 
de WHO 2008, maakte geen onderscheid tussen het aan- of afwezig zijn van 
ringsideroblasten.5 De meest recente morfologische classifi catie, de WHO 2016, 
heeft echter de stratifi catie met ringsideroblasten weer in ere hersteld, waardoor 
de diagnostische classifi catie van de patiënten in de EUMDS registratie volgens 
de WHO 2001 tevens een goede refl ectie is van de huidige WHO 2016 indeling. 
Op wat kleinere verschillen na zoals de defi nitie van patiënten met een MDS 
del(5q), MDS 'unclassifi ed', en introductie van de SF3B1 mutatie als classifi cerend 
element als gevolg van voortschrijdend inzicht binnen de moleculaire mutatie 
analyses in MDS (next-generation sequencing; NGS).6, 7
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Onze data toont aan dat er een grote overeenstemming is wat betreft MDS 
diagnose en dat slechts een zeer klein aantal MDS patiënten (n=6) onterecht 
is geïncludeerd in de EUMDS registratie. Dit is een belangrijke bevinding 
aangezien de gouden standaard om de diagnose MDS te stellen nog altijd is 
gebaseerd op cytomorfologie.
De impact van het aantal metafases in karyotypering
In Hoofdstuk 4 hebben we gekeken naar de prognostische impact van een 
suboptimaal aantal geanalyseerde metafases (MP) in LR-MDS patiënten 
met een normale karyotypering. Karyotypering is nog altijd de meest 
gangbare diagnostiek om te kijken naar genetische afwijkingen. Zowel de 
cytogenetische score volgens de IPSS als de IPSS-R zijn vastgesteld op basis 
van de diagnostische cytogenetica rapporten ten tijde van registratie. Het 
aanbevolen aantal te analyseren MP is 20. 
We hebben in deze studie 1225 patiënten geïncludeerd met een normaal 
karyotype, die hiermee 61% van de LR-MDS populatie vertegenwoordigen. 
Slechts 14% van de patiënten stond geregistreerd met een normaal 
karyotype gebaseerd op minder dan 20 geanalyseerde MP. De geschatte 
algehele overleving evenals progressie-vrije overleving was echter gelijk in 
beide groepen. Daarnaast hebben we 774 patiënten geanalyseerd met een 
afwijkende karyotypering. Zoals verwacht was in deze groep het percentage 
met <20 geanalyseerde MP hoger, namelijk 29%. Dit komt doordat door de 
huidige definitie van clonaliteit in patiënten met een abnormaal karyotype 
aan minder geanalyseerde MP hoeft te worden voldaan om clonaliteit vast te 
stellen. Ook in deze patiënten met afwijkende karyotypering was de geschatte 
overleving evenals progressie-vrije overleving hetzelfde ongeacht het totaal 
aantal geanalyseerde metafases. 
Deze studie laat zien dat patiënten met <20 geanalyseerde MP zich net zo 
gedragen als patiënten met een normaal karyotype. De kanttekening die 
gemaakt moet worden is dat deze gunstige resultaten waarschijnlijk juist 
verkregen zijn omdat altijd het streven is om meer dan 20 MP te analyseren. 
Ons advies is dan ook om te blijven streven naar het analyseren van >20 MP 
om ook kleine clonale afwijkingen zo goed mogelijk te kunnen uitsluiten, 
vooral bij patiënten die in aanmerking komen voor intensieve therapie. Als 
dit niet haalbaar is, meestal door methodologische beperkingen om 20 
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MP te verkrijgen, raden we aan om fl uorescentie in situ hybridisatie (FISH) 
analyse of aanvullende moleculaire technieken (NGS) te overwegen, omdat 
de verwachting is dat ook kleine genetische afwijkingen van invloed kunnen 
zijn op het beloop van de ziekte. DNA sequencing mutaties van onder andere 
EZH2, RUNX1, TP65, NRAS en ASXL1 zijn geassocieerd met minder gunstige 
uitkomsten.8-11
Internationale evaluatie van NTBI en LPI bepalingen
Hoofdstuk 5 beschrijft een internationale laboratorium rondzending van serum 
samples om de toxische ijzerparameters NTBI en LPI te bepalen in patiënten 
met een ijzerstapelingsziekte, zoals erfelijke hemochromatose, β-thalassemie, 
sikkelcelziekte en MDS, in verschillende behandelfases.
IJzer gebonden aan NTBI of LPI heeft een meer instabiele binding dan 
wanneer het gebonden is aan zijn fysiologische transporteiwit: transferrine. 
Daardoor zijn NTBI/LPI complexen vatbaarder voor micro-organismen en is er 
laagdrempeliger interactie met cellen van het hart, de lever en de alvleesklier, 
met oxidatieve stress als gevolg.
We hebben in totaal 10 verschillende testen wereldwijd vergeleken (6 NTBI en 
4 LPI testen). 
Correlatie tussen de testen was groot binnen de groep van NTBI testen en 
binnen de groep van de LPI testen. De absolute waarden verschilden echter 
wel aanzienlijk en waren over het algemeen lager binnen de groep van LPI 
bepalingen dan NTBI bepalingen. De hoogst gemeten waarden werden gemeten 
in patiënten met onbehandelde erfelijke hemochromatose, β-thalassemie 
intermedia, erytrocytentransfusie afhankelijke MDS en β-thalassemie 
major patiënten die met ijzerchelatie werden behandeld. De verschillen in 
de gerapporteerde waarden geven aan dat het hoog tijd is voor validatie 
protocollen, standaardisatie en consensus over de manier van rapporteren, 
voordat de testen in de kliniek kunnen worden toegepast. Verder was een 
belangrijke bevinding dat de waarden van zowel de NTBI als LPI testen een 
duidelijke correlatie met transferrine saturatie (TSAT) toonden, onafhankelijk 
van het soort ijzerstapelingsziekte. Gebaseerd op onze waarnemingen kunnen 
TSAT waarden >70% als handvat dienen voor de mogelijke aanwezigheid 
van toxische ijzercomplexen en ijzerstapeling in de parenchym cellen. Echter, 
voordat de NTBI en LPI assays in de klinische praktijk toegepast kunnen worden 
is het nodig om de assays te standaardiseren, overeenstemming te bereiken 
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over de manier van rapporteren en zal de klinische relevantie van de NTBI en 
LPI uitkomsten en hun toxische grenswaarden bepaald moeten worden.
De invloed van erytroctentransfusies op prognose in LR-MDS patiënten
In Hoofdstuk 6 hebben we LPI kunnen identificeren als relevante marker voor 
een potentieel toxische ijzerfractie en de invloed daarvan op overleving in 
onze MDS populatie. We hebben serum monsters van 100 LR-MDS patiënten in 
de EUMDS registratie geanalyseerd. Iedere 6 maanden werd serum afgenomen 
en werden verscheidene ijzerparameters bepaald om zo gedurende het 
ziektebeloop veranderingen in het ijzermetabolisme te kunnen bekijken, de 
aanwezigheid van toxische ijzercomplexen te bepalen en te kijken naar de 
invloed op overleving.
In onze studiepopulatie vonden we verhoogde LPI waarden in combinatie 
met verhoogde TSAT waarden in alle transfusie afhankelijke (RBCT) patiënten 
en specifiek in MDS patiënten met ringsideroblasten, gekenmerkt door de 
ineffectieve erytropoiese. Verder vonden we dat de aanwezigheid van LPI, maar 
niet NTBI, geassocieerd is met een verminderde overleving in MDS patiënten 
die erytrocytentransfusies krijgen. Het verhoogde risico op overlijden van 
patiënten met te hoge LPI waarden kan niet verklaard worden door klassieke 
lange termijn ijzerstapeling in de organen (longen, lever, hart) na langdurige 
erytrocytentransfusies, omdat de sterfte al optreedt na relatief weinig 
transfusies. We denken dat de aanwezigheid van een te hoog LPI een indicator is 
voor een meer directe vorm van ijzertoxiciteit door het ontstaan van oxidatieve 
stress. Verhoogde LPI waarden vonden we hoofdzakelijk in patiënten met een 
TSAT >80%. Verder bleek dat TSAT >80% an sich geen prognostische factor 
is. Daarom is onze aanbeveling om TSAT ( >70%) te gebruiken als klinische 
screeningsmethode, in tegenstelling tot het veelvuldig gebruikte ferritine, om 
patiënten op het spoor te komen die risico lopen op verhoogde LPI waarden.
Aangezien LPI vooral blijkt te ontstaan in de MDS subtypen gekenmerkt 
door ineffectieve erytropoiese zoals de RARS en RCMD en MDS met hoge 
transfusiebehoefte zou het voornamelijk in deze populatie zeer interessant 
zijn om te zien wat het effect is van ijzerchelatie, als ook nieuwe erytropoiese 
remmende middelen zoals Luspatercept (ACE-536) en hepcidin analogen op 
LPI waarden, transfusiebehoefte, progressie-vrije overleving en kwaliteit van 
leven.12, 13
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Transfusie-afhankelijkheid als indicator van beperkte overleving
In hoofdstuk 7 bestuderen we de invloed van de frequentie van 
erytrocytentransfusies (RBCT) op progressievrije overleving (PFS) in LR-MDS 
patiënten. Vaak worden patiënten die minder dan 1 eenheid RBCT per maand 
krijgen gedefi nieerd als transfusie-onafhankelijk, maar onze hypothese is dat 
ook deze patiënten al nadelige eff ecten hebben van transfusies. De uitdaging 
in deze analyse bevindt zich in het bijzonder op statistisch vlak: we hebben te 
maken met vele variabelen die kunnen veranderen in de tijd, nog afgezien van 
vele andere variabelen die een rol spelen in de levensverwachting van deze 
patiënten op leeftijd. Om dit te ondervangen hebben we een proportioneel 
hazards regressie model met tijd-variabele covarianten ontwikkeld voor deze 
specifi eke vraagstelling. De transfusie-dichtheid hebben we berekend door 
na ieder interval van 6 maanden te kijken naar het aantal ontvangen RBCT 
in de voorgaande periode vanaf de eerste vastgelegde transfusie om zo tot 
een gemiddeld aantal eenheden per maand te komen gedurende de gehele 
observatieperiode. 
In totaal zijn er 1267 patiënten geïncludeerd, waarvan er 317 overleden waren 
aan het eind van de studieperiode en in 162 patiënten was er progressie van 
ziekte. Transfusie-dichtheid was omgekeerd evenredig geassocieerd met PFS 
(p<1x10-4), dit wil zeggen dat de transfusie-dichtheid een steeds grotere kans 
op overlijden (hazard) gaf tot aan een transfusie-dichtheid van 1 eenheid/
maand en vervolgens een plateau fase bereikt. Als we vervolgens corrigeren 
voor behandeling met ESA, lenalidomide of ijzerchelatie zien we dat deze 
plateau-fase niet bereikt wordt maar dat het negatief eff ect van de transfusies 
blijft toenemen tot >2 RBCT eenheden/maand. 
We zien dus in deze studie dat het negatieve eff ect van RBCT al begint bij een 
lage transfusie-dichtheid en dat ook patiënten met MDS lang genoeg leven om 
hinder te ondervinden van de negatieve eff ecten van erytrocytentransfusies. 
Een mogelijke oplossing om dit eff ect tegen te gaan is effi  ciënte ijzerchelatie 
gedurende een langere periode te geven.14
Toekomstperspectief
We laten zien dat middels een prospectieve registratie gedetailleerde informatie 
verzameld kan worden over de diagnose, de therapeutische maatregelen en 
de ingeschatte prognose van LR-MDS patiënten. De studies gepresenteerd in 
dit proefschrift vormen de basis voor vele studies binnen de EUMDS registratie 
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die nog gaan komen. Deze uitgebreide verzameling van informatie stelt ons 
in staat om de huidige behandeling van LR-MDS patiënten te evalueren, zoals 
dat in het dagelijks leven in de kliniek plaats vindt. We laten zien dat naast 
de effectiviteit van verschillende behandelingen, ook bijwerkingen tijdens 
het beloop van de ziekte aan het licht kunnen komen. Bovendien kan zo de 
volgende generatie richtlijnen steeds meer gebaseerd worden op bewezen 
gegevens in tegenstelling tot de huidige aanbevelingen gebaseerd op de 
persoonlijke mening van deskundigen. Prognostische modellen kunnen 
zich verder ontwikkelen door veelbelovende DNA mutaties te includeren, 
door huidige prognostische factoren te verfijnen en/of door nieuwe factoren 
zoals LPI en transfusie-dichtheid toe te voegen. Tevens zijn we meer te weten 
gekomen over de rol van de verschillende ijzerparameters in LR-MDS. We laten 
zien dat TSAT een beter handvat is ten opzichte van ferritine in het opsporen 
van patiënten die een vergrote kans hebben op blootstelling aan toxische 
ijzercomplexen als LPI. Verhoogd LPI en transfusie-afhankelijkheid, zelfs bij een 
lage transfusie-dichtheid, lijken goede indicatoren voor een negatief effect op 
progressie-vrije overleving in deze patiënten populatie op leeftijd. 
Zoals dat gaat met onderzoek zijn ook nog vele vragen onbeantwoord 
gebleven en nieuwe vragen ontstaan. Toekomstig onderzoek vanuit de EUMDS 
registratiestudie zal zich richten op verschillende relevante aspecten van deze 
ziekte. 
-  (Vroege) Detectie van MDS: het is belangrijk om onderscheid te 
maken tussen patiënten met een benigne/voorstadium-maligne 
hematopoietische ziekte zoals ICUS (idiopathische cytopenieën 
van onbepaalde relevantie), CCUS (clonale cytopenieën van 
onbepaalde relevantie) en CHIP (clonale hematopoiese van 
onbepaald potentieel), te onderscheiden van maligne oorzaken 
van cytopenieën als MDS. Het prospectief bestuderen van 
verschillende groepen van patiënten met onbegrepen anemie 
zal bijdragen in het doorontwikkelen van een niet invasief 
diagnostisch algoritme. 
-  Op prognostisch vlak: blijven leren over de ontwikkeling van de 
ziekte in de tijd. Door onder andere te kijken naar het voortschrijden 
van het beenmergfalen door de afname van neutrofielen en 
bloedplaatjes in perifeer bloed in LR-MDS patiënten behandeld 
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met supportive care. Maar ook verder onderzoek naar de bijdrage 
van veelvoorkomende genetische en epigenetische mutaties 
(EZH2, RUNX1, TP53, NRAS, ASXL1, SF3B1) op de veranderde 
bloedaanmaak en ijzerstofwisseling.
-  Op therapeutisch vlak: onder andere door de moleculaire reactie 
te onderzoeken op de behandeling met ESA, lenalidomide, 
transfusies en ijzerchelatie. Lopende prospectieve studies naar de 
behandeling met ijzerchelatie zullen onze kennis vergroten van 
het eff ect op overleving en hematologische respons, evenals de 
impact op LPI en malondialdehyde (MDA) levels in onze patiënten 
met ijzerstapeling. Aangezien de EUMDS registratiestudie 
inmiddels is uitgbreid naar het includeren van hoog-risico MDS 
patiënten zal het op den duur ook mogelijk zijn om de uitkomsten 
van allogene stamceltransplantaties (allo HSCT) binnen de EUMDS 
populatie te vergelijken met de uitgebreide data van de Europese 
vereniging voor bloed- en beenmergtransplantatie (EBMT). 
Andere groepen om ons op te richten zijn onder andere MDS patiënten met 
ringsideroblasten en het eff ect van SF3B1 modulatoren op de de SF3B1 mutatie 
en de interactie met ijzertoxiciteits parameters als NTBI, LPI en oxidatieve stress 
parameters als MDA. Evenals patiënten met auto-immuun fenomenen in MDS 
en het eff ect van hypomethylerende middelen (HMA) daarop. 
Een belangrijke focus ligt echter ook op studies die de ervaren kwaliteit van 
leven van de patiënten met MDS in ogenschouw nemen gedurende het 
beloop van de ziekte. Als ook therapie-trouw en optimalisatie van huidige 
behandelmogelijkheden om zo effi  ciënt en kosten eff ectief gebruik te maken 
van de gezondheidszorg.
Ons ultieme doel is om met de patiënt met laag-risico MDS de juiste zorg op 
het juiste moment te kunnen afstemmen om zo hun kwaliteit van leven te 
optimaliseren, zoals reeds het onderwerp is van ons lopende Horizon 2020 
project.
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Dankwoord (Word of thanks)
Uiteraard had dit proefschrift niet tot stand kunnen komen zonder 
ondersteuning op wetenschappelijk, dan wel mentaal vlak van velen. Een 
aantal van hen wil ik in het bijzonder bedanken:
Ten eerste grote dank aan alle patiënten die hebben besloten om deel te nemen 
aan de EUMDS registratie, voor het delen van jullie ziekte, de vragenlijsten, 
en/of het afstaan van materiaal. Als ook de patiënten die materiaal hebben 
afgestaan voor het Round Robin onderzoek. 
Prof. dr. T.J.M. de Witte, mijn promotor, beste Theo, als piepkuiken van 24 jaar 
kwam ik solliciteren, al binnen een dag hadden jullie besloten om dit avontuur 
met mij aan te gaan waardoor ik de kans heb gekregen om op te groeien 
binnen een internationaal gezelschap. Je hebt ervoor gezorgd dat ik altijd 
gestaag door bleef werken: als de dag weer eens te kort bleek ‘was er altijd ’s 
nachts nog wel tijd’ was je enthousiaste motto. Je hebt me vooral laten zien dat 
het belangrijk is om je werk met plezier te doen, dat is wat het maakt tot een 
uit de hand gelopen hobby in plaats van een opgave. Altijd was er ruimte om te 
brainstormen en kwamen er nieuwe ideeën. Mijn waardering is groot. 
Prof. dr. D.W. Swinkels, mijn promotor, beste Dorine, ik heb me altijd uitermate 
welkom gevoeld binnen je ijzerteam. Je kritische blik zorgde altijd weer voor 
een frisse wind door mijn stukken. Ik waardeer je onuitputtelijke enthousiasme 
voor de wetenschap als ook de eigenschap om even zo enthousiast te zijn toen 
ik mijn pasgeboren baby kwam showen.
Prof. dr. N.M.A. Blijlevens, mijn promotor, beste Nicole, mijn hartelijke dank 
voor de jarenlange ondersteuning van jou en de afdeling hematologie om dit 
proefschrift tot een succesvol einde te kunnen brengen.
Dr. A.G. Smith, my co-supervisor, dear Alex, with a great pleasure I recall my 
visits to you and your epidemiology and statistics team in York. Your enthusiasm 
and all the bubbly personalities on the floor made it to my favourite travel 
destination. 
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De leden van de manuscriptcommissie: Prof. dr. M.G.M. Olde Rikkert, Prof. dr. 
J.H.J.M. van Krieken, Prof. dr. J.J. Zwaginga (LUMC), mijn hartelijke dank voor de 
tijd en moeite die jullie hebben gestoken in het lezen en beoordelen van mijn 
proefschrift.
Members from the EUMDS (steering) committee, in particular David Bowen, 
Jaroslav Čermák, Pierre Fenaux, Ulrich Germing, Eva Hellström-Lindberg, Rafael 
Itzykson, Arjan van de Loosdrecht, Krzysztof Mądry, Luca Malcovati, Antonio 
Medina Almeida, Moshe Mittelman, Aleksandar Savic, Mette Skov Holm, Argiris 
Symeonidis, Guillermo Sanz, Reinhard Stauder and Aurelia Tatic, thank you for 
all the inspirational meetings and conversations.
Colleagues from the Epidemiology and Cancer Statistics Group, dear Tom, 
Simon, Dan, John, Tim and Ge, thank you very much for your dedication 
to the EUMDS registry and all the warm welcomes during my visits to your 
department. I still miss the jacked potatoes with coleslaw and cheese for lunch. 
Colleagues from all the participating centers of the EUMDS registry including 
the operational team members and research staff  in Austria, Croatia, Czech 
Republic, Denmark, France, Germany, Greece, Israel, Italy, the Netherlands, 
Poland, Portugal, Republic of Serbia, Romania, Spain, Sweden, United Kingdom. 
Thank you for you never ending eff ort. 
Beste collega’s van het trial-datacentrum (TDC): project managers, monitors, 
research verpleegkundigen, datamanagers: bedankt voor jullie inzet. In het 
bijzonder Corine van Marrewijk, Bas van Haren, Elise van Pinxten-van Orsouw, 
Nori van Wijngaarden, Margot Reker, Peter Karel, Carla Janssen en Karien 
Croezen. Corine, bedankt voor je betrokkenheid en ondersteuning. 
Beste collega’s van het Radboudumc ijzercentrum: Harold, Siem, Guus, Rian, 
Coby, Erwin, Rachel. Bedankt voor de fi jne samenwerking en de vele NTBI/LPI 
bepalingen van jullie hand. 
Dr. M.A. MacKenzie, beste Marius, de vele uren op de morfologie kamer zorgden 
niet alleen voor een snelle groei van kennis van de cytomorfologie maar ook 
voor vele goede gesprekken. Je hebt een hart van goud.
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Dr. J. Droste, beste Jackie, in de begintijd zijn we geregeld samen op reis 
geweest naar meetings en congressen. Je wist altijd weer de filosoferende 
academici op het rechte pad te brengen.
Vakgroep Interne Geneeskunde Slingeland ziekenhuis, beste Erik, Cees, Aart, 
Alexandra, Inge, Job, Richard, Foeke en Nail, bedankt voor de start-up in de 
kliniek na 4.5 jaar onderzoek en een pasgeboren baby. Beste Foeke, als poli 
mentor, mijn hartelijke dank voor het delen van je kennis, je vertrouwen en je 
luisterend oor.
Vakgroep Maag-Darm-Leverziekten Slingeland ziekenhuis, beste Sybrand, 
Paul, Sven en Edith. Hoewel er zeker goede herinneringen kleven aan mijn 
stage en diensttijd op de MDL, worden de meest blijvende herinneringen toch 
echt gemaakt in een drie-kwartier stilstaande skilift. Santé! 
Vakgroep Longgeneeskunde Slingeland ziekenhuis, beste Frank, Carl, Gerrit, 
Daan en Hugo. Sommige ervaringen zijn life-changing. De grote vraag is 
uiteraard hoe lang jullie het mannenbolwerk in stand zullen houden. 
Collega’s Interne Geneeskunde en SEH Slingeland ziekenhuis, beste Teske, 
Joris, Christa, Lenny, Marwi, Vincent, Houda, Danique, Anke, Jolien, Marjolein, 
Myrella, Marloes, Christine, Lisa, Inke en Krista, bedankt voor de gezellige tijd 
samen zowel binnen- als buitenshuis. Lisa, de rosse woelmuis staat voor eeuwig 
in mijn geheugen gegrift.
Vakgroep Longgeneeskunde Rijnstate ziekenhuis, beste Frank, Toby, Niels, 
Marjo, Petra, Hans, Peter, Linda, Jacqueline en Lisette. Mijn hartelijke dank voor 
jullie steun en begeleiding. Voor de ruimte om dit proefschrift met succes te 
kunnen afronden, de prettige werksfeer en het feit dat ik kan zijn, zoals ik ben.
Collega A(N)IOS Longgeneeskunde Rijnstate ziekenhuis, beste Frank, Corine, 
Germa, Guido, Marjolein, Aniek, Lotte, Maarten, Bibi, Armine, Marit, Leonie, 
Wietse, Vera, Pauli, Robin en Sushil. Stuk voor stuk sterke persoonlijkheden, 
maar toch weten we iedere dag weer als team het werk voor elkaar te krijgen. 
We lachen heel wat af samen.  
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Eline, weliswaar veel uit het oog maar nooit uit het hart. Het is ons gelukt!
Ileana, bij sommige kun je veel zeggen met weinig woorden, bedankt daarvoor.
Wendy, als nieuwbakken junior onderzoeker mocht ik aanschuiven op jouw 
werkkamer. Onze praatjes groeiden uit tot een hele fijne vriendschap. Tot snel 
bij ons volgende etentje.
Teske en Louise, bedankt dat jullie mijn paranimfen zijn en me bijstaan op deze 
dag. 
Teske, vanaf de eerste ontmoeting in het Slingeland ziekenhuis was jij mijn 
maatje. Gelukkig zijn we elkaar niet uit het oog verloren en kunnen we goed 
praten over de dingen die ons allemaal bezighouden, van wetenschap tot 
poepbroeken.
Louise, my other me, als 5-jarigen samen op ballet, sindsdien volgen we elkaar 
door het leven heen, naar het Johan de Witt-gymnasium (jeeej, 2x zoveel kans 
op een goed antwoord als er weer eens ’Louise’ werd geroepen), studeren in 
Leiden en werken in het Radboudumc. Zo veel herinneringen samen. Je zal 
altijd mijn zussie zijn. 
Jerry, broeder, onze BBQ man, het heeft even tijd gekost, maar we kunnen nu 
toch echt dingen waterpas ophangen. Je bent een van de weinigen waar ik 
mijn baby, inmiddels een onstuimige kleuter, met een gerust hart achter kan 
laten.
Lieve Mama, mijn beste vriendin, altijd sta je voor mij klaar, met een lach of met 
een traan. Wir schaffen das immer.
Lieve Sebastian, mijn zoon, mijn kleine grote vriend. Mama houdt zielsveel van 
jou.
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